0001437749-20-016985.txt : 20200807 0001437749-20-016985.hdr.sgml : 20200807 20200807092523 ACCESSION NUMBER: 0001437749-20-016985 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200807 DATE AS OF CHANGE: 20200807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATIONAL RESEARCH CORP CENTRAL INDEX KEY: 0000070487 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 470634000 STATE OF INCORPORATION: WI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35929 FILM NUMBER: 201084008 BUSINESS ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 BUSINESS PHONE: 4024752525 MAIL ADDRESS: STREET 1: 1245 Q STREET CITY: LINCOLN STATE: NE ZIP: 68508 10-Q 1 nrc20200630_10q.htm FORM 10-Q nrc20200630_10q.htm
0000070487 National Research Corporation false --12-31 Q2 2020 143 144 0.01 0.01 2,000,000 2,000,000 0 0 0.001 0.001 60,000,000 60,000,000 30,553,546 30,151,574 25,235,123 24,947,500 5,318,423 5,204,074 75,980 260,481 0.21 38,369 148,284 6,793 28,657 86,247 6,005 0.19 2,977 18,000 0.19 6 1 3 5 0 0 1 0.5 1 0 0 1.10 3.00 1 5 5 10 1 10 3 5 10 0 0 5 478,000 6 1 00000704872020-01-012020-06-30 xbrli:shares 00000704872020-07-28 thunderdome:item iso4217:USD 00000704872020-06-30 00000704872019-12-31 iso4217:USDxbrli:shares 00000704872020-04-012020-06-30 00000704872019-04-012019-06-30 00000704872019-01-012019-06-30 0000070487us-gaap:CommonStockMember2019-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000070487us-gaap:RetainedEarningsMember2019-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000070487us-gaap:TreasuryStockMember2019-12-31 00000704872020-01-012020-03-31 0000070487us-gaap:TreasuryStockMember2020-01-012020-03-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 0000070487us-gaap:RetainedEarningsMember2020-01-012020-03-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-31 0000070487us-gaap:CommonStockMember2020-03-31 0000070487us-gaap:AdditionalPaidInCapitalMember2020-03-31 0000070487us-gaap:RetainedEarningsMember2020-03-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31 0000070487us-gaap:TreasuryStockMember2020-03-31 00000704872020-03-31 0000070487us-gaap:TreasuryStockMember2020-04-012020-06-30 0000070487us-gaap:CommonStockMember2020-04-012020-06-30 0000070487us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-30 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-30 0000070487us-gaap:RetainedEarningsMember2020-04-012020-06-30 0000070487us-gaap:CommonStockMember2020-06-30 0000070487us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000070487us-gaap:RetainedEarningsMember2020-06-30 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000070487us-gaap:TreasuryStockMember2020-06-30 0000070487us-gaap:CommonStockMember2018-12-31 0000070487us-gaap:AdditionalPaidInCapitalMember2018-12-31 0000070487us-gaap:RetainedEarningsMember2018-12-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0000070487us-gaap:TreasuryStockMember2018-12-31 00000704872018-12-31 00000704872019-01-012019-03-31 0000070487us-gaap:TreasuryStockMember2019-01-012019-03-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-31 0000070487us-gaap:RetainedEarningsMember2019-01-012019-03-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-31 0000070487us-gaap:CommonStockMember2019-03-31 0000070487us-gaap:AdditionalPaidInCapitalMember2019-03-31 0000070487us-gaap:RetainedEarningsMember2019-03-31 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-31 0000070487us-gaap:TreasuryStockMember2019-03-31 00000704872019-03-31 0000070487us-gaap:TreasuryStockMember2019-04-012019-06-30 0000070487us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-30 0000070487us-gaap:RetainedEarningsMember2019-04-012019-06-30 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-30 0000070487us-gaap:CommonStockMember2019-06-30 0000070487us-gaap:AdditionalPaidInCapitalMember2019-06-30 0000070487us-gaap:RetainedEarningsMember2019-06-30 0000070487us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000070487us-gaap:TreasuryStockMember2019-06-30 00000704872019-06-30 xbrli:pure utr:Y 0000070487srt:MinimumMember2020-06-30 0000070487srt:MaximumMember2020-06-30 0000070487nrc:DirectExpensesMember2020-04-012020-06-30 0000070487nrc:DirectExpensesMember2019-04-012019-06-30 0000070487nrc:DirectExpensesMember2020-01-012020-06-30 0000070487nrc:DirectExpensesMember2019-01-012019-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-30 0000070487us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-30 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000070487us-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-31 0000070487us-gaap:FairValueMeasurementsRecurringMember2019-12-31 00000704872019-01-012019-12-31 0000070487us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembernrc:CanadianSubsidiaryMember2020-01-012020-06-30 0000070487nrc:CanadianSubsidiaryMember2020-06-30 0000070487stpr:WAus-gaap:SubsequentEventMember2020-07-31 0000070487nrc:CyberAttackMember2020-04-012020-06-30 0000070487nrc:TheInsurerMembernrc:CyberAttackMember2020-04-012020-06-30 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-04-012020-06-30 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-04-012019-06-30 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-06-30 0000070487nrc:SubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-06-30 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-04-012020-06-30 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2019-04-012019-06-30 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-01-012020-06-30 0000070487us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2019-01-012019-06-30 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-04-012020-06-30 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-04-012019-06-30 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-06-30 0000070487nrc:FixedNonSubscriptionServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-06-30 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2020-04-012020-06-30 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2019-04-012019-06-30 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2020-01-012020-06-30 0000070487nrc:UnitPriceServicesMemberus-gaap:TransferredOverTimeMember2019-01-012019-06-30 0000070487nrc:VoCPlatformMember2020-04-012020-06-30 0000070487nrc:VoCPlatformMember2019-04-012019-06-30 0000070487nrc:VoCPlatformMember2020-01-012020-06-30 0000070487nrc:VoCPlatformMember2019-01-012019-06-30 0000070487us-gaap:OtherCurrentAssetsMember2020-06-30 0000070487us-gaap:OtherCurrentAssetsMember2019-12-31 0000070487us-gaap:LongTermContractWithCustomerMember2020-07-012020-06-30 0000070487us-gaap:LongTermContractWithCustomerMember2021-01-012020-06-30 0000070487us-gaap:LongTermContractWithCustomerMember2020-06-30 0000070487nrc:TermLoanMember2020-06-30 0000070487nrc:TermLoanMember2019-12-31 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-06-30 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-05-28 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:DelayedDrawTermLoanMember2020-06-30 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-03-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-01-012020-06-30 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:TermLoanMember2020-06-30 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-06-30 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-06-30 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2019-12-31 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMembernrc:DelayedDrawTermLoanMember2020-01-012020-06-30 0000070487us-gaap:RevolvingCreditFacilityMembernrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-01-012020-06-30 0000070487nrc:CreditAgreementMembernrc:FirstNationalBankOfOmahaMember2020-01-012020-06-30 0000070487nrc:The2001EquityIncentivePlanMemberus-gaap:CommonStockMember2020-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:The2001EquityIncentivePlanMembersrt:MinimumMember2020-01-012020-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:The2001EquityIncentivePlanMembersrt:MaximumMember2020-01-012020-06-30 0000070487nrc:The2001EquityIncentivePlanMember2015-12-31 0000070487nrc:DirectorPlan2004Memberus-gaap:CommonStockMember2020-06-30 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2018-01-012018-12-31 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:DirectorMember2020-01-012020-06-30 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MaximumMembersrt:DirectorMember2020-01-012020-06-30 0000070487nrc:NonqualifiedStockOptionsMembernrc:DirectorPlan2004Membersrt:MinimumMembersrt:DirectorMember2020-01-012020-06-30 0000070487nrc:The2006EquityIncentivePlanMemberus-gaap:CommonStockMember2020-06-30 0000070487nrc:The2006EquityIncentivePlanMembersrt:MinimumMember2020-01-012020-06-30 0000070487nrc:The2006EquityIncentivePlanMembersrt:MaximumMember2020-01-012020-06-30 0000070487nrc:CommonStockOptionsMember2020-01-012020-06-30 0000070487nrc:CommonStockOptionsMember2019-01-012019-06-30 0000070487us-gaap:CommonStockMember2020-01-012020-06-30 0000070487us-gaap:CommonStockMember2019-01-012019-06-30 0000070487nrc:CommonStockOptionsMember2019-12-31 0000070487nrc:CommonStockOptionsMember2019-01-012019-12-31 0000070487nrc:CommonStockOptionsMemberus-gaap:CommonStockMember2019-12-31 0000070487nrc:CommonStockOptionsMemberus-gaap:CommonStockMember2020-01-012020-06-30 0000070487nrc:CommonStockOptionsMember2020-06-30 0000070487nrc:CommonStockOptionsMemberus-gaap:CommonStockMember2020-06-30 0000070487us-gaap:EmployeeStockOptionMember2020-06-30 0000070487us-gaap:EmployeeStockOptionMember2020-01-012020-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2020-04-012020-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2019-04-012019-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2020-01-012020-06-30 0000070487us-gaap:EmployeeStockOptionMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2019-01-012019-06-30 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2019-01-012019-06-30 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2020-01-012020-06-30 0000070487nrc:NonvestedMembernrc:The2006EquityIncentivePlanMember2020-06-30 0000070487nrc:NonvestedMember2020-01-012020-06-30 0000070487nrc:NonvestedMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2020-04-012020-06-30 0000070487nrc:NonvestedMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2019-04-012019-06-30 0000070487nrc:NonvestedMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2020-01-012020-06-30 0000070487nrc:NonvestedMembernrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember2019-01-012019-06-30 0000070487us-gaap:RestrictedStockMember2020-01-012020-06-30 0000070487us-gaap:CommonStockMember2019-12-31 0000070487us-gaap:CommonStockMember2020-01-012020-06-30 0000070487us-gaap:CommonStockMember2020-06-30 0000070487nrc:NonvestedMember2020-06-30 0000070487nrc:TradeNames1Member2020-06-30 0000070487nrc:TradeNames1Member2019-12-31 0000070487us-gaap:CustomerRelationshipsMember2020-06-30 0000070487us-gaap:CustomerRelationshipsMember2019-12-31 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2020-06-30 0000070487us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-31 0000070487us-gaap:TradeNamesMember2020-06-30 0000070487us-gaap:TradeNamesMember2019-12-31 0000070487us-gaap:EmployeeStockOptionMember2020-04-012020-06-30 0000070487us-gaap:EmployeeStockOptionMember2019-04-012019-06-30 0000070487us-gaap:EmployeeStockOptionMember2020-01-012020-06-30 0000070487us-gaap:EmployeeStockOptionMember2019-01-012019-06-30 0000070487nrc:AmeritasLifeInsuranceCorpMember2020-04-012020-06-30 0000070487nrc:AmeritasLifeInsuranceCorpMember2019-04-012019-06-30 0000070487nrc:AmeritasLifeInsuranceCorpMember2020-01-012020-06-30 0000070487nrc:AmeritasLifeInsuranceCorpMember2019-01-012019-06-30 0000070487nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMembernrc:IMAFinancialGroupMember2020-01-012020-06-30 0000070487nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMembernrc:IMAFinancialGroupMember2020-04-012020-06-30 0000070487nrc:PracticingExcellencecomMember2020-04-012020-06-30 0000070487nrc:PracticingExcellencecomMember2019-04-012019-06-30 0000070487nrc:PracticingExcellencecomMember2020-01-012020-06-30 0000070487nrc:PracticingExcellencecomMember2019-01-012019-06-30 0000070487country:US2020-06-30 0000070487country:US2019-12-31 0000070487country:CA2020-06-30 0000070487country:CA2019-12-31
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the quarterly period ended June 30, 2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the transition period from ________ to ________

Commission File Number 001-35929

 

         National Research Corporation         

(Exact name of Registrant as specified in its charter)

 

Wisconsin

 

47-0634000

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

1245 Q Street, Lincoln, Nebraska          68508

 

 

(Address of principal executive offices) (Zip Code)

 

 

 

(402) 475-2525

 

 

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.001 par value

NRC

The NASDAQ stock market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer     

Non-accelerated filer

☐    

Smaller reporting company

 

 

Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes     No  ☒ 

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

Common Stock, $.001 par value, outstanding as of July 28, 2020: 25,241,049

 

 

 

 

NATIONAL RESEARCH CORPORATION

 

FORM 10-Q INDEX

 

For the Quarter Ended June 30, 2020

 

 

 

Page No.

 

 

 

PART I.

FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Financial Statements

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets

3

 

 

Condensed Consolidated Statements of Income

4

 

 

Condensed Consolidated Statements of Comprehensive Income

5

 

 

Condensed Consolidated Statements of Shareholders’ Equity

6-7

 

 

Condensed Consolidated Statements of Cash Flows

8

 

 

Notes to Condensed Consolidated Financial Statements

9-20

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21-28

 

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

29

 

 

 

 

 

Item 4.

Controls and Procedures

29

 

 

 

 

PART II.

OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

30

 

 

 

 

 

Item 1A.

Risk Factors

30

 

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

30

 

 

 

 

 

Item 6.

Exhibits

31

 

 

 

 

Signatures

32

 

 

Special Note Regarding Forward-Looking Statements

 

Certain matters discussed in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), “believes,” “expects,” “may,” “could,” “anticipates,” or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Quarterly Report on Form 10-Q, statements regarding the future value and utility of, and market demand for, our service offerings, our ability to compete successfully in the future, future opportunities for growth with respect to new and existing clients, future acquisition opportunities, future consolidation in the healthcare industry, the future adequacy of our liquidity sources, future revenue sources, future capital expenditures, the future phase out of LIBOR and applicable replacement benchmark rates, future impact of the February 2020 ransomware attack and the expected impact of the COVID-19 pandemic and related government mandates and recommendations, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

 

 

The likelihood that the COVID-19 pandemic will adversely affect our sales, earnings, financial condition and liquidity;

 

 

The possibility of non-renewal of our client service contracts and retention of key clients;

 

 

Our ability to compete in our markets, which are highly competitive with new market entrants, and the possibility of increased price pressure and expenses;

 

 

The effects of an economic downturn;

 

 

The impact of consolidation in the healthcare industry;

 

 

The impact of federal healthcare reform legislation or other regulatory changes;

 

 

Our ability to attract and retain key managers and other personnel;

 

 

The possibility that our intellectual property and other proprietary information technology could be copied or independently developed by our competitors;

 

 

The possibility for failures or deficiencies in our information technology platform;

 

 

The possibility that we could be subject to cyber-attacks, security breaches or computer viruses; and 

 

 

The factors set forth under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, as such section may be updated or supplemented by Part II, Item 1A of our subsequently filed Quarterly Reports on Form 10-Q (including this Report).

 

Shareholders, potential investors and other readers are urged to consider these and other factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Quarterly Report on Form 10-Q and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as required by the federal securities laws.

 

 
 

PART I – Financial Information

ITEM 1. Financial Statements

  

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts and par value)

 

  

June 30,

2020

  

December 31,

2019

 
  

(unaudited)

     

Assets

        

Current assets:

        

Cash and cash equivalents

 $11,957  $13,517 

Trade accounts receivable, less allowance for doubtful accounts of $143 and $144, respectively

  19,882   11,639 

Prepaid expenses

  2,823   2,038 

Income taxes receivable

  272   69 

Other current assets

  1,763   1,894 

Total current assets

  36,697   29,157 
         

Net property and equipment

  12,355   13,530 

Intangible assets, net

  1,541   1,728 

Goodwill

  57,829   57,935 

Deferred contract costs, net

  4,582   4,204 

Operating lease right-of-use assets

  1,312   1,628 

Other

  2,465   2,503 

Total assets

 $116,781  $110,685 
         

Liabilities and Shareholders’ Equity

        

Current liabilities:

        

Current portion of notes payable

 $3,966  $4,378 

Accounts payable

  957   1,279 

Accrued wages, bonus and profit sharing

  6,830   6,086 

Accrued expenses

  2,925   3,408 

Income taxes payable

  308   366 

Dividends payable

  -   5,239 

Deferred revenue

  16,275   16,354 

Other current liabilities

  1,007   1,045 

Total current liabilities

  32,268   38,155 
         

Notes payable, net of current portion and unamortized debt issuance costs

  28,627   29,795 

Deferred income taxes

  7,727   7,399 

Other long term liabilities

  2,585   2,444 

Total liabilities

  71,207   77,793 
         

Shareholders’ equity:

        

Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

  -   - 

Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,553,546 in 2020 and 30,151,574 in 2019, outstanding 25,235,123 in 2020 and 24,947,500 in 2019

  31   30 

Additional paid-in capital

  167,808   162,154 

Retained earnings (accumulated deficit)

  (79,165

)

  (93,357

)

Accumulated other comprehensive loss, foreign currency translation adjustment

  (2,872

)

  (2,209

)

Treasury stock, at cost; 5,318,423 Common shares in 2020 and 5,204,074 shares in 2019

  (40,228

)

  (33,726

)

Total shareholders’ equity

  45,574   32,892 

Total liabilities and shareholders’ equity

 $116,781  $110,685 

 

 See accompanying notes to condensed consolidated financial statements

 

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share amounts, unaudited)

 

   

Three months ended
June 30,

   

Six months ended
June 30,

 
   

2020

   

2019

   

2020

   

2019

 
                                 

Revenue

  $ 31,166     $ 31,414     $ 65,026     $ 62,894  
                                 

Operating expenses:

                               

Direct

    11,634       11,506       24,180       23,160  

Selling, general and administrative

    8,852       8,319       17,600       16,026  

Depreciation and amortization

    1,405       1,440       2,777       2,855  

Total operating expenses

    21,891       21,265       44,557       42,041  
                                 

Operating income

    9,275       10,149       20,469       20,853  
                                 

Other income (expense):

                               

Interest income

    2       8       13       14  

Interest expense

    (450

)

    (533

)

    (914

)

    (1,103

)

Other, net

    (270

)

    (139

)

    360       (419

)

                                 

Total other income (expense)

    (718

)

    (664

)

    (541

)

    (1,508

)

                                 

Income before income taxes

    8,557       9,485       19,928       19,345  
                                 

Provision for income taxes

    842       2,092       458       3,756  
                                 

Net income

  $ 7,715     $ 7,393     $ 19,470     $ 15,589  
                                 

Earnings Per Share of Common Stock:

                               

Basic Earnings Per Share

  $ 0.31     $ 0.30     $ 0.78     $ 0.63  

Diluted Earnings Per Share

  $ 0.30     $ 0.29     $ 0.76     $ 0.61  
                                 

Weighted average shares and share equivalents outstanding:

                               

Basic

    25,148       24,789       25,060       24,777  

Diluted

    25,680       25,586       25,702       25,549  

 

See accompanying notes to condensed consolidated financial statements

 

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, unaudited)

 

   

Three months ended
June 30,

   

Six months ended

June 30,

 
   

2020

   

2019

   

2020

   

2019

 
                                 

Net income

  $ 7,715     $ 7,393     $ 19,470     $ 15,589  

Other comprehensive income:

                               

Foreign currency translation adjustment

    461       255       (663 )     620  

Other comprehensive income

  $ 461     $ 255     $ (663 )   $ 620  
                                 

Comprehensive Income

  $ 8,176     $ 7,648     $ 18,807     $ 16,209  

 

See accompanying notes to condensed consolidated financial statements.

 

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED Consolidated Statements of Shareholders’ Equity

(In thousands except share and per share amounts, unaudited)

  

  

Common
Stock

  

Additional
Paid-in
Capital

  

Retained
Earnings

(Accumulated

Deficit)

  

Accumulated

Other
Comprehensive
Income (Loss)

  

Treasury

Stock

  

Total

 

Balances at December 31, 2019

 $30  $162,154  $(93,357

)

 $(2,209

)

 $(33,726

)

 $32,892 

Purchase of 75,980 shares treasury stock

  --   --   --   --   (4,425

)

  (4,425

)

Issuance of 260,481 common shares for the exercise of stock options

  --   3,145   --   --   --   3,145 

Non-cash stock compensation expense

  --   332   --   --   --   332 

Dividends declared of $0.21 per common share

  --   --   (5,278

)

  --   --   (5,278

)

Other comprehensive loss, foreign currency translation adjustment

  --   --   --   (1,124

)

  --   (1,124

)

Net income

  --   --   11,755   --   --   11,755 

Balances at March 31, 2020

 $30  $165,631  $(86,880

)

 $(3,333

)

 $(38,151

)

 $37,297 

Purchase of 38,369 shares treasury stock

  --   --   --   --   (2,077)  (2,077)

Issuance of 148,284 common shares for the exercise of stock options

  1   2,036   --   --   --   2,037 

Forfeitures of 6,793 restricted common shares

  --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   141   --   --   --   141 

Other comprehensive income, foreign currency translation adjustment

  --   --   --   461   --   461 

Net income

  --   --   7,715   --   --   7,715 

Balances at June 30, 2020

 $31  $167,808  $(79,165

)

 $(2,872

)

 $(40,228

)

 $45,574 

 

See accompanying notes to condensed consolidated financial statements.

 

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED Consolidated Statements of Shareholders’ Equity

(In thousands except share and per share amounts, unaudited)

  

  

Common
Stock

(formerly

Class A)

  

Additional
Paid-in
Capital

  

Retained
Earnings

(Accumulated
Deficit)

  

Accumulated

Other
Comprehensive
Income (Loss)

  

Treasury

Stock

  

Total

 

Balances at December 31, 2018

 $30  $157,312  $(106,339

)

 $(2,916

)

 $(29,004

)

 $19,083 

Purchase of 28,657 shares treasury stock

  --   --   --   --   (1,116

)

  (1,116

)

Issuance of 86,247 common shares for the exercise of stock options

  --   633   --   --   --   633 

Issuance of 6,005 restricted common shares, net of (forfeitures)

  --   --   --   --   --   -- 

Non-cash stock compensation expense

  --   302   --   --   --   302 

Dividends declared of $0.19 per common share

  --   --   (4,724

)

  --   --   (4,724

)

Other comprehensive income, foreign currency translation adjustment

  --   --   --   365   --   365 

Net income

  --   --   8,196   --   --   8,196 

Balances at March 31, 2019

 $30  $158,247  $(102,867

)

 $(2,551

)

 $(30,120

)

 $22,739 

Purchase of 2,977 shares treasury stock

  --   --   --   --   (137

)

  (137

)

Issuance of 18,000 common shares for the exercise
of stock options

  --   137   --   --   --   137 

Non-cash stock compensation expense

  --   307   --   --   --   307 

Dividends declared of $0.19 per common share

  --   --   (4,727

)

  --   --   (4,727

)

Other comprehensive income, foreign currency
translation adjustment

  --   --   --   255   --   255 

Net income

  --   --   7,393   --   --   7,393 

Balances at June 30, 2019

 $30  $158,691  $(100,201

)

 $(2,296

)

 $(30,257

)

 $25,967 

 

See accompanying notes to condensed consolidated financial statements.

 

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

 

   

Six months ended

 
   

June 30,

 
   

2020

   

2019

 

Cash flows from operating activities:

               

Net income

  $ 19,470     $ 15,589  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    2,777       2,855  

Deferred income taxes

    328       472  

Reserve for uncertain tax positions

    143       (251

)

Non-cash share-based compensation expense

    473       609  

Loss on disposal of property and equipment

    -       40  

Net changes in assets and liabilities:

               

Trade accounts receivable

    (8,382

)

    (3,088

)

Prepaid expenses and other current assets

    (557

)

    118  

Deferred contract costs, net

    (379

)

    (259

)

Operating lease assets and liabilities, net

    (1

)

    (4

)

Accounts payable

    (338

)

    432  

Accrued expenses, wages, bonuses and profit sharing

    713       (222

)

Income taxes receivable and payable

    (263

)

    (881

)

Deferred revenue

    (81

)

    696  

Net cash provided by operating activities

    13,903       16,106  
                 

Cash flows from investing activities:

               

Purchases of property and equipment

    (1,427

)

    (2,280

)

Net cash used in investing activities

    (1,427

)

    (2,280

)

                 

Cash flows from financing activities:

               

Borrowings on line of credit

    -       16,500  

Payments on line of credit

    -       (15,500

)

Payments on notes payable

    (1,600

)

    (1,837

)

Payments on finance lease obligations

    (124

)

    (161

)

Proceeds from the exercise of stock options

    538       -  

Payment of employee payroll tax withholdings on share-based awards exercised

    (1,859

)

    (483

)

Payment of dividends on common stock

    (10,517

)

    (21,837

)

Net cash used in financing activities

    (13,562

)

    (23,318

)

                 

Effect of exchange rate changes on cash

    (474

)

    521  

Change in cash and cash equivalents

    (1,560

)

    (8,971

)

Cash and cash equivalents at beginning of period

    13,517       12,991  

Cash and cash equivalents at end of period

  $ 11,957     $ 4,020  
                 

Supplemental disclosure of cash paid for:

               

Interest, net of capitalized amounts

  $ 884     $ 1,066  

Income taxes

  $ 261     $ 4,404  

Supplemental disclosure of non-cash investing and financing activities:

               

Finance lease obligations originated for property and equipment

  $ 105     $ 167  

Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans

  $ 4,644     $ 770  

 

See accompanying notes to condensed consolidated financial statements.

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

  

  

 

 

(1)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Description of business and basis of presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. 

 

Our six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet other aggregation criteria from the Financial Accounting Standards Board (“FASB”) guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.

 

Our condensed consolidated balance sheet at December 31, 2019 was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.

 

Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2020.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Our Canadian subsidiary uses as its functional currency the local currency of the country in which it operates. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the condensed consolidated statements of income. 

 

9


Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 2 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

Identify the contract, or contracts, with a customer;

 

Identify the performance obligations in the contract;

 

Determine the transaction price;

 

Allocate the transaction price to the identified performance obligations; and

 

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.  

 

10

 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $599,000 and $741,000 in the three months ended June 30, 2020 and 2019, respectively. The company deferred incremental costs of obtaining a contract of $2.2 million and $1.6 million in the six-month periods ended June 30, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at June 30, 2020 and December 31, 2019, respectively. Total amortization by expense classification for the three and six-months ended June 30, 2020 and 2019 was as follows:

 

  

Three months

ended
June 30, 2020

  

Three months

ended
June 30, 2019

  

Six month

ended
June 30, 2020

  

Six months

ended
June 30, 2019

 
  

(In thousands)

 

Direct Expenses

 $60  $13  $178  $19 

Selling, general and administrative expenses

  851   628   1,624   1,309 

Total amortization

 $911  $641  $1,802  $1,328 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $3,000 and $1,000 for the three months ended June 30, 2020 and 2019, respectively and $4,000 and $21,000 in the six months ended June 30, 2020 and 2019, respectively.

 

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our condensed consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Some billing and collections efforts were delayed due to the security incident in the first quarter until we received the forensic report in the second quarter, resulting in an increase in accounts receivable. Additionally, the COVID-19 pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the second quarter of 2020 due to our clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the six months ended June 30, 2020 and 2019 (In thousands):

 

  

Balance at

Beginning of

Period

  

Bad Debt

Expense

(Benefit)

  

Write-offs

  

Recoveries

  

Balance at

End of Period

 
                     

Six months ended June 30, 2020

 $144  $40  $62  $21  $143 

Six months ended June 30, 2019

 $176  $(25

)

 $37  $10  $124 

 

Leases

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

11

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

We elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Implementation Costs of Hosting Arrangements

 

When a software license is included in a cloud computing arrangement and we have the ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at June 30, 2020 and December 31, 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of June 30, 2020

                

Money Market Funds

 $3,067  $-  $-  $3,067 

Total Cash Equivalents

 $3,067  $-  $-  $3,067 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $-  $-  $3,662 

Total Cash Equivalents

 $3,662  $-  $-  $3,662 

 

There were no transfers between levels during the three-month period ended June 30, 2020.

 

Our long-term debt described in Note 4 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit. The following are the carrying amount and estimated fair values of long-term debt:

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $32,681  $34,281 

Estimated fair value of long-term debt

 $35,293  $35,205 

 

12

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of June 30, 2020, and December 31, 2019, there was no indication of impairment related to these assets.

 

Annually, we consider whether the recorded goodwill and indefinite lived intangibles have been impaired. However, goodwill and intangibles must be tested between annual tests if an event occurs or circumstances change to indicate that it is more likely than not that an impairment loss has been incurred (“triggering event”). We considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on each of our reporting units. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an interim impairment test to be performed as it is not more likely than not that an impairment loss has been incurred at June 30, 2020.

 

Our Canadian reporting unit generates service revenue from a relatively small number of customers with approximately 62.2% of its annual revenue concentrated in one customer contract which currently expires in March 2021. While historically we have been successful in renewing or retaining contracts with our customers, should we be unable to or choose not to renew a significant contract, it would likely result in an impairment of goodwill at this reporting unit. The carrying amount of goodwill related to our Canadian reporting unit at June 30, 2020 was $2.3 million.

 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. There were no outstanding claims at June 30, 2020.

 

A sales tax accrual of $775,000 was recorded in 2019 after we became aware that a state sales tax liability was both probable and estimable as of December 31, 2019, due to sales taxes that should have been collected from customers in 2019 and certain previous years. In addition, we incurred additional sales tax expense in the three and six-month periods ended June 30, 2020 of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the second quarter of 2020. We began collecting sales tax in July 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In July 2020, we received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020.

 

We received $2.4 million in insurance recoveries in the three-month period ended June 30, 2020, and $400,000 was paid directly to certain vendors from the insurer related to the February incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the three-month period ended June 30, 2020, and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the February incident has not had and we do not expect it to have a significant impact on our consolidated financial statements.

  

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

 

13

 
 

(2)

CONTRACTS WITH CUSTOMERS

 

The following table disaggregates revenue for the three and six-month periods ending June 30, 2020 and 2019 based on timing of revenue recognition (in thousands):

 

  

Three months ended

  

Six months ended

 
  

June 30, 2020

  

June 30, 2019

  

June 30, 2020

  

June 30, 2019

 

Subscription services recognized ratably over time

 $29,572  $27,918  $59,993  $55,831 

Services recognized at a point in time

  191   1,625   1,287   2,625 

Fixed, non-subscription recognized over time

  158   506   675   1,040 

Unit price services recognized over time

  1,245   1,365   3,071   3,398 

Total revenue

 $31,166  $31,414  $65,026  $62,894 

 

Our solutions within the digital VoC platform accounted for 72.9% and 62.1% of total revenue, in the three-month periods ending June 30, 2020 and 2019, respectively, and 70.9% and 60.0% of total revenue in the six-month periods ending June 30, 2020 and 2019, respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

June 30,

2020

  

December 31,

2019

 

Accounts receivables

 $19,882  $11,639 

Contract assets included in other current assets

 $120  $103 

Deferred Revenue

 $(16,275

)

 $(16,354

)

 

Significant changes in contract assets and contract liabilities during the three and six-months ended June 30, 2020 and 2019 are as follows (in thousands): 

 

  

Six months ended
June 30, 2020

  

Six months ended
June 30, 2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(11,934

)

 $-  $(12,226

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   11,821   -   12,751 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (85

)

  -   (46

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

      34       219 

Decreases due to impairment

  -   -   -   - 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  102   -   223   - 

 

We applied the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at June 30, 2020 approximated $281,000, of which $161,000 and $120,000 are expected to be recognized during 2020 and 2021, respectively.

 

14

 
 

(3)

INCOME TAXES

 

The effective tax rate for the three-month period ended June 30, 2020 decreased to 9.8% compared to 22.1% for the same period in 2019 and for the six-month period ended June 30, 2020 decreased to 2.3% compared to 19.4% for the same period in 2019 primarily from the exercise and vesting of shared-based compensation awards partially offset by higher state income taxes since we are filing in more states.

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $237,000 of employer social security tax payments into future years. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

 

 

(4)

NOTES PAYABLE

 

Our long-term debt consists of the following:  

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Term Loans

 $32,681  $34,281 

Less: current portion

  (3,966

)

  (4,378

)

Less: unamortized debt issuance costs

  (88

)

  (108

)

Notes payable, net of current portion

 $28,627  $29,795 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%.

 

Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.43% at June 30, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of June 30, 2020, and December 31, 2019, the Line of Credit did not have a balance. There were no borrowings on the Line of Credit for three and six-month periods ended June 30, 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions.. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities.

As of June 30, 2020, we were in compliance with our financial covenants.

 

15

 
 

(5)

SHARE-BASED COMPENSATION

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.

 

Our 2001 Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over one to five years following the date of grant and option terms are generally five to ten years following the date of grant. Due to the expiration of the 2001 Equity Incentive Plan at December 31, 2015, there were no shares of stock available for future grants.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. Beginning in 2018, on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common Stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant.

 

During the six months ended June 30, 2020 and 2019, we granted options to purchase 70,471 and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2020

  

2019

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

Expected stock price volatility

  33.62

%

  34.01

%

Risk-free interest rate

  1.35

%

  2.38

%

Expected life of options (in years)

  7.4   7.5 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

16

 

The following table summarizes stock option activity under the 2001 and 2006 Equity Incentive Plans and the 2004 Director Plan for the six-month period ended June 30, 2020:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Outstanding at December 31, 2019

  1,245,922  $18.08   4.45  $59,631 

Granted

  70,471  $62.23         

Exercised

  (408,765

)

 $12.68      $17,810 

Forfeited

  (15,490) $48.42         

Outstanding at June 30, 2020

  892,138  $23.51   5.77  $31,281 

Exercisable at June 30, 2020

  492,484  $17.55   4.58  $20.022 

 

As of June 30, 2020, the total unrecognized compensation cost related to non-vested stock option awards was approximately $2.1 million which was expected to be recognized over a weighted average period of 3.2 years.

 

There was $538,000 of cash received from stock options exercised for the three months ended June 30, 2020 and no cash was received from the exercise of options in the same period of 2019. We recognized $216,000 and $235,000 of non-cash compensation for three months ended June 30, 2020 and 2019, respectively, and $498,000 and $464,000 of non-cash compensation for the six months ended June 30, 2020 and 2019, respectively, related to options, which is included in direct fixed and selling, general and administrative expenses.

 

During the six months ended June 30, 2019, we granted 6,005 non-vested shares of Common Stock under the 2006 Equity Incentive Plan. No shares were granted during the six months ended June 30, 2020. As of June 30, 2020, we had 42,761 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized ($75,000) and $73,000 of non-cash compensation for the three months ended June 30, 2020 and 2019, respectively, and ($26,000) and $145,000 of non-cash compensation for the six months ended June 30, 2020 and 2019, respectively, related to this non-vested stock, which is included in direct fixed and selling, general and administrative expenses. During the six months ended June 30 2020, 34,622 shares vested and 6,793 shares were forfeited.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plan for the six-month period ended June 30, 2020:

 

  

Common

Shares

Outstanding

  

Weighted

Average

Grant Date Fair

Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  -   - 

Vested

  (34,622

)

  13.17 

Forfeited

  (6,793

)

 $36.80 

Outstanding at June 30, 2020

  42,761  $17.40 

 

As of June 30, 2020, the total unrecognized compensation cost related to non-vested stock awards was approximately $187,000 and is expected to be recognized over a weighted average period of 3.05 years.

 

17

 
 

(6)

GOODWILL AND OTHER INTANGIBLE ASSETS

 

The following represents a summary of changes in the carrying amount of goodwill for the six-month period ended June 30, 2020:
 

  

(In thousands)

 

Balance as of December 31, 2019

 $57,935 

Foreign currency translation

  (106

)

Balance as of June 30, 2020

 $57,829 

 

Intangible assets consisted of the following:

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Non-amortizing intangible assets:

        

Indefinite trade name

 $1,191  $1,191 

Amortizing intangible assets:

        

Customer related

  9,326   9,338 

Technology

  1,360   1,360 

Trade names

  1,572   1,572 

Total amortizing intangible assets

  12,258   12,270 

Accumulated amortization

  (11,908

)

  (11,733

)

Other intangible assets, net

 $1,541  $1,728 

 

  

 

 

(7)

PROPERTY AND EQUIPMENT

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Property and equipment

 $43,477  $42,078 

Accumulated depreciation

  (31,122

)

  (28,548

)

Property and equipment, net

 $12,355  $13,530 

 

 

 

(8)

EARNINGS PER SHARE

 

Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

18

 

We had 57,719 and 83,225 options of Common Stock for the three-month periods ended June 30, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. We had 52,789 and 143,247 options of Common Stock for the six-month periods ended June 30, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

For the Three Months Ended June 30

  

For the Six Months Ended June 30

 
  

2020

  

2019

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share – basic:

 $7,715  $7,393  $19,470  $15,589 

Net income

                

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (15

)

  (25

)

  (38

)

  (53

)

Net income attributable to common shareholders

  7,700   7,368   19,432   15,536 

Denominator for net income per share – basic:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Net income per share – basic

 $0.31  $0.30  $0.78  $0.63 

Numerator for net income per share – diluted:

                

Net income attributable to common shareholders for basic computation

  7,700   7,368   19,432   15,536 

Denominator for net income per share – diluted:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Weighted average effect of dilutive securities – stock options

  532   797   642   772 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,680   25,586   25,702   25,549 

Net income per share - diluted

 $0.30  $0.29  $0.76  $0.61 

 

 

 

 

 

(9

RELATED PARTY

 

Until January 2020, one of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to serve on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $42,000 and $67,000 in the three-month periods ended June 30, 2020 and 2019, respectively and $114,000 and $127,000 in the six-month periods ended June 30, 2020 and 2019, respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. These purchases totaled $478,000 in the three and six-month periods ended June 30, 2020, respectively.

 

During 2017, we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement was $83,000 and $170,000 in the three-month periods ended June 30, 2020 and 2019, respectively, and $166,000 and $323,000 in six-month periods ended June 30, 2020 and 2019, respectively. We will no longer earn revenue under this agreement after June 30, 2021.

 

19

  
 

(10

SEGMENT INFORMATION

 

The Company’s six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations. The table below presents entity-wide information regarding the Company’s assets, after elimination of intercompany balances by geographic area:

 

  

June 30, 2020

  

December 31, 2019

 
  

(In thousands)

 

Long-lived assets:

        

United States

 $77,621  $78,906 

Canada

  2,463   2,622 

Total

 $80,084  $81,528 

Total assets:

        

United States

 $101,134  $95,668 

Canada

  15,647   15,017 

Total

 $116,781  $110,685 

  

20

 
 

ITEM 2.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our results of operations and financial conditions should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

 

We are a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations. Our solutions enable our clients to understand the voice of the customer with greater clarity, immediacy and depth. Our heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for and design experiences that inspire loyalty and trust, while also facilitating regulatory compliance and the shift to population-based health management. Our ability to measure what matters most and systematically capture, analyze and deliver insights based on self-reported information from patients, families and consumers is critical in today’s healthcare market. We believe that access to and analysis of our extensive consumer-driven information is becoming more valuable as healthcare providers increasingly need to more deeply understand and engage the people they serve to build customer loyalty.

 

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. We partner with clients across the continuum of healthcare services. Our clients include integrated health systems, post-acute providers and payer organizations. We believe this cross-continuum positioning is a unique and an increasingly important capability as evolving payment models drive healthcare providers and payers towards a more collaborative and integrated service model.

 

The outbreak of COVID-19, and the associated responses, have impacted our business in a variety of ways.  Governments have implemented business and travel restrictions, recommended social distancing and other guidelines, and temporarily suspended the requirement for certain healthcare organizations to periodically assess the performance of the care they provide (although many providers continue to do so). Many businesses, including many of our clients, have de-emphasized external business opportunities and restricted in-person meetings while shifting their attention toward addressing COVID-19 planning, business disruptions, higher costs, and revenue shortfalls. At NRC, our workforce remains intact and highly engaged.  The vast majority of our associates are working remotely, and to date we have been capable of providing our services without significant disruption. Historically, we have relied on national travel as part of our sales efforts, but as a result of the pandemic we have placed an indefinite hold on all company related travel. The duration and severity of the COVID-19 pandemic and associated responses on our business, including the impact on our revenue, expenses, and cash flows, cannot be predicted at this time.  Some clients cost reducing measures have included and could continue to include reducing or eliminating the services they purchase from us. Based on the foregoing, we do not expect our recent revenue and earnings growth to be indicative of future expectations.  We do, however, expect to have adequate sources of liquidity to meet our current and expected needs for the foreseeable future.

 

We received $2.4 million in insurance recoveries in the three-month period ended June 30, 2020, and $400,000 was paid directly to certain vendors from the insurer related to the February incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the three-month period ended June 30, 2020, and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the February incident has not had and we do not expect it to have a significant impact on our consolidated financial statements or liquidity.

 

 

Results of Operations

 

The following table and graphs set forth, for the periods indicated, selected financial information derived from our consolidated financial statements, including amounts expressed as a percentage of total revenue and the percentage change in such items versus the prior comparable period (please note that all columns may not add up to 100% due to rounding). The trends illustrated in the following table and graphs may not necessarily be indicative of future results. The discussion that follows the information should be read in conjunction with our consolidated financial statements.

 

 

   

Three months ended June 30,

   

Six months ended June 30,

 
   

2020

   

2019

   

2020

   

2019

 
                                 

Revenue:

    100.0

%

    100.0

%

    100.0

%

    100.0

%

                                 

Operating expenses:

                               

Direct

    37.3       36.6       37.2       36.8  

Selling, general and administrative

    28.4       26.5       27.1       25.5  

Depreciation and amortization

    4.5       4.6       4.3       4.5  

Total operating expenses

    70.2       67.7       68.6       66.8  
                                 

Operating income

    29.8

%

    32.3

%

    31.4

%

    33.2

%

 

 

 

Three Months Ended June 30, 2020, Compared to Three Months Ended June 30, 2019

 

Revenue. Revenue for the three-month period ended June 30, 2020, decreased 0.8% to $31.2 million, compared to $31.4 million, in the three-month period ended June 30, 2019. The decrease was due to revenue reductions from COVID-19 as some clients have reduced or eliminated services they purchase from us as cost reducing measures, partially offset by growth in overall contract value.

 

Direct expenses. Direct expenses increased 1.1% to $11.6 million for the three-month periods ended June 30, 2020, compared to $11.5 million for the same period in 2019. This was due to an increase in fixed expenses of $1.1 million, partially offset by a decrease in variable expenses of $1.0 million. Fixed expenses increased primarily as a result of increased salary and benefit costs and contracted services in the customer service and information technology areas partially offset by lower travel and meal costs due to restricted travel associated with COVID-19. Variable expenses decreased due to less postage, printing, and paper costs, primarily resulting from increased use of digital survey methodologies and decreased conference expenses due to rescheduling of a conference on account of COVID-19. Direct expenses as a percentage of revenue were 37.3% in the three-month period ended June 30, 2020 and 36.6% for the same period in 2019 as expenses increased by 1.1% while revenue for the same period decreased by 0.8% in the June 30, 2020 period compared to the same period in 2019.

 

Selling, general and administrative expenses. Selling, general and administrative expenses increased 6.4% to $8.9 million for the three-month period ended June 30, 2020, compared to $8.3 million for the same period in 2019, primarily due to an increase in salary and benefit costs of $487,000, increased software and platform hosting expenses of $382,000, additional contracted services of $125,000, increased company incentive event costs of $75,000, higher building repair costs of $41,000 and increased business insurance costs of $34,000. These were partially offset by lower travel and meals costs of $447,000 due to restricted travel associated with COVID-19 and lower marketing costs of $161,000. Selling, general and administrative expenses as a percentage of revenue were 28.4% in the three-month periods ended June 30, 2020 and 26.5% for the same period in 2019 as expenses increased by 6.4% and revenue decreased by 0.8% in the June 30, 2020 period compared to the same period in 2019.

 

Depreciation and amortization. Depreciation and amortization was $1.4 million for the three-month period ended June 30, 2020 and 2019. Depreciation and amortization expense as a percentage of revenue was 4.5% for the three-month period ended June 30, 2020, and 4.6% for the same period in 2019.

 

Other income (expense). Other expense, net increased to $718,000 for the three-month period ended June 30, 2020, compared to other expense, net of $664,000 for the same period in 2019, primarily due to foreign exchange rate changes, partially offset by decreased interest expense. Interest expense decreased to $450,000 in the 2020 period from $533,000 for the same period in 2019 primarily due to the declining balance on our Term Loan and no borrowings on our Line of Credit during the 2020 period. Other non-interest expense increased to $270,000 in the 2020 period compared to other expense of $139,000 for the same period of 2019 primarily due to revaluation on intercompany transactions due to changes in the foreign exchange rate.

 

Income tax provision. Income tax provision was $842,000 for the three-month period ended June 30, 2020, compared to $2.1 million for the same period in 2019. The effective tax rate for the three-month period ended June 30, 2020 decreased to 9.8% compared to 22.1% primarily due to increased tax benefits of $1.1 million from the exercise and vesting of share-based compensation awards, partially offset by higher state income taxes since we are filing in more states. 

 

 

 

Six Months Ended June 30, 2020, Compared to Six Months Ended June 30, 2019

 

Revenue. Revenue for the six-month period ended June 30, 2020, increased 3.4% to $65.0 million, compared to $62.9 million in the six-month period ended June 30, 2019. The increase was due to new customer sales, as well as increases in sales to the existing client base. Revenue growth was partially offset by revenue reductions due to COVID-19 as some clients have reduced or eliminated the services they purchase from us as cost reducing measures.

 

Direct expenses. Direct expenses increased 4.4% to $24.2 million for the six-month period ended June 30, 2020, compared to $23.2 million in the same period in 2019. This was due to an increase in fixed expenses of $2.6 million, partially offset by a decrease in variable expenses of $1.6 million. Fixed expenses increased primarily as a result of increased salary and benefit and contracted services costs in the customer service and information technology areas, partially offset by decreased travel and meal costs due to restricted travel from COVID-19. Variable expense decreased mainly due to less postage, printing and paper costs due to lower volumes and increased use of digital survey methodologies. Direct expenses increased as a percentage of revenue to 37.2% in the six-month period ended June 30, 2020, compared to 36.8% during the same period of 2019, as expenses increased by 4.4% while revenue for the same period increased by 3.4%.

 

Selling, general and administrative expenses. Selling, general and administrative expenses increased 9.8% to $17.6 million for the six-month period ended June 30, 2020, compared to $16.0 million for the same period in 2019, primarily due to an increase in salary and benefit costs of $1.0 million, an increase in software license fees and platform hosting expenses of $558,000, an increase in company incentive event costs of $178,000, an increase in business insurance costs of $168,000, additional legal and accounting costs of $156,000 primarily due to an insurance refund of legal expenses associated with litigation related to our April 2018 recapitalization (the “Recapitalization”) in the same period in 2019, an increase in contracted services of $130,000, higher bad debt expense of $65,000 and sales tax expense of $58,000. These were partially offset by a decrease in travel and meals costs of $572,000 due to restricted travel associated with COVID-19 and a decrease in marketing costs of $184,000. Selling, general, and administrative expenses increased as a percentage of revenue to 27.1% for the six-month period ended June 30, 2020, from 25.5% for the same period in 2019 as expenses increased by 9.8% while revenue increased by 3.4% in the 2020 period compared to the 2019 period.

 

Depreciation and amortization. Depreciation and amortization expenses decreased 2.7% to $2.8 million for the six-month period ended June 30, 2020, compared to $2.9 million for the same period in 2019, due to decreased depreciation from computer equipment investments. Depreciation and amortization expenses as a percentage of revenue were 4.3% for the six-month period ended June 30, 2020 and 4.5% for the same period in 2019.

 

Other income (expense). Other expense, net decreased to $541,000 for the six-month period ended June 30, 2020, compared to $1.5 million of other expense, net for the same period in 2019. Interest expense decreased $190,000 primarily due to the declining balance on our Term Loan and no borrowings on our Line of Credit during the 2020 period. Other non-interest income(expense), net changed to other income of $360,000 for the six-month period ended June 30, 2020 compared to other expense of $779,000 for the same period in 2019 primarily due to revaluation of intercompany transactions for changes in the foreign exchange rates.

 

Income tax provision. Income tax provision was $458,000 for the six-month period ended June 30, 2020, compared to $3.8 million for the same period in 2019. The effective tax rate for the six-month period ended June 30, 2020, decreased to a 2.3% effective tax rate from a 19.4% effective tax rate for the same period in 2019 primarily due to increased tax benefits of $3.7 million from the exercise and vesting of share-based compensation awards, partially offset by higher state income taxes since we are filing in more states.

 

 

Liquidity and Capital Resources

 

We believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows, will be sufficient to meet our current and expected needs for the foreseeable future.  Cash dividends in the aggregate amount of $10.5 million paid in the six-month period ended June 30, 2020 were funded with cash on hand. No dividends were declared in the three-month period ended June 30, 2020. Our board of directors considers whether to declare a dividend and the amount of any dividends declared on a quarterly basis. 

 

As of June 30, 2020, our principal sources of liquidity included $12.0 million of cash and cash equivalents, up to $30 million of unused borrowings under our Line of Credit and up to $15 million on our Delayed Draw Term Loan. Of this cash, $3.3 million was held in Canada. On May 28, 2020, the credit agreement with FNB was amended. As part of this amendment the Line of Credit was expanded from $15 million to $30 million. The Delayed Draw Term Loan can only be used to fund permitted future business acquisitions or repurchasing our Common Stock.

 

Working Capital

 

We had a working capital balance of $4.4 million and deficit of $9.0 million on June 30, 2020 and December 31, 2019, respectively. The change was primarily due to increases in trade accounts receivable of $8.2 million, prepaid expenses of $784,000, and income taxes receivable of $198,000; and decreases in dividends payable of $5.2 million, accrued expenses of $483,000, current portion of notes payable of $412,000 and accounts payable of $322,000. These were partially offset by decrease in cash and cash equivalents of $1.6 million and an increase in accrued wages, bonus and profit sharing of $744,000.

 

Trade accounts receivable increased due to the timing of billings and collections on new and renewal contracts. The COVID-19 pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the second quarter of 2020 due to our clients’ cash-flow issues. Accrued wages, bonus and profit sharing increased due to increased payroll accruals. Income taxes receivable changed due to the timing of income tax payments. Accounts payable, accrued expenses and prepaid expenses changed due to timing of payment for services and supplies. Dividends payable varies due to the timing of dividends being declared and paid. The current portion of notes payable decreased due to the changes in the payment terms due to amending the Term Loan. Our working capital is significantly impacted by our large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements. The deferred revenue balances as of June 30, 2020, and December 31, 2019, were $16.3 million and $16.4 million, respectively.

 

The deferred revenue balance is primarily due to timing of initial billings on new and renewal contracts. We typically invoice clients for services before they have been completed. Billed amounts are recorded as billings in excess of revenue earned, or deferred revenue, on our consolidated financial statements, and are recognized as income when earned. In addition, when work is performed in advance of billing, we record this work as revenue earned in excess of billings, or unbilled revenue. Substantially all deferred revenue and all unbilled revenue will be earned and billed, respectively, within 12 months of the respective period ends.

 

Cash Flow Analysis

 

A summary of operating, investing, and financing activities is shown in the following table: 

 

   

Six Months Ended June 30,

 
                 
   

2020

   

2019

 
   

(In thousands)

 

Provided by operating activities

  $ 13,903     $ 16,106  

Used in investing activities

    (1,427

)

    (2,280

)

Used in financing activities

    (13,562

)

    (23,318

)

Effect of exchange rate change on cash

    (474

)

    521  

Net change in cash and cash equivalents

    (1,560

)

    (8,971

)

Cash and cash equivalents at end of period

  $ 11,957     $ 4,020  

 

 

Cash Flows from Operating Activities

 

Cash flows from operating activities consist of net income adjusted for non-cash items including depreciation and amortization, deferred taxes, share-based compensation and related taxes, reserve for uncertain tax positions and the effect of working capital changes.

 

Net cash provided by operating activities was $13.9 million for the six-month period ended June 30, 2020, which included net income of $19.5 million, plus non-cash charges (benefits) for deferred income taxes, depreciation and amortization, reserve for uncertain tax positions and share-based compensation and related taxes totaling $3.7 million. Net changes in assets and liabilities decreased cash flows from operating activities by $9.3 million, primarily due to increases in trade accounts receivable, prepaid and other current assets, and deferred contract costs, as well as decreases in accounts payable, income taxes receivable and payable, which fluctuate due to the timing of payments of prepaids, accounts payable, accrued expenses, direct and incremental costs directly related to sales and timing of income tax payments. Deferred revenue also decreased, which will vary based on the timing and frequency of billings on annual agreements. These decreases to cash flows were partially offset by increases in accrued expenses, wages, bonuses, and profit sharing.

 

Net cash provided by operating activities was $16.1 million for the six-month period ended June 30, 2019, which included net income of $15.6 million, plus non-cash charges (benefits) for deferred tax expense, depreciation and amortization, reserve for uncertain tax positions, non-cash share-based compensation expense, and loss on disposal of property and equipment totaling $3.7 million. Net changes in assets and liabilities decreased cash flows from operating activities by $3.2 million, primarily due to increases in trade accounts receivable, deferred contract costs and decreases in accrued expense, wages, bonus and profit sharing, and income taxes payable and receivable which fluctuate with the timing of income tax payments, partially offset by decreases in prepaids and other current assets and increases in accounts payable and deferred revenue.

 

Cash Flows from Investing Activities

 

Net cash of $1.4 million and $2.3 million was used for investing activities in the six months ended June 30, 2020 and 2019, respectively. These expenditures consisted mainly of computer software classified in property and equipment. We expect similar capital expenditure purchases for the remainder of 2020, consisting primarily of computer software and hardware and other equipment, to be funded through cash generated from operations.

 

Cash Flows from Financing Activities


Net cash used in financing activities was $13.6 million in the six months ended June 30, 2020. Cash was used to repay borrowings under the term notes totaling $1.6 million and for finance lease obligations of $124,000. Cash was also used to pay $10.5 million of dividends on our common stock, and to pay payroll tax withholdings related to share-based compensation of $1.9 million. These decreases to cash flows were partially offset by proceeds from the exercise of stock options of $538,000.

 

Net cash used in financing activities was $23.3 million in the six months ended June 30, 2019. Cash was used to repay borrowings on the Line of Credit of $15.5 million, repay borrowings under the Term Loan totaling $1.8 million, and for finance lease obligations of $161,000. Cash was also used to pay $21.8 million of dividends on common stock, and to pay payroll tax withholdings related to share-based compensation of $483,000. Cash was provided from proceeds of the Line of Credit of $16.5 million.

 

The effect of changes in foreign exchange rates decreased cash and cash equivalents by $474,000 in the six months ended June 30, 2020 and increased cash and cash equivalents by $521,000 in the six months ended June 30, 2019.

 

Capital Expenditures

 

Cash paid for capital expenditures was $1.4 million for the six months ended June 30, 2020. These expenditures consisted mainly of computer software classified in property and equipment. We expect slightly higher capital expenditure purchases for the remainder of 2020 consisting primarily of computer software and hardware and building improvements to be funded through cash generated from operations.

 

 

Debt and Equity

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%.  

 

Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.43% at June 30, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of June 30, 2020, and December 31, 2019, the Line of Credit did not have a balance. There were no borrowings on the Line of Credit for three and six-month periods ended June 30, 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities. As of June 30, 2020, we were in compliance with our financial covenants.

 

All obligations under the Credit Facilities are to be guaranteed by each of our direct and indirect wholly owned domestic subsidiaries, if any, and, to the extent required by the Credit Agreement, direct and indirect wholly owned foreign subsidiaries (each, a “guarantor”).

 

The Credit Facilities are secured, subject to permitted liens and other agreed upon exceptions, by a first-priority lien on and perfected security interest in substantially all of our and our guarantors’ present and future assets (including, without limitation, fee-owned real property, and limited, in the case of the equity interests of foreign subsidiaries, to 65% of the outstanding equity interests of such subsidiaries).

 

LIBOR is currently expected to be phased out in 2021. We are required to pay interest on borrowings under our Line of Credit and Delayed Draw Term Loan at floating rates based on LIBOR. Future debt that we may incur may also require that we pay interest based upon LIBOR. Under the terms of our Credit Agreement with FNB, if LIBOR becomes unavailable during the term of the agreement, FNB may, in its reasonable discretion and in a manner consistent with market practice, designate a substitute index. We currently expect that the determination of interest under our Credit Agreement would be revised as to provide for an interest rate that approximates the existing interest rate as calculated in accordance with LIBOR. Despite our current expectations, we cannot be sure that if LIBOR is phased out or transitioned, the changes to the determination of interest under our agreements would approximate the current calculation in accordance with LIBOR. We do not know what standard, if any, will replace LIBOR if it is phased out or transitioned.

 

 

We have finance leases for computer equipment, office equipment, printing and inserting equipment. The balance of the finance leases as of June 30, 2020 was $767,000.

 

Shareholders’ equity increased $12.7 million to $45.6 million at June 30, 2020, from $32.9 million at December 31, 2019. The increase was mainly due to net income of $19.5 million and share-based compensation of $473,000. This was partially offset by dividends declared of $5.3 million, share repurchases exceeding the cost of stock options exercised of $1.3 million and changes in the cumulative translation adjustment of $663,000.

 

A sales tax accrual of $775,000 was recorded in 2019 after we became aware that a state sales tax liability was both probable and estimable as of December 31, 2019, due to sales taxes that should have been collected from customers in 2019 and certain previous years. In addition, we incurred additional sales tax expense in the three and six-month periods ended June 30, 2020 of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the second quarter of 2020. We began collecting sales tax in July 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In July 2020, we received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020.

 

 

Contractual Obligations

 

We had contractual obligations to make payments in the following amounts in the future as of June 30, 2020:

 

Contractual Obligations(1)

 

Total

Payments

   

Less than

One Year

   

One to

Three Years

   

Three to

Five Years

   

After

Five Years

 

(In thousands)

                                       

Operating leases

  $ 1,643     $ 410     $ 671     $ 445     $ 117  

Finance leases

    779       188       455       136       --  

Uncertain tax positions(2)

    --       --       --       --       --  

Long-term debt

    38,322       2,777       11,112       11,112       13,321  

Total

  $ 40,744     $ 3,375     $ 12,238     $ 11,693     $ 13,438  

 

(1)

Amounts are inclusive of interest payments, where applicable.

(2)

We have $742,000 in liabilities associated with uncertain tax positions. We are unable to reasonably estimate the expected cash settlement dates of these uncertain tax positions with the taxing authorities.

 

We generally do not make unconditional, non-cancelable purchase commitments. We enter into purchase orders in the normal course of business, but these purchase obligations do not exceed one year.

 

Stock Repurchase Program

 

Our Board of Directors authorized the repurchase of up to 2,250,000 then-existing class A shares and 375,000 then-existing class B shares of common stock in the open market or in privately negotiated transactions under a stock repurchase program that was originally approved in February 2006 and subsequently amended in May 2013. In connection with the Recapitalization in April 2018, our Board of Directors further amended the stock repurchase program to eliminate the repurchase of the former class B common stock. As of June 30, 2020, the remaining number of shares of Common Stock that could be purchased under this authorization was 280,491 shares. 

 

Critical Accounting Estimates

 

There have been no changes to our critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2019 that have a material impact on our Condensed Consolidated Financial Statements and the related Notes.

 

 

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

 

There are no material changes to the disclosures regarding our market risk exposures made in its Annual Report on Form 10-K for the year ended December 31, 2019.

 

 

ITEM 4.

Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report, and has concluded that, as of the end of such period, our disclosure controls and procedures were effective.

 

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended June 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II – Other Information

 

ITEM 1.

Legal Proceedings

 

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. There were no outstanding claims at June 30, 2020.

 

ITEM 1A.

Risk Factors

 

The significant risk factors known to us that could materially adversely affect our business, financial condition, or operating results are described in Part I, Item 2:  Management’s Discussion and analysis of Financial Condition and Results of Operations and in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2019, and in Part II, Item 1A of our quarterly report on Form 10-Q for the quarter ended March 31, 2020.

 

 

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

In February 2006 and subsequently amended in May 2013, our Board of Directors authorized the repurchase of 2,250,000 shares of class A common stock and 375,000 shares of class B common stock in the open market or in privately negotiated transactions. In connection with the Recapitalization in April 2018, our Board of Directors further amended the stock repurchase program to eliminate the repurchase of the former class B common stock. Unless terminated earlier by resolution of our Board of Directors, the repurchase program will expire when we have repurchased all shares of Common Stock authorized for repurchase thereunder. No Common Stock was repurchased under that authorization during the three-month period ended June 30, 2020. The remaining shares of Common Stock that may be purchased under that authorization are 280,491. Our Credit Agreement provides that, in order for us to pay dividends, there must be no default or event of default existing or that would result from such payment and we must show that we would comply with the Credit Agreement’s fixed charge coverage ratio and consolidated cash flow leverage ratio after giving pro forma effect to such payment.

 

 

ITEM 6.

Exhibits

 

The exhibits listed in the exhibit index below are filed as part of this Quarterly Report on Form 10-Q.

 

EXHIBIT INDEX  

 

Exhibit
Number

Exhibit Description

 

(3.1)

Amended and Restated Articles of Incorporation of National Research Corporation, effective as of 5:01 pm, CT, on April 17, 2018 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated April 16, 2018 and filed on April 20, 2018 (File No. 001-35929)] 

 

 

(3.2)

By-Laws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.1 to National Research Corporation’s Current Report on Form 8-K dated March 19, 2020 and filed on March 23, 2020 (File No. 001-35929)]

 

 

(4.1)

Amended and Restated Articles of Incorporation of National Research Corporation, effective as of 5:01 pm, CT, on April 17, 2018 [Incorporated by reference to Exhibit 3.3 to National Research Corporation’s Current Report on Form 8-K dated April 16, 2018 and filed on April 20, 2018 (File No. 001-35929)] 

 

 

(4.2)

By-Laws of National Research Corporation, as amended to date [Incorporated by reference to Exhibit 3.1 to National Research Corporation’s Current Report on Form 8-K dated March 19, 2020 and filed on March 23, 2020 (File No. 001-35929)]

 

(10.1)

Amended and Restated Credit Agreement dated May 28, 2020, between National Research Corporation and First National Bank of Omaha

 

(10.2) Form of Grant used in connection with the National Research Corporation 2004 Non-Employee Director Stock Plan, as amended
   

(31.1)

Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.

 

(31.2)

Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.

 

(32)

Written Statement of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

 

(101)

Financial statements from the Quarterly Report on Form 10-Q of National Research Corporation for the quarter ended June 30, 2020, formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Notes to Condensed Consolidated Financial Statements, and (vi) document and entity information.

   
(104) Cover Page Interactive Data File (formatted in the Inline XBRL and contained in Exhibit 101).

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

NATIONAL RESEARCH CORPORATION

 

 

 

 

 

 

 

 

Date: August 7, 2020

By:

/s/ Michael D. Hays 

 

 

 

Michael D. Hays

 

 

 

Chief Executive Officer (Principal

Executive Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

Date: August 7, 2020 

By:

/s/ Kevin R. Karas

 

 

 

Kevin R. Karas

Senior Vice President Finance,

Treasurer, Secretary and Chief

Financial Officer (Principal Financial

and Accounting Officer)

 

 

32
EX-10.1 2 ex_196045.htm EXHIBIT 10.1 ex_196045.htm

Exhibit 10.1

 

 

 

AMENDED AND RESTATED CREDIT AGREEMENT

 

by and between

 

NATIONAL RESEARCH CORPORATION,
as Borrower,

 

and

 

FIRST NATIONAL BANK OF OMAHA,
as Lender

 

______________________________

 

Dated as of May 28, 2020

 

______________________________

 

 

 

 

 

THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of May 28, 2020, is made and entered into by and between NATIONAL RESEARCH CORPORATION, a Wisconsin corporation (“Borrower”), and FIRST NATIONAL BANK OF OMAHA, a national banking association (“Lender”). All capitalized terms used herein and defined in Section 11 are used herein as therein defined.

 

W I T N E S S E T H:

 

WHEREAS, Borrower and Lender are parties to that certain Credit Agreement, dated as of April 18, 2018 (as amended or modified from time to time prior to the Effective Date, the “Existing Credit Agreement”);

 

WHEREAS, Borrower and Lender desire to amend and restate the Existing Credit Agreement to provide for loans and other financial accommodations to the Credit Parties and to make certain other amendments and modifications to the Existing Credit Agreement, all as more fully set forth herein; and

 

WHEREAS, subject to and upon the terms and conditions set forth herein, Lender is willing to amend and restate the Existing Credit Agreement and make available to Borrower the respective credit facilities provided for herein;

 

NOW, THEREFORE, IT IS AGREED:

 

Section 1     Amount and Terms of Credit.

 

1.01.     The Commitments.

 

(a)     Subject to and upon the terms and conditions set forth herein, Lender agrees to make, at any time and from time to time on or after the Effective Date and prior to the Revolving Loan Maturity Date, a revolving loan or revolving loans (each a “Revolving Loan” and, collectively, the “Revolving Loans”) to Borrower, which Revolving Loans (i) shall be denominated in Dollars, (ii) may be repaid and reborrowed in accordance with the provisions hereof, and (iii) shall not exceed in aggregate principal amount at any time the Revolving Loan Commitment.

 

(b)     On the date hereof, the principal amount outstanding under the Repurchase Term Loan (as defined in the Existing Credit Agreement) made pursuant to the Existing Credit Agreement is $33,002,068.79. Such amount shall be deemed to be outstanding as the repurchase term loan under this Agreement (the “Repurchase Term Loan”), and shall be subject to all the terms and conditions stated in this Agreement. The Repurchase Term Loan is fully funded and non-revolving and amounts repaid may not then be reborrowed.

 

(c)     Subject to and upon the terms and conditions set forth herein, Lender agrees to make, on or after the Effective Date and prior to the Delayed Draw-Down Term Loan Maturity Date, one or more term loans (each a “Delayed Draw-Down Term Loan” and collectively, the “Delayed Draw-Down Term Loans”) which Delayed Draw-Down Term Loans (i) shall be denominated in Dollars, (ii) shall not be revolving and amounts repaid may not then be reborrowed, and (iii) shall not exceed in aggregate principal amount at any time the Delayed Draw-Down Term Loan Commitment.

 

1

 

1.02.     Minimum Amount of Each Borrowing. The aggregate principal amount of each Borrowing of Revolving Loans or Delayed Draw-Down Term Loans shall not be less than the Minimum Borrowing Amount applicable to such Loans.

 

1.03.     Notice of Borrowing.

 

(a)     Whenever Borrower desires to incur Delayed Draw-Down Term Loans or the Repurchase Term Loan hereunder, an Authorized Officer shall give Lender at the Notice Office at least three Business Days’ prior notice of each Loan to be incurred hereunder by Notice of Borrowing (as defined below) and any such notice shall be deemed to have been given on a certain day only if given before 3:00 P.M. (Omaha time) on such day, provided that Lender may in its discretion elect to accept as timely requests that are received after 3:00 P.M. (Omaha time) on the applicable Business Day.

 

(b)     Whenever Borrower desires to incur Revolving Loans hereunder, except as provided in Section 1.03(d), an Authorized Officer shall give Lender at the Notice Office at least the same day of such proposed Borrowing, a Notice of Borrowing for such Revolving Loan to be incurred hereunder and any such notice shall be deemed to have been given on a certain day only if given before 12:00 P.M. (Omaha time) on such day, provided that Lender may in its discretion elect to accept as timely requests that are received after 12:00 P.M. (Omaha time) on the applicable Business Day.

 

(c)     Each such notice described in Section 1.03(a) or Section 1.03(b) (each a “Notice of Borrowing”) shall be irrevocable and shall be in writing, or by telephone promptly confirmed in writing (provided, that at Lender’s election the failure to provide written confirmation will not affect the validity of the request), in the form of Exhibit A, appropriately completed to specify: (i) the aggregate principal amount of the Loans to be incurred pursuant to such Borrowing, and (ii) the date of such Borrowing (which shall be a Business Day).

 

(d)     Notwithstanding anything to the contrary in this Section 1.03, Borrower hereby requests and authorizes Lender, without any other request or authorization therefor from Borrower and without notice to Borrower and subject to the terms and conditions set forth in this Agreement, make a Revolving Loan at the end of any day in which Borrower shall have an overdraft (negative ledger balance) in the Primary Concentration Account (after crediting all deposits received in immediately available funds and debiting all withdrawals made and checks presented against the Primary Concentration Account and honored by Lender as of such date), which Revolving Loan shall be in the amount of the negative ledger balance and shall be deposited in the Primary Concentration Account. A Notice of Borrowing shall not be required in connection with a Revolving Loan made by Lender to cover any negative ledger balance amount on a day-to-day basis as set forth in the preceding sentence.

 

(e)     Without in any way limiting the obligation of Borrower to confirm in writing any telephonic notice of any Borrowing or prepayment of Loans, Lender may act without liability upon the basis of telephonic notice of such Borrowing or prepayment, as the case may be, believed by Lender in good faith to be from an Authorized Officer of Borrower, prior to receipt of written confirmation. Borrower agrees that Lender’s record of any telephonic notice of such Borrowing or prepayment of the Loans, as the case may be, will be binding on Borrower absent manifest error.

 

2

 

1.04.     Disbursement of Funds. No later than 1:00 P.M. (Omaha time) on the date specified in each Notice of Borrowing, Lender will make available such Borrowing requested to be made on such date. All such amounts will be made available in Dollars and in immediately available funds by deposit into the Primary Concentration Account, or as otherwise directed by Borrower.

 

1.05.     Notes.

 

(a)     Borrower’s obligation to pay the principal of, and interest on, the Loans made by Lender shall be evidenced in the books and records maintained by Lender and shall, if requested by Lender, also be evidenced (i) in the case of Revolving Loans, by a promissory note duly executed and delivered by Borrower substantially in the form of Exhibit B-1, with blanks appropriately completed in conformity herewith (the “Revolving Note”), (ii) in the case of the Repurchase Term Loan, by a promissory note duly executed and delivered by Borrower substantially in the form of Exhibit B-2, with blanks appropriately completed in conformity herewith (the “Repurchase Term Loan Note”), and (iii) in the case of Delayed Draw-Down Term Loans, by a promissory note duly executed and delivered by Borrower substantially in the form of Exhibit B-3, with blanks appropriately completed in conformity herewith (the “Delayed Draw-Down Term Loan Note”).

 

(b)     In accordance with Section 12.15, Lender will note on its internal records the amount of each Loan made by it and each payment in respect thereof (and such records will be conclusive and binding on the parties absent manifest error) and prior to any transfer of any of its Notes may endorse on the reverse side thereof the outstanding principal amount of Loans evidenced thereby. Failure to make any such notation or any error in such notation shall not affect Borrower’s obligations in respect of such Loans.

 

1.06.     Interest.

 

(a)     Repurchase Term Loan. Interest will accrue in respect of the unpaid principal amount of the Repurchase Term Loan from the date of Borrowing thereof until the maturity date thereof (whether by acceleration or otherwise), at a fixed rate per annum equal to five percent (5.00%).

 

3

 

(b)     Revolving Loans / Delayed Draw-Down Term Loans. The interest rate applicable to Revolving Loans and Delayed Draw-Down Term Loans is subject to change from time to time based on changes in an independent index which is the London Interbank Offered Rate (commonly known as “LIBOR”) for U.S. Dollar Deposits published by the Wall Street Journal as the “One (1) Month LIBOR Rate” (the “Index”). The Index is not necessarily the lowest rate charged by Lender on its loans. Lender will tell Borrower the current Index rate upon Borrower’s request. The interest rate change will not occur more often than each first (1st) day of every month during the term of this Agreement. The interest rate will be adjusted and determined without notice to Borrower using the Index as of the date that is two (2) London Banking Days prior to each interest rate change date. “London Banking Day” means any day, other than a Saturday or Sunday, on which commercial banking institutions in London, England, are generally open for business. At Lender’s option, the Index and/or the interest rate may be rounded upwards to the next higher one one-hundredth of one percent (0.01%). If at any time the Index is less than zero, then it shall be deemed to be zero for the purpose of calculating the interest rate on Revolving Loans and the Delayed Draw-Down Term Loans. Interest will accrue on the unpaid principal balance of any Revolving Loan or Delayed Draw-Down Term Loan from the date of each Borrowing thereunder (i.e., a “Revolving Loan Effective Date” or a “Delayed Draw-Down Term Loan Effective Date”) and will be calculated as described in Section 12.07(b) using a rate of two and one-quarter of one percent percentage points (2.25%) over the Index. If at any time Lender determines (which determination shall be conclusive absent manifest error) that (A) the Index is or will be no longer available, either because (1) the Index is not being quoted or published, (2) any relevant agency or authority has announced that the Index will no longer be published or is no longer representative or (3) any similar circumstance exists such that the Index has or will become unavailable or ceased to exist or (B) similar loans are being documented to incorporate or adopt a new benchmark interest rate to replace the Index, then Lender may, in its sole discretion, replace the Index with a successor rate (which may include a successor index and a spread adjustment), taking into consideration any selection or recommendation of a replacement rate by any relevant agency or authority and evolving or prevailing market conventions. In connection with the selection and implementation of any such replacement rate, Lender may make any technical, administrative or operational changes that Lender decides may be appropriate to reflect the adoption and implementation of such replacement rate. Lender does not warrant or accept any responsibility for the administration or submission of, or any other matter related to, the Index or with respect to any alternative or successor rate thereto, or replacement rate thereof, including without limitation whether any such alternative, successor or replacement rate will have the same value as, or be economically equivalent to, the Index.

 

(c)     During the continuance of an Event of Default, principal and, to the extent permitted by law, overdue interest in respect of each Loan shall, in each case, bear interest at a rate per annum equal to the rate which is 2.00% in excess of the rate then borne by such Loans and interest that accrues under this Section 1.06(c) shall be payable on demand.

 

1.07.     Increased Costs. If any Change in Law after the Effective Date shall (i) change the basis of taxation of payment to Lender of the principal of or interest on the Loans or the Notes or any other amounts payable hereunder (except for (x) Indemnified Taxes, (y) taxes described in Section 4.04(a), and (z) Connection Income Taxes) or (ii) change official reserve or similar requirements (except any reserve requirements reflected in calculating the Index) that has the effect of increasing the amount of capital or liquidity required or expected to be maintained by Lender or any corporation controlling Lender based on the existence of the Commitments or Loans hereunder or its obligations hereunder, then, in any such event, Lender shall promptly give notice (by telephone promptly confirmed in writing) to Borrower, which notice shall show in reasonable detail the basis for calculation of such additional amounts. Thereafter, Borrower agrees to pay to Lender, upon Lender’s written request therefor, such additional amounts (in the form of an increased rate of, or a different method of calculating, interest or otherwise as Lender in its reasonable discretion shall determine) as shall be required to compensate Lender for such increased costs or reductions in the rate of return to Lender. In determining such additional amounts, Lender will act reasonably and in good faith and will use calculation methods which are reasonable, provided that such Lender’s determination of compensation owing under this Section 1.07 shall, absent manifest error, be final and conclusive and binding on all the parties hereto.

 

4

 

1.08.     Compensation. Borrower agrees to compensate Lender, upon its written request (which request shall set forth in reasonable detail the basis for requesting such compensation), for all losses, liabilities and reasonable expenses (including, without limitation, any loss, expense or liability incurred by reason of the liquidation or reemployment of deposits or other funds required by Lender to fund the Loans but excluding loss of anticipated profits) which Lender may sustain: (i) if for any reason (other than as a result of a default by Lender) a Borrowing of Revolving Loan or Delayed Draw-Down Term Loan does not occur on a date specified therefor in a Notice of Borrowing; (ii) if any prepayment or repayment (including any prepayment or repayment made pursuant to Section 4.01, Section 4.02 or as a result of an acceleration of the Loans pursuant to Section 10) occurs on a date which is not the last day of a LIBOR interest period with respect thereto; or (iii) Borrower fails to repay any Loan when required by the terms of this Agreement or any Note held by Lender. Lender’s determination of compensation owing to it under this Section 1.08 shall, absent manifest error, be final and conclusive and binding on all the parties hereto.

 

Section 2     [Reserved].

 

Section 3     Commitment Commission; Fees; Reductions of Commitment.

 

3.01.     Fees.

 

(a)     Borrower agrees to pay to Lender a non-use fee, for the period from the Effective Date through and including the Revolving Loan Maturity Date (or such earlier date on which the Revolving Loan Commitment has been terminated), at the rate of 20 basis points (.20%) per annum of the average daily unused amount of the Revolving Loan Commitment for the applicable period. For purposes of calculating usage under this Section, the Revolving Loan Commitment shall be deemed used to the extent of the aggregate principal amount of all outstanding Revolving Loans. Such non-use fee shall be payable in arrears on the first day of each full fiscal quarter occurring after the Effective Date and on the Revolving Loan Maturity Date (or such earlier date on which the Revolving Loan Commitment has been terminated) for any period then ending for which such non-use fee shall not have previously been paid. The non-use fee shall be computed for the actual number of days elapsed on the basis of a year of 360 days.

 

(b)     Borrower agrees to pay to Lender a non-use fee, for the period from Effective Date through and including the Delayed Draw-Down Term Loan Maturity Date (or such earlier date on which the Delayed Draw-Down Term Loan Commitment has been terminated), at the rate of 20 basis points (.20%) per annum of the average daily unused amount of the Delayed Draw-Down Term Loan Commitment for the applicable period. For purposes of calculating usage under this Section, the Delayed Draw-Down Term Loan Commitment shall be deemed used to the extent of the aggregate principal amount of all outstanding Delayed Draw-Down Term Loans. Such non-use fee shall be payable in arrears on the first day of each full fiscal quarter occurring after the Effective Date and on the Delayed Draw-Down Term Loan Maturity Date (or such earlier date on which the Total Delay Draw-Down Term Loan Commitment has been terminated) for any period then ending for which such non-use fee shall not have previously been paid. The non-use fee shall be computed for the actual number of days elapsed on the basis of a year of 360 days.

 

5

 

Section 4     Prepayments; Payments; Taxes.

 

4.01.     Voluntary Prepayments.

 

(a)     Borrower shall have the right to prepay the Delayed Draw-Down Term Loans, without premium or penalty, in whole or in part at any time and from time to time on the following terms and conditions: (i) Borrower shall give Lender prior to 12:00 P.M. (Omaha time) at the Notice Office at least two Business Days’ prior written notice (or telephonic notice promptly confirmed in writing, provided, that, at Lender’s election, the failure to provide written confirmation will not affect the validity of the notice) of its intent to prepay such Loans, which notice (in each case) shall specify whether Delayed Draw-Down Term Loans shall be prepaid and the amount of such prepayment; and (ii) each partial prepayment of Delayed Draw-Down Term Loans pursuant to this Section 4.01(a) shall be in an aggregate principal amount of at least $10,000 (or such lesser amount as is acceptable to Lender). Each notice delivered by Borrower pursuant to this Section 4.01(a) shall be irrevocable, provided that a notice of prepayment of any Delayed Draw-Down Term Loans then outstanding may state that such notice is conditioned upon the receipt of proceeds from the incurrence or issuance of Indebtedness or equity interests or the effectiveness of other credit facilities. Notwithstanding the foregoing, in the event the prepayment of any Delayed Draw-Down Term Loan is directly or indirectly financed with proceeds from a third-party financing source other than Lender, concurrently with the prepayment of such Delayed Draw-Down Term Loan under this Section 4.01(a), Borrower will pay to Lender a prepayment fee equal to one percent (1.00%) of the principal amount so repaid.

 

(b)     Borrower shall have the right to prepay the Repurchase Term Loan, without premium or penalty, in whole or in part at any time and from time to time on the following terms and conditions: (i) Borrower shall give Lender prior to 12:00 Noon (Omaha time) at the Notice Office at least two Business Days’ prior written notice (or telephonic notice promptly confirmed in writing, provided, that, at Lender’s election, the failure to provide written confirmation will not affect the validity of the notice) of its intent to prepay such Loans, which notice (in each case) shall specify, the amount of such prepayment; and (ii) each partial prepayment of the Repurchase Term Loan pursuant to this Section 4.01(b) shall be in an aggregate principal amount of at least $50,000 (or such lesser amount as is acceptable to Lender). Each notice delivered by Borrower pursuant to this Section 4.01(b) shall be irrevocable, provided that a notice of prepayment of Repurchase Term Loan then outstanding may state that such notice is conditioned upon the receipt of proceeds from the incurrence or issuance of Indebtedness or equity interests or the effectiveness of other credit facilities. Notwithstanding the foregoing, in the event the prepayment of the Repurchase Term Loan is directly or indirectly financed with proceeds from a third-party financing source other than Lender, concurrently with the prepayment under this Section 4.01(b), Borrower will pay to Lender a prepayment fee equal to one percent (1.00%) of the principal amount so repaid.

 

(c)     Borrower shall have the right to prepay the Revolving Loans, without premium or penalty, in the whole or in part at any time during normal banking hours and from time to time without prior written notice to Lender.

 

6

 

4.02.     Repayments of Principal and Interest on the Loans.

 

(a)     Revolving Loans.

 

(i)     Accrued interest on the aggregate principal amount outstanding under the Revolving Loans will be payable on the first (1st) day of the first full month following any Revolving Loan Effective Date, and on the first (1st) day of each succeeding month thereafter through and including the Revolving Loan Maturity Date or such earlier date on which the Revolving Loan Commitment has been terminated.

 

(ii)     On the Revolving Loan Maturity Date, or such earlier date on which the Revolving Loan Commitment has been terminated, the aggregate outstanding principal balance of the Revolving Loans and all accrued interest thereon shall be repaid in full.

 

(iii)     Notwithstanding the foregoing, on any day on which the sum of the aggregate outstanding principal amount of all Revolving Loans (after giving effect to all other repayments thereof on such date), exceeds the Revolving Loan Commitment at such time, Borrower shall prepay not later than the next Business Day the principal of Revolving Loans in an amount equal to such excess.

 

(b)     Repurchase Term Loan.

 

(i)     For the period from the Effective Date and continuing thereafter through and including the Repurchase Term Loan Maturity Date, equal principal and interest payments each in an amount sufficient to fully amortize the principal balance of the Repurchase Term Loan and interest thereon over a period of seven (7) years will be payable on the first (1st) day of each full month through and including the Repurchase Term Loan Maturity Date. The parties hereto acknowledge and agree that the payment of principal of the Repurchase Term Loan due and owing on May 1, 2020 pursuant to the terms of the Existing Credit Agreement shall be deferred and constitute the first payment due pursuant to this Section 4.02(b), provided that interest shall continue to accrue on such amount. Such deferral is not intended to supersede, waive, reduce, restrict or otherwise affect the terms of this Agreement or any other Credit Document and the rights of Lender hereunder and thereunder.

 

(ii)     On the Repurchase Term Loan Maturity Date the outstanding principal balance of the Repurchase Term Loan and all accrued interest thereon shall be repaid in full.

 

(c)     Delayed Draw-Down Term Loan.

 

(i)     For the period beginning on the first (1st) day of the first full month following a Delayed Draw-Down Term Loan Effective Date and continuing thereafter through and including the Delayed Draw-Down Term Loan Maturity Date, equal principal and interest payments in an amount sufficient to fully amortize the principal balance of such Delayed Draw-Down Term Loan and interest thereon over a period of seven (7) years.

 

(ii)     On the Delayed Draw-Down Loan Maturity Date, the aggregate outstanding principal balance of the Delayed Draw-Down Term Loans and all accrued interest thereon shall be repaid in full.

 

Notwithstanding anything in this Agreement to the contrary, whenever increases occur in the interest rate, Lender, at its option, increase Borrower’s payments to cover accruing interest.

 

7

 

4.03.     Method and Place of Payment. Except as otherwise specifically provided herein, all payments under this Agreement and under any Note shall be made to Lender not later than 12:00 Noon (Omaha time) on the date when due and shall be made in Dollars in immediately available funds at the Payment Office. Whenever any payment to be made hereunder or under any Note shall be stated to be due on a day which is not a Business Day, the due date thereof shall be extended to the next succeeding Business Day and, with respect to payments of principal, interest shall be payable at the applicable rate during such extension.

 

4.04.     Taxes.

 

(a)     Payments Free of Taxes. All payments made by Borrower under any Credit Document will be made without setoff, counterclaim or other defense. Except as required by applicable law, all such payments will be made free and clear of, and without deduction or withholding for, any present or future taxes, levies, imposts, duties, fees, assessments or other charges of whatever nature now or hereafter imposed by any jurisdiction or by any political subdivision or taxing authority thereof or therein with respect to such payments (the foregoing, together with all interest, penalties or similar liabilities with respect thereto, being referred to collectively as “Indemnified Taxes”).

 

(b)     Evidence of Payments. Borrower will furnish to Lender as soon as practicable after request from Lender after the date on which the payment of any Indemnified Taxes is due pursuant to applicable law certified copies of tax receipts evidencing such payment by Borrower or other documentation reasonably satisfactory to Lender.

 

(c)     Indemnification by Borrower. Borrower agrees to indemnify and hold harmless Lender and reimburse Lender upon its written request, for the amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 4.04) so levied or imposed and payable by Lender whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to Borrower by Lender shall be conclusive absent manifest error.

 

(d)     Payment of Other Taxes by Borrower. Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of Lender timely reimburse it for the payment of, any Other Taxes.

 

(e)     Survival. Each party’s obligations under this Section 4.04 shall survive the termination of the Commitments and the repayment, satisfaction or discharge of all obligations under any Credit Document.

 

Section 5     Conditions Precedent to the Effective Date. The occurrence of the Effective Date pursuant to Section 12.10 and the obligation of Lender to make Loans on the Effective Date, are subject to the satisfaction of the following conditions:

 

5.01.     Execution of Agreement; Notes. On or prior to the Effective Date, (i) this Agreement shall have been executed and delivered as provided in Section 12.10 and (ii) there shall have been delivered to Lender the Revolving Note, the Repurchase Term Loan Note, and the Delayed Draw-Down Term Loan Note executed by Borrower, in each case in the amount, maturity and as otherwise provided herein.

 

8

 

5.02.     Officer’s Certificate. On the Effective Date, Lender shall have received a certificate, dated the Effective Date and signed on behalf of Borrower by the chairman of the board, the chief executive officer, the chief financial officer, the president or any vice president of Borrower, certifying on behalf of Borrower that all of the conditions in Sections 5.05, 5.06, 5.07 and 6.01 have been satisfied on such date.

 

5.03.     Opinions of Counsel. On the Effective Date, Lender shall have received from counsel to Borrower an opinion addressed to and dated the Effective Date, in form and substance reasonably satisfactory to Lender.

 

5.04.     Corporate Documents; Proceedings; Etc.

 

(a)     On the Effective Date, Lender shall have received a certificate from Borrower, dated the Effective Date, signed by the chairman of the board, the chief executive officer, the president, the chief financial officer or any vice president of Borrower, and attested to by the secretary, any assistant secretary, the general counsel or any vice president of Borrower, substantially in the form of Exhibit C with appropriate insertions, which shall be in form and substance reasonably acceptable to Lender, together with copies of the certificate of incorporation and by-laws of Borrower and the resolutions of Borrower referred to in such certificate, which resolutions shall be in form and substance reasonably acceptable to Lender.

 

(b)     On the Effective Date, Lender shall have received a good standing certificate (or equivalent document) of Borrower from the relevant office in Borrower’s jurisdiction of organization (to the extent relevant, customary and available in the jurisdiction of organization of Borrower) dated as of a recent date prior hereto.

 

5.05.     Adverse Change, Approvals.

 

(a)     Since December 31, 2019, there shall have been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to have a Material Adverse Effect.

 

(b)     On or prior to the Effective Date, Lender shall have received true, correct and complete copies of all documents relevant to the Transaction, as determined in Lender’s reasonable discretion, and all necessary governmental (domestic and foreign) and material third party approvals and/or consents in connection with the Transaction (and the payment of all fees, costs and expenses in connection therewith) and the other transactions contemplated hereby shall have been obtained and remain in effect, and all applicable waiting periods with respect thereto shall have expired without any action being taken by any competent authority which, in the reasonable judgment of Lender, restrains, prevents, or imposes materially adverse conditions upon, the consummation of the Transaction or the other transactions contemplated by the Credit Documents or otherwise referred to herein or therein.

 

9

 

(c)     On the Effective Date, there shall not exist any judgment, order, injunction or other restraint prohibiting or imposing materially adverse conditions upon the Transaction or the other transactions contemplated by the Credit Documents or otherwise referred to herein or therein.

 

5.06.     Litigation. On the Effective Date, no litigation by any entity (private or governmental) shall be pending or, to the knowledge of Borrower or any of its Subsidiaries, threatened with respect to this Agreement or any other Credit Document or any documentation executed in connection herewith or therewith, or with respect to the Transaction that has had, or could reasonably be expected to have, a Material Adverse Effect.

 

5.07.     Financial Covenants. As of December 31, 2019, Borrower shall be in compliance with the financial covenants contained in Sections 9.08 and 9.09 on a Pro Forma Basis as if any Borrowing on the Effective Date had occurred on December 31, 2019 (without netting the proceeds of any Borrowing on the Effective Date).

 

5.08.     Interest. Borrower shall pay to Lender accrued interest on the Repurchase Term Loan that was due and payable as of May 1, 2020 pursuant to the terms of the Existing Credit Agreement in the amount of $137,508.62.

 

5.09.     Subsidiaries Guaranty. On the Effective Date, each Subsidiary Guarantor shall have duly authorized, executed and delivered the Amended and Restated Subsidiaries Guaranty in the form of Exhibit D (as amended, modified or supplemented from time to time, the “Subsidiaries Guaranty”), and the Subsidiaries Guaranty shall be in full force and effect.

 

5.10.     Security Agreement. On the Effective Date, Borrower shall have duly authorized, executed and delivered the amendment to the Security Agreement among Borrower, the other guarantors from time to time party thereto, and Lender, dated April 18, 2018 (as amended, modified or supplemented from time to time, the “Security Agreement”), and the Security Agreement shall remain in full force and effect.

 

5.11.     [Reserved.]

 

5.12.     Financial Statements. On or prior to the Effective Date, Lender shall have received true and correct copies of the historical consolidated financial statements referred to in Section 7.05(a) (including through filing such information electronically with the SEC’s EDGAR system).

 

5.13.     Solvency Certificate. On the Effective Date, Lender shall have received a solvency certificate from the chief financial officer of Borrower in the form of Exhibit E.

 

5.14.     [Reserved.]

 

5.15.    Fees, Etc. On the Effective Date, all costs, fees, expenses (including, without limitation, reasonable legal fees and expenses) and other compensation contemplated hereby, payable to the Lender (and its Affiliates) or otherwise payable in respect of the Transaction shall have been paid by Borrower to the extent due and, in the case of expenses, invoiced.

 

10

 

5.16.     Shareholders’ Agreements; Management Agreements; Tax Sharing Agreements; and Existing Indebtedness Agreements. On or prior to the Effective Date, there shall have been delivered to Lender true and correct copies of the following documents; provided, that the filing of any such document with the Securities and Exchange Commission shall be deemed to satisfy the delivery requirements of this Section 5.16:

 

(a)     all agreements entered into by Borrower or any of its Subsidiaries governing the terms and relative rights of such Person’s equity interests and any agreements entered into by such Person’s shareholders relating to any such entity with respect to its equity interests that will remain in place after giving effect to the Transaction (collectively, the “Shareholders’ Agreements”);

 

(b)     all material agreements with members of, or with respect to, the management of Borrower or any of its Subsidiaries that will remain in place after giving effect to the Transaction (collectively, the “Management Agreements”);

 

(c)     all tax sharing, tax allocation and other similar agreements entered into by Borrower or any of its Subsidiaries that will remain in place after giving effect to the Transaction (collectively, the “Tax Sharing Agreements”); and

 

(d)     all agreements evidencing or relating to Indebtedness of Borrower or any of its Subsidiaries (other than with respect to Capitalized Lease Obligations) which are to remain outstanding after giving effect to the Transaction (the “Existing Indebtedness Agreements”);

 

all of which Shareholders’ Agreements, Management Agreements, Tax Sharing Agreements and Existing Indebtedness Agreements shall be in form and substance reasonably satisfactory to Lender and shall be in full force and effect on the Effective Date.

 

Section 6     Conditions Precedent to All Credit Events. The obligation of Lender to make Loans (including Loans made on the Effective Date) are subject, at the time of each such Credit Event (except as hereinafter indicated), to the satisfaction of the following conditions:

 

6.01.     No Default; Representations and Warranties. At the time of each such Credit Event and also after giving effect thereto (i) there shall exist no Default or Event of Default and (ii) all representations and warranties contained herein and in the other Credit Documents shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality in which case they shall be true and correct in all respects) with the same effect as though such representations and warranties had been made on the date of such Credit Event (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified date).

 

6.02.     Notice of Borrowing. Prior to the making of each Loan, Lender shall have received a Notice of Borrowing meeting the requirements of Section 1.03(c).

 

The acceptance of the benefits of each Credit Event shall constitute a representation and warranty by Borrower to Lender that all the conditions specified in Section 5 or Section 6.01 and applicable to such Credit Event are satisfied as of that time. All of the Notes, certificates, legal opinions and other documents and papers referred to in Section 5 and in this Section 6, unless otherwise specified, shall be in form and substance reasonably satisfactory to Lender.

 

11

 

Section 7     Representations, Warranties and Agreements. In order to induce Lender to enter into this Agreement and to make the Loans as provided herein, Borrower makes the following representations, warranties and agreements, in each case after giving effect to the Transaction, all of which shall survive the execution and delivery of this Agreement and the Notes and the making of the Loans, with the occurrence of the Effective Date and each Credit Event on or after the Effective Date being deemed to constitute a representation and warranty that the representations and warranties contained in this Section 7 are true and correct in all material respects (except for those representations and warranties that are qualified by materiality in which case they shall be true and correct in all respects) on and as of the Effective Date and with the same effect as though such representations and warranties had been made on the date of each such other Credit Event (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as of such specified date).

 

7.01.     Organizational Status. Each Credit Party (a) is duly organized and validly existing and in good standing under the laws of the jurisdiction of its organization, (b) has the organizational power and authority to own its property and assets and to transact the business in which it is engaged and presently proposes to engage and (c) is duly qualified and is authorized to do business and is in good standing in each jurisdiction where the ownership, leasing or operation of its property or the conduct of its business requires such qualifications, except in the case of this clause (c) as could not reasonably be expected to have a Material Adverse Effect.

 

7.02.     Power and Authority. Each Credit Party has the organizational power and authority to execute, deliver and perform the terms and provisions of each of the Credit Documents to which it is party and has taken all necessary organizational action to authorize the execution, delivery and performance by it of each of such Credit Documents. Borrower has duly executed and delivered each of the Credit Documents to which it is party, and each of such Credit Documents constitutes its legal, valid and binding obligation enforceable in accordance with its terms, except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles (regardless of whether enforcement is sought in equity or at law).

 

7.03.     No Violation. Neither the execution, delivery or performance by any Credit Party of the Credit Documents to which it is a party, nor compliance by it with the terms and provisions thereof, (a) will contravene any provision of any law, statute, rule or regulation (including, without limitation, any Health Care Law) or any order, writ, injunction or decree of any court or governmental instrumentality, (b) (i) will conflict with or result in any breach of any of the terms, covenants, conditions or provisions of, or constitute a default under any indenture, mortgage, deed of trust, credit agreement or loan agreement, or any other material agreement, contract or instrument or (ii) result in the creation or imposition of (or the obligation to create or impose) any Lien upon any of the property or assets of Borrower or any of its Subsidiaries pursuant to the terms of any indenture, mortgage, deed of trust, credit agreement or loan agreement, or any other material agreement, contract or instrument, in each case to which Borrower or any of its Subsidiaries is a party or by which it or any its property or assets is bound (including, without limitation, from and after the execution and delivery thereof, any Permitted Subordinated Debt Documents), or (c) will violate any provision of the certificate of incorporation or by-laws of Borrower, except to the extent that such contravention, conflict or violation described in clauses (a) – (c) could not reasonably be expected to result in a Material Adverse Effect.

 

12

 

7.04.     Approvals. No order, consent, approval or authorization with, by, or from any governmental or public body or authority is required to be obtained or made by, or on behalf of, Borrower or any of its Subsidiaries in connection with, (a) the execution, delivery and performance of any Credit Document or (b) the legality, validity, binding effect or enforceability of any Credit Document, except for those that have been obtained or made and are in full force and effect.

 

7.05.     Financial Statements; No Material Adverse Effect.

 

(a)     The audited consolidated balance sheet of Borrower and its Subsidiaries, and the related audited consolidated statements of income, cash flows and retained earnings of Borrower and its Subsidiaries for the fiscal year ended December 31, 2019, copies of which have been furnished to Lender prior to the Effective Date (including through filing such information electronically with the SEC’s EDGAR system), present fairly in all material respects the consolidated financial position of Borrower and its Subsidiaries at the respective dates of such balance sheets and the consolidated results of the operations of Borrower for the respective periods covered thereby. The foregoing historical financial statements have been prepared in accordance with generally accepted accounting principles consistently applied.

 

(b)     On and as of the Effective Date and after giving effect to the Transaction and after giving effect to all Indebtedness (including the Loans) being issued, incurred or assumed by Borrower in connection therewith, (i) the sum of the assets, at a fair valuation, of Borrower and its Subsidiaries, taken as a whole, will exceed its debts, (ii) Borrower and its Subsidiaries taken as a whole have not incurred and do not intend to incur, debts beyond Borrower’s and its Subsidiaries’ ability, taken as a whole, to pay such debts as such debts mature, and (iii) Borrower and its Subsidiaries, taken as a whole, will have sufficient capital with which to conduct their business. For purposes of this Section 7.05(b), “debt” means any liability on a claim, and “claim” means (a) right to payment, whether or not such a right is reduced to judgment, liquidated, unliquidated, fixed, contingent, matured, unmatured, disputed, undisputed, legal, equitable, secured, or unsecured or (b) right to an equitable remedy for breach of performance if such breach gives rise to a payment, whether or not such right to an equitable remedy is reduced to judgment, fixed, contingent, matured, unmatured, disputed, undisputed, secured or unsecured. The amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability. For the avoidance of doubt, the determination of the value of the assets of Borrower and its Subsidiaries includes intangible assets including goodwill and going concern value.

 

(c)     [Reserved].

 

(d)     Since December 31, 2019, there has been no event or circumstance, either individually or in the aggregate, that has had, or could reasonably be expected to have, a Material Adverse Effect.

 

13

 

7.06.     Litigation. Except as previously disclosed to Lender, on the Effective Date, there are no actions, suits or proceedings pending or, to the knowledge of Borrower or any of its Subsidiaries, threatened (a) with respect to any Credit Document or (b) that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.

 

7.07.     True and Complete Disclosure. All factual information (taken as a whole) furnished by or on behalf of Borrower and its Subsidiaries in writing to Lender (including, without limitation, all information contained in the Credit Documents, but excluding, for the avoidance of doubt, any forward-looking information and information of a general economic nature and general information about Borrower’s industry) for purposes of or in connection with this Agreement and the other Credit Documents, and all other such factual information (taken as a whole) hereafter furnished by or on behalf of Borrower in writing to Lender does not or will not, when furnished, contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, taken as a whole, not materially misleading, in light of the circumstances under which such information was provided.

 

7.08.     Margin Regulations. No part of any Credit Event (or the proceeds thereof) will be used to purchase or carry any Margin Stock or to extend credit for the purpose of purchasing or carrying any Margin Stock. Neither the making of any Loan nor the use of the proceeds thereof nor the occurrence of any other Credit Event will violate or conflict with the provisions of Regulation T, U or X of the Board of Governors of the Federal Reserve System.

 

7.09.     Tax Payments. Borrower and each of its Subsidiaries have paid all taxes and assessments payable by it which have become due, other than (i) those for which the failure to pay could not reasonably be expected to have a Material Adverse Effect and (ii) those being contested in good faith and adequately disclosed and fully provided for on the financial statements of Borrower and its Subsidiaries in accordance with generally accepted accounting principles. There is no action, suit, proceeding, investigation, audit or claim now pending or, to the knowledge of Borrower, threatened by any authority regarding any taxes relating to Borrower or any of its Subsidiaries that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.

 

7.10.     Compliance with ERISA.

 

(a)     Except as would not reasonably be expected to have a Material Adverse Effect, (i) each ERISA Plan (and each related trust, insurance contract or fund) is in substantial compliance with its terms and with all applicable laws, including, without limitation, ERISA and the Code and (ii) each ERISA Plan (and each related trust, if any) which is intended to be qualified under Section 401(a) of the Code has received or can otherwise rely upon a determination letter from the Internal Revenue Service to the effect that it meets the requirements of Sections 401(a) and 501(a) of the Code. As of the Effective Date, neither Borrower nor any of its Subsidiaries or ERISA Affiliates has ever maintained or contributed to, or had any obligation to maintain or contribute to (or borne any liability with respect to) any “employee pension benefit plan,” within the meaning of Section 3(2) of ERISA, that is a “multiemployer plan,” within the meaning of Section 3(37) of ERISA, or that is subject to the minimum funding standards of Section 412 of the Code or Section 302 of ERISA or subject to Title IV of ERISA. Except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect: all contributions required to be made with respect to an ERISA Plan have been timely made; neither Borrower nor any of its Subsidiaries nor any ERISA Affiliate has incurred any liability (including any indirect, contingent or secondary liability) to or on account of an ERISA Plan pursuant to Section 409, 502(i), 502(l), 515, 4204 or 4212 of ERISA or Section 4975 of the Code or expects to incur any such liability under any of the foregoing sections with respect to any ERISA Plan; no action, suit, proceeding, hearing, audit or investigation with respect to the administration, operation or the investment of assets of any ERISA Plan (other than routine claims for benefits) is pending, expected or, to the knowledge of Borrower, threatened which, if adversely determined, could reasonably be expected to result in a liability to Borrower or any of its Subsidiaries; each group health plan (as defined in Section 607(1) of ERISA or Section 4980B(g)(2) of the Code) which covers or has covered employees or former employees of Borrower or any of its Subsidiaries or ERISA Affiliates has at all times been operated in compliance with the provisions of Part 6 of subtitle B of Title I of ERISA and Section 4980B of the Code; no lien imposed under the Code or ERISA on the assets of Borrower or any of its Subsidiaries or any ERISA Affiliate exists or is likely to arise on account of any ERISA Plan; and Borrower and its Subsidiaries may cease contributions to or terminate any employee benefit plan maintained by any of them.

 

14

 

(b)     Except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect: each Foreign Pension Plan has been maintained in substantial compliance with its terms and with the requirements of any and all applicable laws, statutes, rules, regulations and orders and has been maintained, where required, in good standing with applicable regulatory authorities; all contributions required to be made with respect to a Foreign Pension Plan have been timely made; and neither Borrower nor any of its Subsidiaries have incurred any material obligation in connection with the termination of, or withdrawal from, any Foreign Pension Plan. The present value of the accrued benefit liabilities (whether or not vested) under each Foreign Pension Plan, determined as of the end of Borrower’s most recently ended fiscal year on the basis of actuarial assumptions, which taken as a whole are reasonable, did not exceed the current value of the assets of such Foreign Pension Plan allocable to such benefit liabilities by a material amount.

 

7.11.     Priority of Liens. All Liens of Lender in the Collateral are duly perfected, first priority Liens, subject only to Permitted Liens that are expressly allowed to have priority over Lender’s Liens.

 

7.12.     Properties. Borrower and each of its Subsidiaries have good and marketable title to, or a validly subsisting leasehold interest in, all material properties owned or leased by it and used in the ordinary course of its business, except for Permitted Liens and such defects in title as could not reasonably be expected to have a Material Adverse Effect.

 

7.13.     Capitalization. On the Effective Date, the authorized capital stock of Borrower consists of (a) 60,000,000 shares of common stock, par value $0.001 per share (“Borrower Common Stock”), and (b) 2,000,000 shares of preferred stock, par value $0.01 per share. All outstanding shares of the capital stock of Borrower have been duly and validly issued and are fully paid and non-assessable. Except as disclosed from time to time in Borrower’s filings with the Securities and Exchange Commission or as otherwise disclosed in writing to Lender, there are no outstanding purchase options, warrants, subscription rights, agreements to issue or sell, convertible interests, or phantom rights or share repurchase plans relating to the capital stock of Borrower.

 

15

 

7.14.     Subsidiaries; Etc.

 

(a)     Borrower has no Subsidiaries other than (i) those Subsidiaries listed on Schedule I (which Schedule identifies (x) the direct owner of each such Subsidiary on the Effective Date and Borrower’s percentage ownership therein and (y) each Wholly-Owned Subsidiary) and (ii) new Subsidiaries created or acquired after the Effective Date in accordance with the terms of this Agreement.

 

(b)     Schedule I also sets forth, as of the Effective Date, the exact legal name of each Borrower and each of its Subsidiaries, the type of organization of such Subsidiary, whether or not such Subsidiary is a registered organization (within the meaning of the Nebraska UCC), the jurisdiction of organization of such Subsidiary, the location (within the meaning of the Nebraska UCC) of such Subsidiary, and the organizational identification number (if any) of such Subsidiary. All outstanding shares of the capital stock of Borrower’s Subsidiaries have been duly and validly issued and are fully paid and non-assessable. Except as set forth on Schedule II, no Subsidiary has any outstanding any securities convertible into or exchangeable for its capital stock or outstanding any rights to subscribe for or to purchase, or any options for the purchase of, or any agreement providing for the issuance (contingent or otherwise) of, or any calls, commitments or claims of any character relating to, its capital stock, except for options, rights or warrants that have been issued or may be issued from time to time to purchase shares of Borrower Common Stock.

 

7.15.     Compliance with Statutes, Etc. Borrower and each of its Subsidiaries are in compliance with all applicable statutes, regulations and orders of, and all applicable restrictions imposed by, all governmental bodies, domestic or foreign, in respect of the conduct of its business and the ownership of its property (including, without limitation, applicable Health Care Laws and statutes, regulations, orders and restrictions relating to environmental standards and controls), except such noncompliance as could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

7.16.     Investment Company Act. Neither Borrower nor any of its Subsidiaries are an “investment company” or a company “controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended.

 

7.17.     Environmental Matters.

 

(a)     Borrower and each of its Subsidiaries are in compliance with all applicable Environmental Laws and the requirements of any permits issued under such Environmental Laws. There are no pending or, to the knowledge of Borrower, threatened Environmental Claims against Borrower or any of its Subsidiaries or any Real Property owned, leased or operated by Borrower or any of its Subsidiaries (including any such claim arising out of the ownership, lease or operation by Borrower or any of its Subsidiaries of any Real Property formerly owned, leased or operated by Borrower or any of its Subsidiaries but no longer owned, leased or operated by Borrower or any of its Subsidiaries). There are no facts, circumstances, conditions or occurrences with respect to the business or operations of Borrower or any of its Subsidiaries, or any Real Property owned, leased or operated by Borrower or any of its Subsidiaries (including any Real Property formerly owned, leased or operated by Borrower or any of its Subsidiaries but no longer owned, leased or operated by Borrower or any of its Subsidiaries) or, to the knowledge of Borrower, any property adjoining or adjacent to any such Real Property that could be reasonably expected (i) to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries or any Real Property owned, leased or operated by Borrower or any of its Subsidiaries or (ii) to cause any Real Property owned, leased or operated by Borrower or any of its Subsidiaries to be subject to any restrictions on the ownership, lease, occupancy or transferability of such Real Property by Borrower or any of its Subsidiaries under any applicable Environmental Law.

 

16

 

(b)     To the knowledge of Borrower, Hazardous Materials have not at any time been generated, used, treated or stored on, or transported to or from, or Released on or from, any Real Property owned, leased or operated by Borrower or any of its Subsidiaries, or, to the knowledge of Borrower, any property adjoining or adjacent to any Real Property, where such generation, use, treatment, storage, transportation or Release has violated or could be reasonably expected to violate any applicable Environmental Law or give rise to an Environmental Claim against Borrower or any of its Subsidiaries.

 

(c)     Notwithstanding anything to the contrary in this Section 7.17, the representations and warranties made in this Section 7.17 shall be untrue only if the effect of any or all conditions, violations, claims, restrictions, failures and non-compliances of the types described above could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

7.18.     Labor Relations. Neither Borrower nor any of its Subsidiaries is engaged in any unfair labor practice that could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. There is (a) no unfair labor practice complaint pending against Borrower or any of its Subsidiaries or, to the knowledge of Borrower, threatened against any of them, before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against Borrower or any of its Subsidiaries or, to the knowledge of Borrower, threatened against any of them, (b) no strike, labor dispute, slowdown or stoppage pending against Borrower or any of its Subsidiaries or, to the knowledge of Borrower, threatened against Borrower or any of its Subsidiaries and (c) no union representation question exists with respect to the employees of Borrower or any of its Subsidiaries, except (with respect to any matter specified in clause (a), (b) or (c) above, either individually or in the aggregate) such as could not reasonably be expected to have a Material Adverse Effect.

 

7.19.     Intellectual Property, Etc. Each of Borrower and its Subsidiaries owns or has the right to use all the patents, trademarks, permits, domain names, service marks, trade names, copyrights, licenses, franchises, inventions, trade secrets, proprietary information and know-how of any type, whether or not written (including, but not limited to, rights in computer programs and databases) and formulas, or rights with respect to the foregoing, and has obtained assignments of all leases, licenses and other rights of whatever nature, necessary for the present conduct of its business in all material respects, without any known conflict with the rights of others which, or the failure to obtain which, as the case may be, could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

7.20.     Indebtedness. Schedule III sets forth a true and complete list of all Indebtedness (including Contingent Obligations, but excluding the Loans) of Borrower and its Subsidiaries as of the Effective Date (the “Existing Indebtedness”) and which is to remain outstanding after giving effect to the Transaction, in each case showing the aggregate principal amount thereof as of May 15, 2020, and the name of Borrower and any Credit Party or any Subsidiaries which directly or indirectly guarantees such Indebtedness.

 

17

 

7.21.     Insurance. Schedule IV sets forth a true and complete listing of the material insurance policies maintained by Borrower and its Subsidiaries as of the Effective Date, with the amounts insured (and any deductibles) set forth therein.

 

7.22.     Subordination. After the execution and delivery thereof, each Permitted Subordinated Debt Document is enforceable against Borrower and the holders of the Permitted Subordinated Debt evidenced thereby, and all Obligations hereunder and under the other Credit Documents are within the definition of “Senior Debt” (or any relevant similar term) included in the subordination provisions of such Permitted Subordinated Debt Documents.

 

7.23.     Anti-Corruption Laws and Sanctions. Borrower, its Subsidiaries and, to the knowledge of Borrower, their respective officers, employees, and directors, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. None of (i) Borrower or, to the knowledge of Borrower, any Subsidiary thereof, any of their respective directors, officers or employees, or (ii) to the knowledge of Borrower, any agent of Borrower or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Borrowing, use of proceeds or issuance of a Letter of Credit will violate Anti-Corruption Laws or applicable Sanctions.

 

7.24.     EEA Financial Institutions. Borrower is not an EEA Financial Institution.

 

Section 8     Affirmative Covenants. Borrower hereby covenants and agrees that on and after the Effective Date and until the Commitments have terminated and the Loans, Notes and Fees and all other Obligations (other than indemnities described in this Agreement and the other Credit Documents which are not then due and payable) incurred hereunder and thereunder, are paid in full:

 

8.01.     Information Covenants. Borrower will furnish to Lender:

 

(a)     Quarterly Financial Statements. Within 45 days after the close of each of the first three quarterly accounting periods in each fiscal year of Borrower, (i) the unaudited consolidated balance sheet of Borrower and its Subsidiaries as at the end of such quarterly accounting period and the related unaudited consolidated statements of income and retained earnings and statement of cash flows for such quarterly accounting period and for the elapsed portion of the fiscal year ended with the last day of such quarterly accounting period, in each case setting forth comparative figures for the corresponding quarterly accounting period in the prior fiscal year, all of which shall be certified by an Authorized Officer of Borrower that they fairly present in all material respects in accordance with generally accepted accounting principles the financial condition of Borrower and its Subsidiaries as of the dates indicated and the results of their operations for the periods indicated, subject to normal year-end audit adjustments and the absence of footnotes, and (ii) management’s discussion and analysis of the important operational and financial developments during such quarterly accounting period.

 

18

 

(b)     Annual Financial Statements. Within 90 days after the close of each fiscal year of Borrower, (i) the audited consolidated balance sheet of Borrower and its Subsidiaries as at the end of such fiscal year and the related audited consolidated statements of income and retained earnings and statement of cash flows for such fiscal year setting forth comparative figures for the preceding fiscal year and certified by KPMG or other independent certified public accountants of recognized national standing, together with a report of such accounting firm (which report shall be without a “going concern” or like qualification or exception and without any qualification or exception as to scope of audit) and (ii) management’s discussion and analysis of the important operational and financial developments during such fiscal year.

 

(c)     Management Letters. To the extent not otherwise included in Borrower’s applicable Form 10K or Form 10Q filed with the SEC, promptly after Borrower’s or any of its Subsidiaries’ receipt thereof, a copy of any “management letter” received from its certified public accountants and management’s response thereto.

 

(d)     Forecast. No later than 90 days following the first day of each fiscal year of Borrower, a rolling four-quarter “run-rate” forecast in form reasonably satisfactory to Lender for each of the four quarterly accounting periods of such fiscal year prepared in detail; provided, however, that Borrower shall not be required to deliver such forecast for the fiscal year ending on December 31, 2020, unless requested by Lender, in which event, Borrower shall deliver such forecast within 15 days after Lender’s request.

 

(e)     Officer’s Certificates. At the time of the delivery of the financial statements provided for in Sections 8.01(a) and (b), a compliance certificate from an Authorized Officer of Borrower in the form of Exhibit F (a “Compliance Certificate”) certifying on behalf of Borrower that, to such officer’s knowledge after due inquiry, (i) no Default or Event of Default has occurred and is continuing or, if any Default or Event of Default has occurred and is continuing, specifying the nature and extent thereof and (ii) each of the representations and warranties contained in the Credit Agreement and the other Credit Documents is true and correct in all material respects (except for those representations and warranties that are qualified by materiality in which case they shall be true and correct in all respects) as of the date thereof, except to the extent that any such representation and warranty by its terms is made as of a specified date, in which case any such representation or warranty is true and correct in all material respects only as of such specified date, which certificate shall (x) set forth in reasonable detail the calculations required to establish whether Borrower and its Subsidiaries were in compliance with the provisions of Sections 9.08 and 9.09 at the end of such fiscal quarter or year, as the case may be and (y) with respect to the annual financial statements provided for in Section 8.01(b), list all Subsidiaries of Borrower as of the end of such year, provided, however, such list of Subsidiaries may be delivered electronically and shall be deemed to have been delivered on the date on which such information is posted on Borrower’s website or filed electronically with the SEC’s EDGAR system.

 

(f)     Notice of Default, Litigation and Material Adverse Effect. Promptly, and in any event within three Business Days after the chief executive officer or chief financial officer of Borrower obtains knowledge thereof, notice of (i) the occurrence of any event which constitutes a Default or an Event of Default, (ii) any litigation or governmental investigation or proceeding pending against Borrower or any of its Subsidiaries (x) which, either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or results in uninsured liability to Borrower or any of its Subsidiaries in excess of $3,000,000 or (y) with respect to any Credit Document, or (iii) any violation or asserted violation (by written notice to Borrower or any Subsidiary) of any law, rule or regulation, or any other event, change or circumstance, in each case, that has or could reasonably be expected to have, a Material Adverse Effect.

 

19

 

(g)     Other Reports and Filings. Promptly after the filing or delivery thereof, copies of all financial information, proxy materials and reports, if any, which Borrower or any of its Subsidiaries shall publicly file with the Securities and Exchange Commission or any successor thereto (the “SEC”) or deliver to holders (or any trustee, agent or other representative therefor) of any Permitted Subordinated Debt or any other material Indebtedness pursuant to the terms of the documentation governing such Indebtedness; provided that so long as Borrower is a reporting company, the posting to the SEC’s website (www.sec.gov/edgar) of financial statements or other information required by this Section 8.01 shall be deemed to satisfy the delivery requirement of such information under this Section 8.01.

 

(h)     Environmental Matters. Promptly after Borrower’s chief executive officer or chief financial officer obtains knowledge thereof, notice of one or more of the following environmental matters to the extent that such environmental matters, either individually or when aggregated with all other such environmental matters, could reasonably be expected to have a Material Adverse Effect:

 

(i)     any pending or threatened Environmental Claim against Borrower or any of its Subsidiaries or any Real Property owned, leased or operated by Borrower or any of its Subsidiaries;

 

(ii)     any condition or occurrence on or arising from any Real Property owned, leased or operated by Borrower or any of its Subsidiaries that (a) results in noncompliance by Borrower or any of its Subsidiaries with any applicable Environmental Law or (b) could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries or any such Real Property;

 

(iii)     any condition or occurrence on any Real Property owned, leased or operated by Borrower or any of its Subsidiaries that could reasonably be expected to cause such Real Property to be subject to any restrictions on the ownership, lease, occupancy, use or transferability by Borrower or any of its Subsidiaries of such Real Property under any Environmental Law; and

 

(iv)     the taking of any removal or remedial action in response to the actual or alleged presence of any Hazardous Material on any Real Property owned, leased or operated by Borrower or any of its Subsidiaries as required by any Environmental Law or any governmental or other administrative agency; provided that in any event Borrower shall deliver to each Lender all written notices received by Borrower or any of its Subsidiaries from any government or governmental agency under, or pursuant to, CERCLA which identify Borrower or any of its Subsidiaries as potentially responsible parties for remediation costs or which otherwise notify Borrower or any of its Subsidiaries of potential liability under CERCLA.

 

All such notices shall describe in reasonable detail the nature of the claim, investigation, condition, occurrence or removal or remedial action and Borrower’s or such Subsidiary’s response thereto.

 

20

 

(i)     [Reserved].

 

(j)     Other Information. From time to time, such other information or documents (financial or otherwise) with respect to Borrower or any of its Subsidiaries as Lender may reasonably request.

 

8.02.     Books, Records and Inspections. Borrower will, and will cause each of its Subsidiaries to, keep proper books of record and accounts that contain full, true and correct entries which permit the preparation of financial statements in accordance with generally accepted accounting principles and which conform in all material respects to all requirements of law. Borrower will, and will cause each of its Subsidiaries to, permit officers and designated representatives of Lender to visit and inspect, under guidance of officers of Borrower or such Subsidiary, any of the properties of Borrower or such Subsidiary, and to examine the books of account of Borrower or such Subsidiary and discuss the affairs, finances and accounts of Borrower or such Subsidiary with, and be advised as to the same by, its and their officers and independent accountants, all upon reasonable prior notice and at such reasonable times and intervals and to such reasonable extent Lender may reasonably request.

 

8.03.     Maintenance of Property; Insurance. Borrower will, and will cause each of its Subsidiaries to, (a) keep all property necessary to the business of Borrower and its Subsidiaries in good working order and condition, ordinary wear and tear and casualty and dispositions in accordance with Section 9.02 excepted, (b) maintain with financially sound and reputable insurance companies insurance on all such property and against all such risks as is consistent and in accordance with industry practice for companies similarly situated owning similar properties and engaged in similar businesses as Borrower and its Subsidiaries, and (c) deliver from time to time upon request of Lender, in form and substance satisfactory to Lender, certificates evidencing Borrower’s and its Subsidiaries’ maintenance of all insurance required by this Section 8.03, including, but not limited to such originals or copies as Lender may request of certificates of insurance, riders and endorsements relating to such insurance.

 

8.04.     Existence; Franchises. Borrower will, and will cause each of its Subsidiaries to, do or cause to be done, all things necessary to preserve and keep in full force and effect its existence and its material rights, franchises, licenses, permits, copyrights, trademarks and patents; provided, however, that nothing in this Section 8.04 shall prevent (a) sales of assets and other transactions by Borrower or any of its Subsidiaries in accordance with Section 9.02 or (b) the withdrawal by Borrower or any of its Subsidiaries of its qualification as a foreign corporation, partnership or limited liability company, as the case may be, in any jurisdiction if such withdrawal could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

8.05.     Compliance with Laws. Borrower will, and will cause each of its Subsidiaries to, comply with all applicable statutes, regulations and orders of, and all applicable restrictions imposed by, all governmental bodies, domestic or foreign in respect of the conduct of its business and the ownership of its property (including applicable statutes, regulations, orders and restrictions relating to Health Care Laws, Anti-Corruption Laws, and environmental standards and controls), except such noncompliance as could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

21

 

8.06.     Compliance with Environmental Laws.

 

(a)     Except as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, Borrower (i) will comply, and will cause each of its Subsidiaries to comply, with all Environmental Laws and permits applicable to, or required by, the ownership, lease or use of its Real Property now or hereafter owned, leased or operated by Borrower or any of its Subsidiaries, and will promptly pay or cause to be paid all costs and expenses incurred in connection with such compliance, (ii) will keep or cause to be kept all such Real Property free and clear of any Liens (other than Permitted Liens) imposed pursuant to such Environmental Laws, and (iii) will not generate, use, treat, store, Release or dispose of, or permit the generation, use, treatment, storage, Release or disposal of Hazardous Materials on any Real Property now or hereafter owned, leased or operated by Borrower or any of its Subsidiaries, or transport or permit the transportation of Hazardous Materials to or from any such Real Property, except for Hazardous Materials generated, used, treated, stored, Released or disposed of at any such Real Properties in compliance in all material respects with all applicable Environmental Laws and as required in connection with the normal operation, use and maintenance of the business or operations of Borrower or any of its Subsidiaries.

 

(b)     (i) After the receipt by Lender of any notice of the type described in Section 8.01(h), (ii) at any time that Borrower or any of its Subsidiaries are not in compliance with Section 8.06(a), or (iii) in the event that Lender has exercised any of the remedies pursuant to the last paragraph of Section 10, Borrower will (in each case) provide, at the sole expense of Borrower and at the request of Lender, an environmental site assessment report concerning any Real Property owned, leased or operated by Borrower or any of its Subsidiaries, prepared by an environmental consulting firm reasonably approved by Lender, indicating the presence or absence of Hazardous Materials and the potential cost of any removal or remedial action in connection with such Hazardous Materials on such Real Property. If Borrower fails to provide the same within 45 days after such request was made, Lender may order the same, the cost of which shall be borne by Borrower, and Borrower shall grant and hereby grants to Lender and their respective agents access to such Real Property and specifically grants Lender an irrevocable non-exclusive license, subject to the rights of tenants, to undertake such an assessment at any reasonable time upon reasonable notice to Borrower, all at the sole expense of Borrower.

 

8.07.     ERISA. Borrower will, and will cause each of its Subsidiaries to, (a) except as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, comply in all material respects with the provisions of ERISA and the Code applicable to ERISA Plans and the laws applicable to any Foreign Pension Plan, (b) furnish to Lender as soon as possible after, and in any event within ten (10) days after any responsible officer of Borrower, any of its Subsidiaries or any ERISA Affiliate knows or has reason to know that any event described in Section 10.06 has occurred or is reasonably expected to occur that, alone or together with any other event described therein that has occurred or is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect, a statement of the chief financial officer of Borrower setting forth details as to such event and the action, if any, that Borrower, or any of its Subsidiaries proposes to take with respect thereto and (c) promptly and in any event within ten (10) days after the filing thereof with the (x) United States Department of Labor, furnish to Lender copies of each Schedule SB (Actuarial Information) to the Annual Report (Form 5500 Series) and (y) PBGC, furnish to Lender copies of material correspondence with respect to any of the events referred to in clause (b) above, in each case with respect to each ERISA Plan.

 

22

 

8.08.     End of Fiscal Years; Fiscal Quarters. Borrower will cause (i) each of its, and each of its Subsidiaries, fiscal years to end on December 31 of each year and (ii) each of its, each of its Subsidiaries, fiscal quarters to end on March 31, June 30, September 30 and December 31.

 

8.09.     Performance of Obligations. Borrower will, and will cause each of its Subsidiaries to, perform all of its obligations under the terms of each mortgage, indenture, security agreement, loan agreement or credit agreement and each other agreement, lease, contract or instrument by which it is bound, except such non-performances as could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

8.10.     Payment of Taxes. Borrower will pay and discharge, and will cause each of its respective Subsidiaries to pay and discharge, all taxes, assessments and governmental charges or levies imposed upon it or upon its income or profits or upon any properties belonging to it, in each case on a timely basis, and all lawful claims which, if unpaid, might become a Lien or charge upon any properties of Borrower or any of its Subsidiaries not otherwise permitted under Section 9.01(a); provided that neither Borrower nor any of its Subsidiaries shall be required to pay any such tax, assessment, charge, levy or claim which (a) could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or (b) is being contested in good faith and by proper proceedings if it has maintained adequate reserves with respect thereto in accordance with generally accepted accounting principles.

 

8.11.     Use of Proceeds. Borrower will exclusively use all proceeds of (a) the Delayed Draw-Down Term Loan to fund Permitted Share Repurchases or Permitted Acquisitions, and (b) Revolving Loans for the working capital and general corporate purposes of Borrower and its Subsidiaries, including to pay the fees and expenses incurred in connection with the Transaction.

 

8.12.     Additional Security; Further Assurances; Etc.

 

(a)     Except as otherwise provided in Section 9.13, Borrower will, and will cause each of its Wholly-Owned Domestic Subsidiaries to, grant to the Lender security interests and mortgages in such assets and properties of Borrower and such Wholly-Owned Domestic Subsidiaries as are not covered by the original Security Documents and as may be reasonably requested from time to time by Lender (collectively, the “Additional Security Documents”). All such security interests and mortgages shall be granted pursuant to documentation reasonably satisfactory in form and substance reasonably satisfactory to Lender and shall constitute, after appropriate filings have been made (to the extent required to be so made), valid and enforceable perfected security interests and mortgages superior to and prior to the rights of all third Persons and subject to no other Liens except for Permitted Liens. The Additional Security Documents or instruments related thereto shall have been duly recorded or filed in such manner and in such places as are required by law to establish, perfect, preserve and protect the Liens in favor of Lender required to be granted pursuant to the Additional Security Documents and all taxes, fees and other charges payable in connection therewith shall have been paid in full.

 

23

 

(b)     Borrower will, and will cause each of the other Credit Parties to, at the expense of Borrower, make, execute, endorse, acknowledge, file and/or deliver to Lender from time to time such vouchers, invoices, schedules, confirmatory assignments, conveyances, financing statements, transfer endorsements, powers of attorney, certificates, real property surveys, reports, landlord waivers, bailee agreements, control agreements and other assurances or instruments and take such further steps relating to the Collateral covered by any of the Security Documents as Lender may reasonably require. Furthermore, Borrower will, and will cause the other Credit Parties to, deliver to Lender such opinions of counsel, title insurance and other related documents as may be reasonably requested by Lender to assure itself that this Section 8.12 has been complied with.

 

(c)     If Lender reasonably determines that they are required by law or regulation to have appraisals prepared in respect of any Real Property of Borrower and its Subsidiaries constituting Collateral, Borrower will, at its own expense, provide to Lender appraisals which satisfy the applicable requirements of the Real Estate Appraisal Reform Amendments of the Financial Institution Reform, Recovery and Enforcement Act of 1989, as amended, and which shall otherwise be in form and substance reasonably satisfactory to Lender.

 

(d)     Borrower agrees that each action required by clauses (a) through (c) of this Section 8.12 shall be completed as soon as reasonably practicable, but in no event later than 90 days after such action is required to be taken or is requested to be taken, as the case may be, at the direction of Lender.

 

8.13.     Foreign Subsidiaries Security. Following a change in the relevant sections of the Code or the regulations, rules, rulings, notices or other official pronouncements issued or promulgated thereunder, with respect to any Foreign Subsidiary of Borrower which has not already had all of its stock pledged pursuant to the Security Agreement, Lender may request in writing that Borrower deliver to Lender within 60 days after such request evidence reasonably satisfactory to Lender that (i) a pledge of 66% or more of the total combined voting power of all classes of capital stock of such Foreign Subsidiary entitled to vote, (ii) the entering into by such Foreign Subsidiary of a security agreement in substantially the form of the Security Agreement and (iii) the entering into by such Foreign Subsidiary of a guaranty in substantially the form of the Subsidiaries Guaranty, in any such case would not reasonably be expected to cause (x) any undistributed earnings of such Foreign Subsidiary as determined for Federal income tax purposes to be treated as a deemed dividend to such Foreign Subsidiary’s United States parent for Federal income tax purposes, (y) other materially adverse income tax or other consequences to the Credit Parties or (z) violate or conflict with the laws applicable to such Foreign Subsidiary, and, to the extent such evidence is so delivered (or no evidence to the contrary is delivered within such 60-day period) Borrower will, at the written request of Lender, take one or more of the actions described in the immediately succeeding sentence. Provided that the actions set forth in clauses (i) through (iii) above would not cause the conditions set forth in either clause (x) or (y) above to be met, then within 45 days after Lender’s request, (I) Borrower will, or will cause its applicable Subsidiary to, pledge that portion of each such Foreign Subsidiary’s outstanding capital stock not theretofore pledged pursuant to the Security Agreement to Lender pursuant to the Security Agreement (or another pledge agreement in substantially similar form, if needed), (II) Borrower will cause each such Foreign Subsidiary (to the extent that it is a Wholly-Owned Subsidiary) to execute and deliver the Security Agreement (or another security agreement or pledge agreement in substantially similar form, if needed), granting Lender a security interest in all of each such Foreign Subsidiary’s assets and securing the Obligations of Borrower under the Credit Documents, under any Interest Rate Protection Agreement or Other Hedging Agreement and under any secured cash management arrangement and, in the event the Subsidiaries Guaranty shall have been executed by such Foreign Subsidiary, the obligations of such Foreign Subsidiary thereunder, and (III) Borrower will cause each such Foreign Subsidiary (to the extent it is a Wholly-Owned Subsidiary) to execute and deliver the Subsidiaries Guaranty (or another guaranty in substantially similar form, if needed), guaranteeing the Obligations of Borrower under the Credit Documents, under any Interest Rate Protection Agreement or Other Hedging Agreement and under any secured cash management arrangement, in each case to the extent that the entering into the Security Agreement or Subsidiaries Guaranty is permitted by the laws of the respective foreign jurisdiction applicable to such Foreign Subsidiary and with all documents delivered pursuant to this Section 8.13 to be in form and substance reasonably satisfactory to Lender.

 

24

 

8.14.     Ownership of Subsidiaries; Etc. Except (i) for non-Wholly-Owned Subsidiaries existing as of the Effective Date or (ii) as otherwise permitted by the definition of Permitted Acquisition, Borrower will, and will cause each of its Subsidiaries to, either solely or together with one or more other Wholly-Owned Subsidiaries, own 100% of the capital stock and other equity interests of each of their Subsidiaries (other than, in the case of a Foreign Subsidiary, directors’ qualifying shares and nominal shares held by local nationals, in each case to the extent required by applicable law).

 

8.15.     Permitted Acquisitions.

 

(a)     Subject to the provisions of this Section 8.15 and the requirements contained in the definition of Permitted Acquisition, Borrower and each of its Wholly-Owned Subsidiaries (provided, that any Permitted Acquisition requiring Acquisition Consideration of $5,000,000 or greater must be by Borrower or a Subsidiary Guarantor) may from time to time effect Permitted Acquisitions, so long as (in each case except to the extent Lender otherwise specifically agrees in writing in the case of a specific potential acquisition): (i) no Default or Event of Default shall have occurred and be continuing at the time of the consummation of the proposed Permitted Acquisition or immediately after giving effect thereto; (ii) Borrower shall have given to Lender at least 5 Business Days’ prior written notice of any Permitted Acquisition (or such shorter period of time as may be reasonably acceptable to Lender), which notice shall describe in reasonable detail the principal terms and conditions of such Permitted Acquisition; (iii) Lender shall have received, to the extent available, the most recent year-end financial statements then available (audited, if applicable) and the most recent interim unaudited quarterly financial statements then available for the then current fiscal year of the Acquired Entity or Business being acquired pursuant to such proposed Permitted Acquisition, although to the extent that such audited year-end financial statements are not available, Lender shall be reasonably satisfied with the form and scope of all financial statements for such Acquired Entity or Business for the then most recently ended fiscal year of such Acquired Entity or Business and for the then current fiscal year of such Acquired Entity or Business; (iv) calculations are made by Borrower with respect to the financial covenants contained in Sections 9.08 (to the extent required) and 9.09 for the respective Calculation Period on a Pro Forma Basis as if the respective Permitted Acquisition (as well as all other Permitted Acquisitions and Dividends (including Permitted Share Repurchases) theretofore consummated after the first day of such Calculation Period (but excluding from Consolidated Fixed Charge Coverage Ratio the portion(s) of any Permitted Acquisition(s), Permitted Share Repurchases and Special Dividends funded with Cash on Hand unless required to be included due to a Covenant Inclusion Event)) had occurred on the first day of such Calculation Period, and such calculations shall show that such financial covenants would have been complied with as of the last day of such Calculation Period; (v) if such Permitted Acquisition is required to be included in the calculation of Consolidated Fixed Charge Coverage Ratio pursuant to Section 9.08, upon Lender’s request, a forecast is provided by Borrower showing compliance with such covenant for the subsequent three (3) fiscal quarters ended after such Permitted Acquisition, and (vi) all of the representations and warranties contained herein and in the other Credit Documents shall be true and correct in all material respects with the same effect as though such representations and warranties had been made on and as of the date of such Permitted Acquisition (both before and after giving effect thereto), unless stated to relate to a specific earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date; and (vii) Borrower shall have delivered to Lender (with copies for Lender) a certificate executed by one of its Authorized Officers certifying compliance with the requirements of preceding clauses (i) through (vi), inclusive (to the extent applicable), and containing the calculations (in reasonable detail) required by preceding clause (iv).

 

25

 

(b)     Within ten (10) days after each Permitted Acquisition involving the creation or acquisition of a Subsidiary, or the acquisition of capital stock or other equity interest of any Person, the capital stock or other equity interests thereof created or acquired in connection with such Permitted Acquisition shall be pledged for the benefit of Lender pursuant to the Security Agreement.

 

(c)     Borrower will cause (i) each Wholly-Owned Domestic Subsidiary, and (ii) to the extent required by Section 8.13, each Wholly-Owned Foreign Subsidiary, to execute and deliver all of the documentation as and to the extent required by, Sections 8.12 and 9.13, to the reasonable satisfaction of Lender.

 

(d)     The consummation of each Permitted Acquisition shall be deemed to be a representation and warranty by Borrower that the certifications pursuant to this Section 8.15 and the definition of Permitted Acquisition are true and correct and that all conditions thereto have been satisfied (or waived, to the extent applicable, in a prior writing by Lender) and that same is permitted in accordance with the terms of this Agreement, which representation and warranty shall be deemed to be a representation and warranty for all purposes hereunder, including, without limitation, Sections 7 and 10.

 

8.16.     Cash Management Services Etc. Borrower and its Wholly-Owned Subsidiaries (other than Foreign Subsidiaries) shall maintain substantially all of their cash management services from Lender other than (i) nominal amounts of cash, (ii) Restricted cash, (iii) cash required to be maintained at Subsidiary Guarantors in order to (but only to the extent required to) maintain capital or net worth requirements imposed on such Subsidiary Guarantors by governmental authorities due to the regulated nature of such Subsidiary Guarantors’ operations, (iv) payroll accounts, and (v) local checking accounts and other operating cash accounts for local offices provided that the funds in such accounts shall not at any time exceed $250,000 in the aggregate.

 

26

 

8.17.     Margin Regulations. Except as provided in the second succeeding sentence, Borrower will take all actions so that at all times the fair market value of all Margin Stock owned by Borrower and its Subsidiaries (other than capital stock of Borrower held in treasury) shall not exceed $50,000. So long as the covenant contained in the immediately preceding sentence is complied with, all Margin Stock at any time owned by Borrower and its Subsidiaries will not constitute Collateral and no security interest shall be granted therein pursuant to any Credit Document. If at any time the fair market value of all Margin Stock owned by Borrower and its Subsidiaries (other than capital stock of Borrower held in treasury) exceeds $50,000, then (x) all Margin Stock owned by the Credit Parties (other than capital stock of Borrower held in treasury) shall be pledged, and delivered for pledge, pursuant to the Security Agreement and (y) Borrower will execute and deliver to Lender appropriate completed forms (including, without limitation, Forms G-3 and U-1, as appropriate) establishing compliance with Regulations T, U and X. If at any time any Margin Stock is required to be pledged as a result of the provisions of the immediately preceding sentence, repayments of outstanding Obligations shall be required, and subsequent Credit Events shall be permitted, only in compliance with the applicable provisions of Regulations T, U and X.

 

8.18.     Primary Concentration Account. Borrower will maintain its Primary Concentration Account with Lender.

 

Section 9     Negative Covenants. Borrower hereby covenants and agrees that on and after the Effective Date and until the Commitments have terminated and the Loans, Notes, Fees and all other Obligations (other than any indemnities described in this Agreement or the other Credit Documents which are not then due and payable) incurred hereunder and thereunder, are paid in full:

 

9.01.     Liens. Borrower will not, nor will it permit any of its Subsidiaries to, create, incur, assume or suffer to exist any Lien upon or with respect to any property or assets (real or personal, tangible or intangible) of Borrower or any of its Subsidiaries, whether now owned or hereafter acquired; provided that the provisions of this Section 9.01 shall not prevent the creation, incurrence, assumption or existence of the following (Liens described below are herein referred to as “Permitted Liens”):

 

(a)     Liens for taxes, assessments or governmental charges or levies not yet due or Liens for taxes, assessments or governmental charges or levies that are in amounts that could not reasonably be expected to have a Material Adverse Effect or are being contested in good faith and by appropriate proceedings for which adequate reserves have been established in accordance with generally accepted accounting principles;

 

(b)     Liens in respect of property or assets of Borrower or any of its Subsidiaries imposed by law, which were incurred in the ordinary course of business and do not secure Indebtedness for borrowed money, such as carriers’, warehousemen’s, materialmen’s, repairmen’s, supplier’s and mechanics’ liens and other similar Liens arising in the ordinary course of business, and (x) which do not in the aggregate materially impair the value of Borrower’s and its Subsidiaries’ property or assets taken as a whole or materially impair the use thereof in the operation of the business of Borrower and its Subsidiaries taken as a whole or (y) which are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the forfeiture or sale of the property or assets subject to any such Lien;

 

27

 

(c)     Liens in existence on the Effective Date which are listed, and the property subject thereto described, in Schedule V;

 

(d)     Liens that are replacements of Liens otherwise permitted under this Section 9.01, provided that (x) the aggregate principal amount of the Indebtedness, if any, secured by such Liens does not increase from that amount outstanding at the time of any such renewal, replacement or extension and (y) any such renewal, replacement or extension does not encumber any additional assets or properties of Borrower or any of its Subsidiaries;

 

(e)     licenses, sublicenses, leases or subleases granted to other Persons that do not materially impair the conduct of the business of Borrower or any of its Subsidiaries;

 

(f)     Liens upon assets of Borrower or any of its Subsidiaries subject to purchase money debt or Capitalized Lease Obligations to the extent such purchase money debt or Capitalized Lease Obligations are permitted by Section 9.04, provided that (x) such Liens only serve to secure the payment of Indebtedness arising under such purchase money debt or Capitalized Lease Obligation and (y) the Lien encumbering the asset giving rise to the purchase money debt or Capitalized Lease Obligation does not encumber any other asset of Borrower or any Subsidiary (except for customary cross-collateralization provisions pursuant to which the lien of the single financial institution may extend to all assets financed by such financial institution and its affiliates);

 

(g)     easements, rights-of-way, restrictions, encroachments and other similar charges or encumbrances, and minor title deficiencies, in each case not securing Indebtedness and that do not materially impair the conduct of the business of Borrower or any of its Subsidiaries;

 

(h)     Liens arising from precautionary UCC financing statement filings regarding operating leases entered into in the ordinary course of business;

 

(i)     Liens arising out of the existence of judgments or awards in respect of which Borrower or any of its Subsidiaries shall be contesting in good faith, so long as such judgments or awards do not constitute an Event of Default hereunder;

 

(j)     statutory and common law landlords’ liens under leases to which Borrower or any of its Subsidiaries is a party;

 

(k)     Liens (other than Liens imposed under ERISA) incurred in the ordinary course of business in connection with (x) workers compensation claims, unemployment insurance, social security benefits and other similar forms of governmental insurance benefits and (y) deposits securing the performance of bids, tenders, leases (other than Capitalized Lease Obligations) and contracts (other than Indebtedness) in the ordinary course of business, statutory obligations, surety bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business (exclusive of obligations in respect of the payment for borrowed money);

 

(l)     Liens on property or assets of Borrower or any of its Subsidiaries in favor of Lender;

 

(m)     customary Liens in favor of banking institutions encumbering deposits (including the right of set-off) held by such banking institutions incurred in the ordinary course of business;

 

28

 

(n)     Permitted Encumbrances;

 

(o)     deposit, escrow or similar accounts held by customers of Borrower or any of its Subsidiaries as security for the obligations of Borrower or any of its Subsidiaries under customer contracts entered into in the ordinary course of business on a basis consistent with past practices;

 

(p)     Liens solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any letter of intent or purchase agreement with respect to a Permitted Acquisition;

 

(q)     Liens in respect of the Indebtedness permitted by Section 9.04(e) and (m); provided, that Liens in respect of the Indebtedness permitted by Section 9.04(m) must be limited to the assets originally secured prior to such Permitted Acquisition; and

 

(r)     Liens not otherwise permitted by clauses (a) through (q) of this Section 9.01 on property or assets with an aggregate fair value not in excess of, and securing liabilities not in excess of, $5,000,000.

 

9.02.     Consolidation, Merger or Sale of Assets, Etc. Borrower will not, nor will it permit any of its Subsidiaries to, wind up, liquidate or dissolve its affairs or enter into any partnership, joint venture, or transaction of merger or consolidation, or convey, sell, lease or otherwise dispose of all or any part of its property or assets, except:

 

(a)     sales of inventory in the ordinary course of business;

 

(b)     the sale, abandonment or other disposition of obsolete, uneconomic, damaged or worn-out property or property that is otherwise no longer used or useful in the ordinary course of business;

 

(c)     the sale or discount, in each case without recourse and in the ordinary course of business, of accounts receivable arising in the ordinary course of business, but only in connection with the compromise or collection thereof and not as part of any financing transaction or bulk sale;

 

(d)     the granting of licenses, sublicenses, leases or subleases (including, without limitation, leases and subleases of Real Property and non-exclusive licenses of patents, trademarks, copyrights and other intellectual property rights) to other Persons that do not materially impair the conduct of the business of Borrower or any of its Subsidiaries;

 

(e)     the use or transfer of cash or Cash Equivalents in a manner that is not prohibited by the terms of the Credit Documents;

 

(f)     the granting of Permitted Liens, the making of Investments to the extent permitted by Section 9.05 and the making of Dividends to the extent permitted by the Credit Documents;

 

(g)     any involuntary loss, damage or destruction of property which is covered by adequate insurance;

 

29

 

(h)     any involuntary condemnation, seizure or taking, by exercise of the power of eminent domain or otherwise, or confiscation or requisition of use of property;

 

(i)     the sale or issuance of equity interests to the extent permitted by the Credit Documents;

 

(j)     (i) the lapse of registered patents, trademarks, copyrights and other intellectual property of the Borrower or any Subsidiary to the extent not commercially desirable in the conduct of its business or (ii) the abandonment of patents, trademarks, copyrights or other intellectual property rights in the ordinary course of business;

 

(k)     the expiration of leasehold interests or the termination of leasehold interests;

 

(l)     sales, trades, leases, subleases and other dispositions of non-Collateral assets;

 

(m)     sales, trades, leases, subleases or other dispositions of assets not otherwise permitted in clauses (a) through (l) above, so long as (i) each such disposition is made at fair market value and (ii) the aggregate fair market value of all assets disposed of in any one fiscal year does not exceed $250,000;

 

(n)     any Subsidiary of Borrower may merge with and into, or be dissolved or liquidated into, or transfer any of its assets to Borrower or any Wholly-Owned Domestic Subsidiary of Borrower which is a Subsidiary Guarantor so long as (i) in the case of any such merger, dissolution or liquidation involving Borrower, Borrower is the surviving corporation of any such merger, dissolution or liquidation, (ii) in all other cases, a Wholly-Owned Domestic Subsidiary which is a Subsidiary Guarantor is the surviving corporation of any such merger, dissolution or liquidation, (iii) the security interests granted to Lender pursuant to the Security Documents in the assets of such Subsidiary shall remain in full force and effect and perfected (to at least the same extent as in effect immediately prior to such merger, dissolution or liquidation), and (iv) in the case of any such transaction pursuant to which any consideration is paid to a Person that is not a Wholly-Owned Subsidiary of Borrower, such consideration shall be permitted to be paid at such time only to the extent that it could otherwise have been paid pursuant to (and Borrower shall be required to satisfy the provisions of) Section 8.15 and Section 9.05(h), as applicable; and

 

(o)     (A) any Subsidiary of Borrower that has no assets or liabilities (other than immaterial assets or liabilities) may be dissolved or liquidated, (B) any Subsidiary of Borrower may merge with and into, or be dissolved or liquidated into, or transfer any or all of its assets to, a Subsidiary of Borrower so long as (i) in the case of any such transfer, merger, dissolution or liquidation involving a Wholly-Owned Subsidiary, a Wholly-Owned Subsidiary of Borrower is the surviving entity of any such transaction and (ii) in the case of any such transaction pursuant to which any consideration is paid to a Person that is neither Borrower nor a Wholly-Owned Subsidiary thereof, such consideration shall be permitted to be paid at such time only to the extent that it could otherwise have been paid pursuant to (and Borrower shall be required to satisfy the provisions of) Section 8.15 and Section 9.05(h), as applicable, and (C) any Foreign Subsidiary may merge into another Foreign Subsidiary.

 

30

 

9.03.     Dividends. Borrower will not, nor will it permit any of its Subsidiaries to, authorize, declare or pay any Dividends with respect to Borrower or any of its Subsidiaries, except that:

 

(a)     any Subsidiary of Borrower may (x) pay Dividends to Borrower or to any Wholly-Owned Subsidiary of Borrower and (y) if such Subsidiary is not a Wholly-Owned Subsidiary of Borrower, pay Dividends to its shareholders, partners or members generally so long as Borrower or its respective Subsidiary which owns the equity interest or interests in the Subsidiary paying such Dividends receives at least its proportionate share thereof (based upon its relative holdings of equity interests in the Subsidiary paying such Dividends and taking into account that the relative preferences, if any, of the various classes of equity interests in such Subsidiary);

 

(b)     Borrower may effect Permitted Share Repurchases funded with any combination of Cash on Hand, proceeds from a Revolving Loan, proceeds from a Delayed Draw-Down Term Loan, or proceeds from Permitted Subordinated Debt so long as (i) no Default or Event of Default then exists or would result therefrom, (ii) Borrower provides Lender prior notice of its intent to effect Permitted Share Repurchases based on authorization of a repurchase plan by the Board of Directors of Borrower, (iii) calculations are made by Borrower with respect to the financial covenants contained in Sections 9.08 (to the extent required) and 9.09 for the respective Calculation Period on Pro Forma Basis as if the respective portion of the Permitted Share Repurchase funded with Cash on Hand (as well as all Dividends (including Permitted Share Repurchases) and Permitted Acquisitions theretofore paid or made after the first day of such Calculation Period (but excluding (A) the portion of any other Permitted Share Repurchase or Permitted Acquisition funded with Cash on Hand and (B) Special Dividends from Consolidated Fixed Charge Coverage Ratio (in each case of (A) or (B)) unless such amounts are required to be included due to a Covenant Inclusion Event)) had occurred on the first day of such Calculation Period, and such calculations shall show that such financial covenants would have been complied with as of the last day of such Calculation Period, (iv) if such Permitted Share Repurchase is required to be included in the calculation of Consolidated Fixed Charge Coverage Ratio pursuant to Section 9.08, upon Lender’s request, a forecast is provided by Borrower showing compliance with such covenant for the subsequent three (3) fiscal quarters ended after such Permitted Share Repurchase, and (v) in connection with the payment or making of such Permitted Share Repurchase, Borrower shall have delivered to Lender a certificate executed by one of its Authorized Officers certifying compliance with the requirements of preceding clauses (i) through (v), inclusive, and containing the calculations (in reasonable detail) required by preceding clause (ii), and (iii) if applicable.

 

(c)     Borrower may pay or make Dividends (other than Dividends arising on account of repurchases by Borrower of common stock or other equity interests in Borrower or Special Dividends) so long as (i) no Default or Event of Default then exists or would result therefrom, (ii) calculations are made by Borrower with respect to the financial covenants contained in Sections 9.08 and 9.09 for the respective Calculation Period on Pro Forma Basis as if the respective Dividend (as well as all other Dividends (including Permitted Share Repurchases) or Permitted Acquisitions theretofore paid or made after the first day of such Calculation Period (but excluding (A) the portion of any Permitted Share Repurchase or Permitted Acquisition funded with Cash on Hand and (B) Special Dividends (in each case of (A) or (B)) from Consolidated Fixed Charge Coverage Ratio unless such amounts are required to be included due to a Covenant Inclusion Event)) had occurred on the first day of such Calculation Period, and such calculations shall show that such financial covenants would have been complied with as of the last day of such Calculation Period, and (iii) in connection with the payment or making of cash Dividends to holders of its capital stock, Borrower shall have delivered to Lender a certificate executed by one of its Authorized Officers certifying compliance with the requirements of preceding clauses (i) through (iii), inclusive, and containing the calculations (in reasonable detail) required by preceding clause (ii).

 

31

 

(d)     Borrower may pay or make Special Dividends so long as (i) no Default or Event of Default then exists or would result therefrom, (ii) calculations are made by Borrower with respect to the financial covenants contained in Sections 9.08 (to the extent required) and 9.09 for the respective Calculation Period on a Pro Forma Basis as if the respective Dividend (as well as all other Dividends (including Permitted Share Repurchases) and Permitted Acquisitions theretofore paid or made after the first day of such Calculation Period but excluding (A) the portion of any Permitted Share Repurchase or Permitted Acquisition funded with Cash on Hand and (B) Special Dividends (in each case of (A) or (B)) from Consolidated Fixed Charge Coverage Ratio unless such amounts are required to be included due to a Covenant Inclusion Event) had occurred on the first day of such Calculation Period, and such calculations shall show that such financial covenants would have been complied with as of the last day of such Calculation Period, (iii) if such Special Dividend is required to be included in the calculation of Consolidated Fixed Charge Coverage Ratio pursuant to Section 9.08, upon Lender’s request, a forecast is provided by Borrower showing compliance with such covenant for the subsequent three (3) fiscal quarters ended after the payment of the Special Dividend, and (iv) in connection with the payment or making of such Special Dividend, Borrower shall have delivered to Lender a certificate executed by one of its Authorized Officers certifying compliance with the requirements of preceding clauses (i) through (iv), inclusive, and containing the calculations (in reasonable detail) required by preceding clauses (ii) and (iii) if applicable.

 

(e)     For purposes of compliance with this Section 9.03, unless an Event of Default has occurred and is continuing, Borrower may pay any Dividend within 70 days after the date of declaration thereof, if at the date of declaration such payment would have complied with the provisions of this Agreement.

 

9.04.     Indebtedness. Borrower will not, nor will it permit any of its Subsidiaries to, contract, create, incur, assume or suffer to exist any Indebtedness, except:

 

(a)     Indebtedness incurred pursuant to this Agreement and the other Credit Documents;

 

(b)     Indebtedness outstanding on the Effective Date and listed on Schedule III (as reduced by any permanent repayments of principal thereof);

 

(c)     any Indebtedness that is an extension, renewal or refinancing of Indebtedness permitted by this Section 9.04; provided, that the aggregate principal amount of the Indebtedness to be extended, renewed or refinanced does not increase from that amount outstanding at the time of any such extension, renewal or refinancing;

 

(d)     Indebtedness of Borrower under Interest Rate Protection Agreements entered into with respect to other Indebtedness permitted under this Section 9.04 so long as the entering into of such Interest Rate Protection Agreements are bona fide hedging activities and are not for speculative purposes;

 

32

 

(e)     Indebtedness of Borrower under Other Hedging Agreements providing protection to Borrower and its Subsidiaries against fluctuations in currency values in connection with Borrower’s or any of its Subsidiaries’ foreign operations so long as the entering into of such Other Hedging Agreements are bona fide hedging activities and are not for speculative purposes;

 

(f)     Indebtedness consisting of guaranties by Borrower of Indebtedness of a Subsidiary permitted under this Agreement and with a maximum liability not in excess of $1,000,000;

 

(g)     Indebtedness in respect of overdrafts and related liabilities arising from treasury, depository, credit or debit card, purchasing card, procurement card, stored value card, or cash management services (including any automated clearing house transfers of funds netting services, automatic clearinghouse arrangements, overdraft protections and similar arrangements) in each case in connection with deposit accounts incurred in the ordinary course of business;

 

(h)     Indebtedness of Borrower or any of its Subsidiaries which may be deemed to exist in connection with agreements providing for indemnification, purchase price adjustments and similar obligations in connection with the acquisition or disposition of assets in accordance with the requirements of this Agreement so long as any such obligations are those of the Person making the respective acquisition or sale, and are not guaranteed by any other Person except as permitted by Section 9.04(f);

 

(i)     Permitted Subordinated Debt of Borrower in an aggregate principal amount not in excess of $25,000,000 at any one time outstanding, so long as (i) all such Indebtedness is incurred in accordance with the requirements of the definition of Permitted Subordinated Debt, (ii) no Default or Event of Default exists at the time of incurrence thereof or would result therefrom, (iii) the Net Debt Proceeds therefrom are used to effect a Permitted Acquisition or Permitted Share Repurchase in accordance with the requirements of this Agreement, (iv) calculations are made by Borrower with respect to the financial covenants contained in Sections 9.08 and 9.09 for the respective Calculation Period on a Pro Forma Basis as if such Permitted Subordinated Debt (as well as all other Permitted Subordinated Debt theretofore incurred after the first day of such Calculation Period) had been incurred on the first day of such Calculation Period, and such calculations shall show that such financial covenants would have been complied with as of the last day of such Calculation Period and (v) Borrower shall have delivered to Lender a certificate executed by one of its Authorized Officers certifying compliance with the requirements of preceding clauses (i) through (iv), inclusive, and containing the calculations (in reasonable detail) required by preceding clause (iv);

 

(j)     Indebtedness consisting of the financing of insurance premiums in the ordinary course of business;

 

(k)     Indebtedness representing deferred compensation to employees of a Borrower or any of its Subsidiaries incurred in the ordinary course of business;

 

(l)     Indebtedness of Borrower supported by a letter of credit in a principal amount not to exceed the face amount of such letter of credit;

 

(m)     Indebtedness of Borrower or its Subsidiaries assumed in a Permitted Acquisition;

 

33

 

(n)     Indebtedness constituting Investments to the extent permitted by Section 9.05;

 

(o)     accrual of interest, accretion or amortization of original issue discount, or the payment of interest in kind, in each case, on Indebtedness that is otherwise permitted hereunder;

 

(p)     unsecured Indebtedness of Borrower or its Subsidiaries consisting of earn-out, performance bonus, consulting or deferred compensation or purchase price adjustment owing to sellers of assets or equity interests the Borrower or its Subsidiaries that is incurred in connection with the consummation of one or more Permitted Acquisitions; and

 

(q)     Indebtedness (including purchase money debt and Capitalized Lease Obligations) not otherwise permitted by clauses (a) through (p) of this Section 9.04 not in excess of (i) $7,500,000 in the aggregate at any time outstanding through and including December 31, 2021 and (ii) $5,000,000 in the aggregate at any time outstanding after December 31, 2021.

 

9.05.     Advances, Investments and Loans. Borrower will not, and will not permit its Subsidiaries to, directly or indirectly, lend money or credit or make advances to any Person, or purchase or acquire any stock, obligations or securities of, or any other interest in, or make any capital contribution to, any other Person, or purchase or own a futures contract or otherwise become liable for the purchase or sale of currency or other commodities at a future date in the nature of a futures contract, or hold any cash or Cash Equivalents (each of the foregoing an “Investment” and, collectively, “Investments”), except that the following shall be permitted:

 

(a)     Borrower and its Subsidiaries may acquire and hold accounts receivable owing to any of them, if created or acquired in the ordinary course of business;

 

(b)     Borrower and its Subsidiaries may acquire and hold cash and Cash Equivalents;

 

(c)     Borrower and its Subsidiaries may make Investments in negotiable instruments deposited or to be deposited for collection in the ordinary course of business;

 

(d)     Borrower and its Subsidiaries may hold the Investments held by them on the Effective Date and described on Schedule VI, provided that any additional Investments made with respect thereto shall be permitted only if permitted under the other provisions of this Section 9.05;

 

(e)     Borrower and its Subsidiaries may acquire and own investments (including debt obligations) received in connection with the bankruptcy or reorganization of suppliers and customers and in good faith settlement of delinquent obligations of, and other disputes with, customers and suppliers or otherwise arising in the ordinary course of business, including in connection with the foreclosure or enforcement of any Lien in favor of Borrower or any of its Subsidiaries;

 

(f)     Borrower and its Subsidiaries may enter into Interest Rate Protection Agreements to the extent permitted by Section 9.04(d);

 

(g)     Borrower and its Subsidiaries may enter into Other Hedging Agreements to the extent permitted by Section 9.04(e);

 

34

 

(h)     Borrower and the Subsidiary Guarantors may make capital contributions to their respective Subsidiaries that are Subsidiary Guarantors;

 

(i)     Borrower may enter into guarantees to the extent permitted under Section 9.04;

 

(j)     Permitted Acquisitions shall be permitted in accordance with Section 8.15;

 

(k)     Borrower may acquire and hold obligations of one or more officers, directors or other employees of Borrower or any of its Subsidiaries in connection with such officers’, directors’ or employees’ acquisition of shares of capital stock of Borrower so long as no cash is paid by Borrower or any of its Subsidiaries to such officers, directors or employees in connection with the acquisition of any such obligations;

 

(l)     Borrower may make loans and advances to Borrower’s or any of its Subsidiaries’ officers, directors or employees for reasonable and customary business and relocation expenses in the ordinary course of business;

 

(m)     Borrower and its Subsidiaries may make intercompany loans and advances to each other (provided, however, that intercompany loans and advances made by Borrower or its Domestic Subsidiaries to its or their Foreign Subsidiaries shall not exceed $10,000,000 in the aggregate at any time outstanding); and

 

(n)     Borrower may make Investments not otherwise permitted by clauses (a) through (m) of this Section 9.05 not in excess of $5,000,000 in the aggregate at any time outstanding.

 

9.06.     Transactions with Affiliates. Borrower will not, and will not permit its Subsidiaries to, enter into any transaction or series of related transactions with any Affiliate of Borrower or any of its Subsidiaries, other than in the ordinary course of business and on terms and conditions substantially as favorable to Borrower or such Subsidiary as would reasonably be obtained by Borrower or such Subsidiary at that time in a comparable arm’s length transaction with a Person other than an Affiliate, except that:

 

(a)     Dividends may be paid to the extent provided in Section 9.03;

 

(b)     loans may be made and other transactions may be entered into by Borrower and its Subsidiaries to the extent permitted by Sections 9.02, 9.04 and 9.05;

 

(c)     customary fees, indemnities and reimbursements may be paid to officers and directors of Borrower and its Subsidiaries;

 

(d)     Borrower and its Subsidiaries may enter into, and may make payments under, employment agreements, employee benefits plans, stock option plans, indemnification provisions, severance arrangements, net share settlement, and other similar compensatory arrangements with officers, employees and directors of Borrower and its Subsidiaries in the ordinary course of business;

 

(e)     periodic allocations of operating and overhead expenses among Borrower and its Subsidiaries may be made;

 

35

 

(f)     any Subsidiary of Borrower may pay to Borrower or any other Subsidiary, management, consulting or similar fees on a basis consistent with past practices;

 

(g)     Borrower and its Subsidiaries may enter into transactions that are approved by a majority of the Disinterested Directors; and

 

(h)     Borrower and its Subsidiaries may incur Permitted Subordinated Debt from an Affiliate.

 

Notwithstanding anything to the contrary contained in this Agreement, Borrower will not, and will not permit any of its Subsidiaries to, pay any management, consulting or similar fees to any of their respective Affiliates that are not Subsidiary Guarantors other than as permitted by clause (f) above.

 

9.07.     Changes to Legal Names, Organizational Identification Numbers, Jurisdiction or Type or Organization. Borrower will not, and will not permit any of the other Credit Parties to, change its legal name until (a) it shall have given to Lender not less than 30 days' prior written notice of its intention so to do (or such shorter period of time as may be acceptable to Lender), clearly describing such new name and providing other information in connection therewith as Lender may reasonably request, and (b) with respect to such new name, it shall have taken all action reasonably requested by Lender to maintain the security interests of Lender in the Collateral intended to be granted pursuant to the applicable Security Documents at all times fully perfected and in full force and effect. In addition, to the extent that any Credit Party does not have an organizational identification number on the Effective Date and later obtains one, or if there is any change in the organizational identification number of any Credit Party, Borrower or such other Credit Party shall promptly notify Lender of such new or changed organizational identification number and shall take all actions reasonably satisfactory to Lender to the extent necessary to maintain the security interests of Lender in the Collateral intended to be granted pursuant to the applicable Security Documents fully perfected and in full force and effect. Furthermore, Borrower will not, and will not permit any of the other Credit Parties to, change its jurisdiction of organization or its type of organization until (i) it shall have given to Lender not less than 15 days prior written notice of its intention so to do (or such shorter period of time as may be acceptable to Lender), clearly describing such new jurisdiction of organization and/or type of organization and providing such other information in connection therewith as Lender may reasonably request (although no change pursuant to this Section 9.07 shall be permitted to the extent that it involves a “registered organization” (within the meaning of the Nebraska UCC) ceasing to constitute same) and (ii) with respect to such new jurisdiction and/or type of organization, it shall have taken all actions reasonably requested by Lender to maintain the security interests of Lender in the Collateral intended to be granted pursuant to the Security Documents at all times fully perfected and in full force and effect.

 

36

 

Consolidated Fixed Charge Coverage Ratio. Borrower will not permit the Consolidated Fixed Charge Coverage Ratio for any Test Period ending on the last day of any fiscal quarter of Borrower to be less than 1.10:1.00. Notwithstanding anything to the contrary, any (a) Special Dividend, (b) the portion of the purchase price for any Permitted Share Repurchase paid with Cash on Hand, or (c) the portion of any Acquisition Consideration for a Permitted Acquisition paid with Cash on Hand (each applicable Special Dividend, Permitted Share Repurchase or Permitted Acquisition, a “Covenant Inclusion Event”) will be included in the calculation of Consolidated Fixed Charge Coverage Ratio upon the occurrence of any of the following: (i) immediately prior to and after giving effect to the closing of the transaction giving rise to the Covenant Inclusion Event, Borrower’s Liquidity does not meet or exceed the Minimum Liquidity Threshold; (ii) Borrower’s financial forecast at the time of the closing of the transaction giving rise to the Covenant Inclusion Event reflects that Borrower’s Liquidity will not meet or exceed the Minimum Liquidity Threshold for the subsequent three (3) fiscal quarters ended after such Covenant Inclusion Event; or (iii) Borrower’s Liquidity does not meet or exceed the Minimum Liquidity Threshold for the subsequent three (3) fiscal quarters ended after such the closing of the transaction giving rise to such Covenant Inclusion Event. Any Covenant Inclusion Event required to be included in the calculation of Consolidated Fixed Charge Coverage Ratio pursuant to the foregoing sentence shall be added to Consolidated Fixed Charge Coverage Ratio effective as of the fiscal quarter upon which the closing of the transaction giving rise to such Covenant Inclusion Event occurred and shall continue to be added to Consolidated Fixed Charge Coverage Ratio for the subsequent three (3) fiscal quarters thereafter.

 

9.08.     Consolidated Cash Flow Leverage Ratio. Borrower will not permit the Consolidated Cash Flow Leverage Ratio for any Test Period ending on the last day of any fiscal quarter of Borrower to be greater than 3.00:1.00.

 

9.09.     Limitations on Payments of Permitted Subordinated Debt; Modifications of Certificate of Incorporation, By-Laws and Documents Governing Permitted Subordinated Debt. Borrower will not, and will not permit its Subsidiaries to:

 

(a)     make (or give any notice in respect of) any voluntary or optional payment or prepayment on or redemption or acquisition for value of, or any prepayment or redemption as a result of any asset sale, change of control or similar event of (including, in each case without limitation, by way of depositing with the trustee with respect thereto, or with any other Person, money or securities before due for the purpose of paying when due), any Permitted Subordinated Debt, provided, however, so long as no Default or Event of Default then exists or would result therefrom, Borrower may pay in cash interest which due on such Permitted Subordinated Debt.

 

(b)     on and after the execution and delivery of any Permitted Subordinated Debt Document, amend or modify (or permit the amendment or modification of) any Permitted Subordinated Debt Document, other than any such amendment or modification that (i) makes the provisions thereof less restrictive on Borrower and its Subsidiaries (including with respect to any representation, warranty, covenant, default or event of default), (ii) reduces interest rates, commissions or fees paid (or to be paid) by Borrower or any of its Subsidiaries in connection therewith, (iii) extends the stated maturity of any Indebtedness thereunder, (iv) reduces or eliminates any prepayment premiums or (v) is otherwise not adverse to Lender in any material respect (in the reasonable opinion of Lender), provided that no amendment or modification may be made to the subordination provisions contained in any Permitted Subordinated Debt Document without the prior written consent of Lender; and

 

(c)  amend, modify or change its certificate or articles of incorporation (including, without limitation, by the filing or modification of any certificate or articles of designation), certificate of formation, limited liability company agreement or by-laws (or the equivalent organizational documents), as applicable, or any agreement entered into by it with respect to its capital stock or other equity interests, or enter into any new agreement with respect to its capital stock or other equity interests, unless such amendment, modification, change or other action contemplated by this clause (c) is permitted under Section 9.07 or could not reasonably be expected to be adverse to the interests of Lender in any material respect.

 

37

 

9.10.     Use of Proceeds. Borrower will not request any Borrowing, and Borrower shall not directly, or, to its knowledge, indirectly use the proceeds of any Borrowing or (a) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (b) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country, (c) in any manner that would result in the violation of any Sanctions applicable to any party hereto or (d) in violation of Section 7.08.

 

9.11.     Business, Etc. Borrower will not, and will not permit any of its Subsidiaries to, engage in any business other than the businesses engaged in by Borrower and its Subsidiaries as of the Effective Date and reasonable extensions thereof and businesses ancillary or complementary thereto.

 

9.12.     Limitation on Creation of Subsidiaries. Borrower will not, and will not permit any of its Subsidiaries to, establish, create or acquire after the Effective Date any Subsidiary, provided that Borrower and its Wholly-Owned Subsidiaries may (x) establish, create and, to the extent permitted by this Agreement, acquire Wholly-Owned Subsidiaries and (y) establish, create and acquire non-Wholly-Owned Subsidiaries to the extent permitted by the definition of Permitted Acquisition, in each case so long as (i) all of the capital stock and other equity interests of such new Subsidiary (except in the case of a Foreign Subsidiary, in which case, 65% of the capital stock and other equity interests) are (to the extent owned by a Credit Party) pledged to the Lender pursuant to, and to the extent required by, the Security Agreement, (ii) each such new Wholly-Owned Domestic Subsidiary (and, to the extent required by Section 8.13, each new Wholly-Owned Foreign Subsidiary) executes and delivers to the Lender a counterpart of the Subsidiaries Guaranty and the Security Agreement, (iii) each such new Wholly-Owned Domestic Subsidiary (and, to the extent required by Section 8.13, each new Wholly-Owned Foreign Subsidiary) enters into such mortgages and other Additional Security Documents as Lender may require pursuant to Section 8.12 and (iv) each such new Wholly-Owned Domestic Subsidiary (and to the extent required by Section 8.13, each new Wholly-Owned Foreign Subsidiary) executes and delivers all other relevant documentation (including opinions of counsel, resolutions, officers’ certificates and UCC financing statements) of the type described in Section 5 as such new Subsidiary would have had to deliver if it were a Credit Party on the Effective Date.

 

9.14     Limitation on Issuance of Capital Stock.

 

(a)      Borrower will not, and will not permit any of its Subsidiaries to, issue (i) any preferred stock or other preferred equity interests other than (x) Qualified Preferred Stock of Borrower or (y) any preferred stock issued by a Subsidiary of Borrower except to the extent that such preferred stock is held by Borrower or a Wholly-Owned Subsidiary thereof or (ii) any redeemable common stock or other redeemable common equity interests other than redeemable common stock or other redeemable common equity interests that is redeemable at the sole option of Borrower or such Subsidiary, as the case may be.

 

38

 

(b)      Borrower will not permit any of its Subsidiaries to issue any capital stock or other equity interests (including by way of sales of treasury stock) or any options or warrants to purchase, or securities convertible into, capital stock or other equity interests, except (i) for transfers and replacements of then-outstanding shares of capital stock or other equity interests, (ii) for stock splits, stock dividends and issuances which do not decrease the percentage ownership of Borrower or any of its Subsidiaries in any class of the capital stock or other equity interests of such Subsidiary, (iii) in the case of Foreign Subsidiaries, to qualify directors and other nominal amounts required to be held by local nationals in each case to the extent required by applicable law, or (iv) for issuances by newly created or acquired Subsidiaries in accordance with the terms of this Agreement.

 

Section 10     Events of Default. Upon the occurrence of any of the following specified events (each an “Event of Default”):

 

10.01.     Payments. Borrower shall default in the payment when due of any principal or interest of any Loan or any Note, and such failure shall continue unremedied for a period of three Business Days; or

 

10.02.     Representations, Etc. Any representation, warranty or statement made or deemed made by Borrower herein or in any other Credit Document or in any certificate delivered to Lender pursuant hereto or thereto shall prove to be untrue in any material respect on the date as of which made or deemed made; or

 

10.03.     Covenants. Borrower or any of its Subsidiaries shall (i) default in the due performance or observance by it of any term, covenant or agreement contained in Section 8.01(f)(i), 8.04 (solely with respect to Borrower), 8.08, or 8.11 or Section 9 or (ii) default in the due performance or observance by it of any other term, covenant or agreement contained in this Agreement or in any other Credit Document (other than those set forth in Sections 10.01 and 10.02) and such default pursuant to this sub clause (ii) shall continue unremedied for a period of 30 days after written notice thereof to the defaulting party by Lender; or

 

10.04.     Default Under Other Agreements. (i) Borrower or any of its Subsidiaries shall (x) default in any payment of any Indebtedness (other than the Obligations) beyond the period of grace, if any, provided in an instrument or agreement under which such Indebtedness was created or (y) default in the observance or performance of any agreement or condition relating to any Indebtedness (other than the Obligations) or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, the effect of which default or other event or condition is to cause, or to permit the holder or holders of such Indebtedness (or a trustee or agent on behalf of such holder or holders) to cause (determined without regard to whether any notice is required), any such Indebtedness to become due prior to its stated maturity, or (ii) any Indebtedness (other than the Obligations) of Borrower or any of its Subsidiaries shall be declared to be (or shall become) due and payable, or required to be prepaid other than by a regularly scheduled required prepayment, prior to the stated maturity thereof, provided that it shall not be a Default or an Event of Default under this Section 10.04 unless the aggregate principal amount of all Indebtedness as described in preceding clauses (i) and (ii) is at least $3,000,000; or

 

39

 

10.05.     Bankruptcy, Etc. Borrower or any of its Subsidiaries shall commence a voluntary case concerning itself under Title 11 of the United States Code entitled “Bankruptcy,” as now or hereafter in effect, or any successor thereto (the “Bankruptcy Code”); or an involuntary case is commenced against Borrower or any of its Subsidiaries, and the petition is not controverted within 10 days, or is not dismissed within 60 days, after commencement of the case; or a custodian (as defined in the Bankruptcy Code) is appointed for, or takes charge of, all or substantially all of the property of Borrower or any of its Subsidiaries which custodian is not dismissed within 60 days after the date of such appointment or the date such custodian takes charge, or Borrower or any of its Subsidiaries commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to Borrower or any of its Subsidiaries, or there is commenced against Borrower or any of its Subsidiaries any such proceeding which remains undismissed for a period of 60 days, or Borrower or any of its Subsidiaries is adjudicated insolvent or bankrupt; or any order of relief or other order approving any such case or proceeding is entered; or Borrower or any of its Subsidiaries suffers any appointment of any custodian or the like for it or any substantial part of its property to continue undischarged or unstayed for a period of 60 days; or Borrower or any of its Subsidiaries makes a general assignment for the benefit of creditors; or any corporate, limited liability company or similar action is taken by Borrower or any of its Subsidiaries for the purpose of effecting any of the foregoing; or

 

10.06.     ERISA. (a) Except as would not, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, any ERISA Plan shall fail to satisfy the minimum funding standard required for any plan year or part thereof under Section 412 of the Code or Section 302 of ERISA or a waiver of such standard or extension of any amortization period is sought or granted under Section 412 of the Code or Section 303 or 304 of ERISA, a Reportable Event shall have occurred, a contributing sponsor (as defined in Section 4001(a)(13) of ERISA) of an ERISA Plan subject to Title IV of ERISA shall be subject to the advance reporting requirement of PBGC Regulation Section 4043.61 (without regard to subparagraph (b)(1) thereof) and an event described in subsection .62, .63, .64, .65, .66, .67 or .68 of PBGC Regulation Section 4043 shall be reasonably expected to occur with respect to such ERISA Plan within the following 30 days, any ERISA Plan which is subject to Title IV of ERISA shall have had or is likely to have a trustee appointed to administer such ERISA Plan, any ERISA Plan which is subject to Title IV of ERISA is, shall have been or is likely to be terminated or to be the subject of termination proceedings under ERISA, any ERISA Plan shall have an Unfunded Current Liability, a contribution required to be made with respect to an ERISA Plan or a Foreign Pension Plan has not been timely made, Borrower or any of its Subsidiaries or any ERISA Affiliate has incurred or is likely to incur any liability to or on account of an ERISA Plan under Section 409, 502(i), 502(l), 515, 4062, 4063, 4064, 4069, 4201, 4204 or 4212 of ERISA or Section 436(f), 4971 or 4975 of the Code or on account of a group health plan (as defined in Section 607(1) of ERISA or Section 4980B(g)(2) of the Code) under Section 4980B of the Code, or Borrower or any of its Subsidiaries have incurred or is likely to incur liabilities pursuant to one or more employee welfare benefit plans (as defined in Section 3(1) of ERISA) that provide benefits to retired employees or other former employees (other than as required by Section 601 of ERISA) or ERISA Plans or Foreign Pension Plans, a “default” within the meaning of Section 4219(c)(5) of ERISA shall occur with respect to any ERISA Plan, any Change in Law, or, as a result of a Change in Law, an event occurs following a Change in Law, with respect to or otherwise affecting any ERISA Plan; and (b) there shall result from any such event or events the imposition of a lien, the granting of a security interest, or a liability, which lien, security interest or liability, either individually and/or in the aggregate, has had, or could reasonably be expected to have, in the reasonable opinion of Lender, a Material Adverse Effect; or

 

40

 

10.07.     Security Documents. After the execution and delivery thereof, any of the Security Documents shall cease to be in full force and effect, or shall cease to give Lender the Liens, rights, powers and privileges purported to be created thereby (including, without limitation, a perfected security interest in, and Lien on, all of the Collateral, in favor of Lender, superior to and prior to the rights of all third Persons (except as permitted by Section 9.01)), other than a waiver or release by Lender and other than UCC financing statements (if any) the effectiveness of which have lapsed as a result of Lender’s failure to file proper continuation statements as required by the UCC, and subject to no other Liens (except as permitted by Section 9.01), or any Credit Party shall default in the due performance or observance of any term, covenant or agreement on its part to be performed or observed pursuant to any such Security Document and such default shall continue beyond the period of grace, if any, specifically applicable thereto pursuant to the terms of such Security Document; or

 

10.08.     Subsidiaries Guaranty. The Subsidiaries Guaranty or any provision thereof shall cease to be in full force or effect as to any Subsidiary Guarantor, or any Subsidiary Guarantor or any Person acting for or on behalf of such Subsidiary Guarantor shall deny or disaffirm such Subsidiary Guarantor’s obligations under the Subsidiaries Guaranty or any Subsidiary Guarantor shall default in the due performance or observance of any term, covenant or agreement on its part to be performed or observed pursuant to the Subsidiaries Guaranty; or

 

10.09.     Judgments. One or more judgments or decrees shall be entered against Borrower or any of its Subsidiaries and such judgments and decrees either shall be final and non-appealable or shall not be vacated, discharged or stayed or bonded pending appeal for any period of 30 consecutive days, (a) involving in the aggregate for Borrower and its Subsidiaries a liability (not paid or fully covered by a reputable and solvent insurance company), and the aggregate amount of all such judgments equals or exceeds $5,000,000, or (b) with respect to the Transaction, this Agreement or any other Credit Document, or any documentation executed in connection herewith or therewith, that has had, or could reasonably be expected to have, a Material Adverse Effect; or

 

10.10.     Change of Control. A Change of Control shall occur;

 

then, and in any such event, and at any time thereafter, if any Event of Default shall then be continuing, Lender may, by written notice to Borrower, take any or all of the following actions, without prejudice to the rights of Lender or the holder of any Note to enforce its claims against Borrower (provided that, if an Event of Default specified in Section 10.05 shall occur with respect to Borrower, the result which would occur upon the giving of written notice by Lender as specified in clauses (i) and (ii) below shall occur automatically without the giving of any such notice): (i) declare the any or all of the Commitments terminated, whereupon the Commitments of Lender shall forthwith terminate immediately; (ii) declare the principal of and any accrued interest in respect of all Loans and the Notes and all other Obligations owing hereunder and thereunder to be, whereupon the same shall become, forthwith due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by Borrower; and (iii) apply any cash collateral held by Lender pursuant to Section 4.02 to the repayment of the Obligations.

 

41

 

10.11.     Application of Proceeds. Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, Borrower irrevocably waives the right to direct the application of any and all payments received by Lender from or on behalf of Borrower or any guarantor during the continuance of such Event of Default against all of any part of the Obligations, and Lender shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as the Lender may deem advisable notwithstanding any previous application by the Lender.

 

Section 11     Defined Terms. As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined):

 

“Acquired Entity or Business” shall mean either (x) the assets constituting a business, division or product line of any Person not already a Subsidiary of Borrower or (y) 100% of the capital stock of any such Person, which Person shall, as a result of such stock acquisition, become a Wholly-Owned Subsidiary of Borrower (or shall be merged with and into Borrower or a Wholly-Owned Subsidiary of Borrower, with Borrower or such Wholly-Owned Subsidiary being the surviving Person).

 

“Acquisition Consideration” shall mean, with respect to any Permitted Acquisition, the sum (without duplication) of (i) the fair market value of Borrower Common Stock (based on (x) the closing and/or trading price of Borrower Common Stock on the date of such Permitted Acquisition or such other date as agreed in the definitive documentation relating to such Permitted Acquisition on the stock exchange on which Borrower Common Stock is listed or the automated quotation system on which Borrower Common Stock is quoted, or (y) if Borrower Common Stock is not listed on an exchange or quoted on a quotation system, the bid and asked prices of Borrower Common Stock in the over-the-counter market at the close of trading or (z) if Borrower Common Stock is not so listed, based on a good faith determination of the Board of Directors of Borrower) issued (or to be issued) as consideration in connection with such Permitted Acquisition, (ii) the fair market value of all Qualified Preferred Stock of Borrower (based on a good faith determination of the Board of Directors of Borrower) issued (or to be issued) as consideration in connection with such Permitted Acquisition, (iii) the aggregate amount of all cash paid (or to be paid) by Borrower or any of its Subsidiaries in connection with such Permitted Acquisition (including payments of fees, costs, expenses and taxes in connection therewith), (iv) the aggregate principal amount of, and other obligations due under, all Indebtedness assumed, incurred and/or issued by Borrower or any of its Subsidiaries in connection with such Permitted Acquisition, (v) the aggregate amount that could reasonably be expected to be paid (based on good faith projections prepared by Borrower) pursuant to any earn-out, performance bonus, consulting or deferred compensation or purchase price adjustment for such Permitted Acquisition and (vi) the fair market value (based on a good faith determination of Borrower) of all other consideration payable in connection with such Permitted Acquisition.

 

“Additional Security Documents” shall have the meaning provided in Section 8.12(a).

 

42

 

“Affiliate” shall mean, with respect to any Person, any other Person directly or indirectly controlling (including, but not limited to, all directors and officers of such Person), controlled by, or under direct or indirect common control with, such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such other Person, whether through the ownership of voting securities, by contract or otherwise; provided, however, that neither Lender nor any Affiliate thereof shall be considered an Affiliate of Borrower or any Subsidiary thereof.

 

“Agreement” shall mean this Amended and Restated Credit Agreement, as modified, supplemented, amended, restated (including any amendment and restatement hereof), extended or renewed from time to time.

 

“Anti-Corruption Laws” shall mean the United States Foreign Corrupt Practices Act of 1977, any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law, in each case, as amended.

 

“Attributable Debt” shall mean, as of any date of determination thereof, without duplication, (i) in connection with a Sale and Leaseback Transaction, the net present value (discounted according to generally accepted accounting principles at the cost of debt implied in the lease) of the obligations of the lessee for rental payments during the then remaining term of any applicable lease, and (ii) the principal balance outstanding under any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing (including an off-balance sheet receivables financing) product to which such Person is a party.

 

“Authorized Officer” shall mean, with respect to (i) delivering Notices of Borrowing, and similar notices, any person or persons that has or have been authorized by the board of directors of Borrower to deliver such notices pursuant to this Agreement and that has or have appropriate signature cards or incumbency certificates on file with Lender, (ii) delivering financial information and officer’s certificates pursuant to this Agreement, the chief financial officer, the treasurer or the principal accounting officer of Borrower, and (iii) any other matter in connection with this Agreement or any other Credit Document, any officer (or a person or persons so designated by any two officers) of Borrower.

 

“Bail-In Action” shall mean the exercise of any Write-Down and Conversion Powers by the applicable EEA Resolution Authority in respect of any liability of an EEA Financial Institution.

 

“Bail-In Legislation” shall mean, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule.

 

“Bankruptcy Code” shall have the meaning provided in Section 10.05.

 

“Board of Directors” shall mean, as to any Person, the board of directors or other comparable governing body of such Person or any committee thereof duly authorized to act on behalf of the board of directors or comparable governing body.

 

43

 

“Borrower” shall have the meaning provided in the first paragraph of this Agreement.

 

“Borrower Common Stock” shall have the meaning provided in Section 7.13.

 

“Borrowing” shall mean a borrowing under the Revolving Loan, the Repurchase Term Loan or the Delayed Draw-Down Term Loan, as the context may require.

 

“Business Day(s)” shall mean any day except Saturday, Sunday and any day which shall be in Omaha, Nebraska, a legal holiday or a day on which banking institutions are authorized or required by law or other government action to close.

 

“Calculation Period” shall mean, in the case of any Permitted Acquisition or any other event expressly required to be calculated on a Pro Forma Basis pursuant to the terms of this Agreement, the Test Period most recently ended prior to the date of any such Permitted Acquisition or other event for which financial statements have been delivered to the Lender pursuant to this Agreement.

 

“Capital Expenditures” shall mean, with respect to any Person, all expenditures by such Person which should be capitalized in accordance with generally accepted accounting principles and, without duplication, the amount of Capitalized Lease Obligations incurred by such Person.

 

“Capitalized Lease Obligations” shall mean, with respect to any Person, all rental obligations of such Person which, under generally accepted accounting principles, are or will be required to be capitalized on the books of such Person, in each case taken at the amount thereof accounted for as indebtedness in accordance with such principles.

 

“Cash Equivalents” shall mean, as to any Person, (i) securities issued or directly and fully guaranteed or insured by the United States or any agency, instrumentality or sponsored corporation thereof and backed by the full faith and credit of the United States, and in each case having maturities of not more than two years from the date of acquisition, (ii) Dollar denominated time deposits, certificates of deposit, overnight bank deposits and bankers’ acceptances with Lender or any commercial bank of recognized standing, having capital and surplus in excess of $250,000,000 and the commercial paper of the holding company of which, at the time of acquisition thereof, is rated at least A-2 or the equivalent thereof by S&P or at least P-2 or the equivalent thereof by Moody’s (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), or, if no such commercial paper rating is available, a long-term debt rating, at the time of acquisition thereof, of at least A or the equivalent thereof by S&P or at least A-2 or the equivalent thereof by Moody’s (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), (iii) repurchase obligations with a term of not more than 92 days for underlying securities of the types described in clause (i) above and entered into with any commercial bank meeting the qualifications specified in clause (ii) above, (iv) other investment instruments offered or sponsored by financial institutions having capital and surplus in excess of $250,000,000 and the commercial paper of the holding company of which, at the time of acquisition thereof, is rated at least A-1 or the equivalent thereof by S&P or at least P-1 or the equivalent thereof by Moody’s (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), or, if no such commercial paper rating is available, a long-term debt rating, at the time of acquisition thereof, of at least A+ or the equivalent thereof by S&P or at least A-1 or the equivalent thereof by Moody’s (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), (v) readily marketable direct obligations issued by any state of the United States or any political subdivision thereof having, at the time of acquisition thereof, one of the two highest rating categories obtainable from either Moody’s or S&P (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), (vi) commercial paper or corporate bonds rated, at the time of acquisition thereof, at least A-1 or the equivalent thereof by S&P or at least P-1 or the equivalent thereof by Moody’s (or if at such time neither is issuing ratings, then a comparable rating of another nationally recognized rating agency), in each case maturing within two years after the date of acquisition, (vii) investments in money market funds which invest substantially all their assets in securities of the types described in clauses (i) through (vi) above, and (viii) in the case of any Foreign Subsidiary of Borrower, (x) certificates of deposit (or comparable instruments) of any bank with which such Foreign Subsidiary regularly transacts business and with maturities of not more than six months from the date of acquisition by such Foreign Subsidiary, (y) overnight deposits and demand deposit accounts maintained with any bank that such Foreign Subsidiary regularly transacts business and (z) securities of the type and maturity described in clause (i) above but issued by the principal Governmental Authority in which such Foreign Subsidiary is organized so long as such security has the highest rating available from either S&P or Moody’s.

 

44

 

“Cash on Hand” shall mean, at any time, the aggregate total of Unrestricted Cash and Unrestricted Cash Equivalents on Borrower’s balance sheet and available for use.

 

“CERCLA” shall mean the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as the same has been amended and may hereafter be amended from time to time, 42 U.S.C. § 9601 et seq.

 

“Change in Law” shall mean the occurrence of any of the following: (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority, or (iii) the making or issuance of any request, rules, guideline, requirement or directive (whether or not having the force of law) by any Governmental Authority; provided, however, that notwithstanding anything herein to the contrary, (a) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, requirements and directives thereunder, issued in connection therewith or in implementation thereof, and (b) all requests, rules, guidelines, requirements and directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law” after the Effective Date regardless of the date enacted, adopted, issued or implemented.

 

“Change of Control” shall mean (i) any “Person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act as in effect on the Effective Date) other than the Permitted Holders, (A) is or shall become the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act as in effect on the Effective Date), directly or indirectly, of 33% or more of the outstanding total Voting Power of Borrower’s (or the Successor Borrower’s, as applicable) capital stock (determined on a fully diluted basis) or (B) shall have obtained the power (whether or not exercised) to elect a majority of Borrower’s (or the Successor Borrower’s, as applicable) directors, (ii) at any time the Board of Directors of Borrower (or the Successor Borrower’s, as applicable) shall cease to consist of a majority of Continuing Directors, or (iii) a “change of control” (or similar event) shall occur as provided in any Permitted Subordinated Debt Document.

 

45

 

“Code” shall mean the U.S. Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder. Section references to the Code are to the Code as in effect at the date of this Agreement and any subsequent provisions of the Code amendatory thereof, supplemental thereto or substituted therefor.

 

“Collateral” shall mean all property (whether real or personal) with respect to which any security interests have been granted (or purported to be granted) by any Credit Party pursuant to any Security Document, including, without limitation, all Security Agreement Collateral, all Mortgaged Properties and all cash and Cash Equivalents delivered as collateral or held by Lender.

 

“Commitment” means the Revolving Loan Commitment, the Repurchase Term Loan Commitment, the Delayed Draw-Down Term Loan Commitment, or any combination thereof (as the context requires).

 

“Compliance Certificate” shall have the meaning provided in Section 8.01(e).

 

“Connection Income Taxes” means taxes that are imposed on or measured by net income (however denominated) or that are franchise taxes or branch profits taxes, in each case, imposed as a result of a present or former connection between Lender and the jurisdiction imposing such tax (other than connections arising from Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Credit Document, or sold or assigned an interest in any Credit Document).

 

“Consolidated Cash Flow Leverage Ratio” shall mean, at any time, the ratio of (a) (i) Consolidated Indebtedness minus (ii) the principal amount of Permitted Subordinated Debt at such time, minus (iii) Cash on Hand to (b) Consolidated EBITDA.

 

“Consolidated EBITDA” shall mean, for any period, Consolidated Net Income for such period adjusted by (x) adding thereto, without duplication and to the extent deducted in arriving at Consolidated Net Income for such period: (a) Consolidated Interest Expense; (b) provision for federal, state, local or foreign franchise taxes or taxes based on income; (c) the amount of all amortization of intangibles and depreciation; (d) non-cash charges for the impairment of goodwill or other intangibles or the write-off of goodwill, intangibles or other assets; (e) the amortization or write-off of deferred financing, legal and accounting costs with respect to the Transaction or any Permitted Acquisition; and (f) the amount of all other non-cash charges (including non-cash compensation expenses) or non-cash losses, and (y) deducting therefrom, the amount of all cash payments during such period that are associated with any non-cash charges or non-cash losses that were added back to Consolidated Net Income in a previous period pursuant to preceding clause (x)(f); and, in each case, without giving effect to (i) any extraordinary gains, (ii) any gains or losses from sales of assets other than from sales of inventory in the ordinary course of business, and (iii) any non cash income; it being understood that in determining the Consolidated Cash Flow Leverage Ratio, Consolidated EBITDA for any period shall be calculated on a Pro Forma Basis to give effect to any Acquired Entity or Business acquired during such period pursuant to a Permitted Acquisition and not subsequently sold or otherwise disposed of by Borrower or any of its Subsidiaries during such period.

 

46

 

“Consolidated Fixed Charge Coverage Ratio” shall mean the ratio of (a) (i) Consolidated EBITDA for a period minus (ii) unfinanced Capital Expenditures for such period (excluding unfinanced Capital Expenditures for Permitted Acquisitions, unless otherwise required to be included pursuant to Section 9.08) minus (iii) tax expenses paid in cash for such period minus (iv) Dividends (excluding Dividends which are (A) Permitted Share Repurchases or (B) Special Dividends, unless (in each case of (A) or (B)) otherwise required to be included pursuant to Section 9.08) for such period to (b) the sum of (i) Consolidated Interest Expense paid in cash for such period plus (ii) scheduled principal amortization payments or redemptions (as initially scheduled on the incurrence of such debt and excluding optional prepayments thereof) on Indebtedness required to be paid in cash for such period (other than “balloon” payments made at maturity of purchase money debt or Capitalized Lease Obligations to the extent financed with the proceeds of Indebtedness refinanced as permitted under this Agreement or the disposition of capital assets secured by funded Indebtedness), and (iii) Capitalized Lease Obligations payments for such period.

 

“Consolidated Indebtedness” shall mean, at any time, the remainder of the sum of, without duplication, (i) the aggregate principal amount of all Indebtedness (or, if greater, the aggregate face amount of any Indebtedness issued at a discount) of Borrower and its Subsidiaries at such time (including, without limitation, all Loans, drawn amounts under letters of credit, Capitalized Lease Obligations and guaranties of other Indebtedness) and (ii) the aggregate outstanding amount of all Attributable Debt of Borrower and its Subsidiaries at such time; provided that for purposes of this definition, the amount of Indebtedness in respect of Interest Rate Protection Agreements and Other Hedging Agreements shall be at any time the unrealized net loss position, if any, of Borrower and/or its Subsidiaries thereunder on a marked-to-market basis determined no more than one month prior to such time.

 

“Consolidated Interest Expense” shall mean, for any period, the sum of the total consolidated interest expense of Borrower and its Subsidiaries for such period (calculated without regard to any limitations on the payment thereof) plus, without duplication, (i) that portion of Capitalized Lease Obligations of Borrower and its Subsidiaries representing the interest factor for such period whether or not actually paid during such period, (ii) all Fees accrued during such period pursuant to Sections 3.01(a), (b) and (c), and (iii) the interest component (or imputed interest) of any lease payment or other off balance sheet financing under Attributable Debt transactions paid by Borrower and its Subsidiaries for such period.

 

“Consolidated Net Income” shall mean, for any period, the net income (or loss) of Borrower and its Subsidiaries for such period, determined on a consolidated basis (after any deduction for minority interests), provided that (i) in determining Consolidated Net Income, the net income of any other Person which is not a Subsidiary of Borrower or is accounted for by Borrower by the equity method of accounting shall be included only to the extent of the payment of cash dividends or cash distributions by such other Person to Borrower or a Subsidiary thereof during such period, (ii) the net income of any Subsidiary of Borrower shall be excluded to the extent that the declaration or payment of cash dividends or similar cash distributions by that Subsidiary of that net income is not at the date of determination permitted by operation of its charter or any agreement, instrument or law applicable to such Subsidiary, and (iii) except for determinations expressly required to be made on a Pro Forma Basis, the net income (or loss) of any Person accrued prior to the date it becomes a Subsidiary of Borrower or all or substantially all of the property or assets of such Person are acquired by Borrower or a Subsidiary of Borrower shall be excluded.

 

47

 

“Contingent Obligation” shall mean, as to any Person, any obligation of such Person as a result of such Person being a general partner of any other Person, unless the underlying obligation is expressly made non-recourse as to such general partner, and any obligation of such Person guaranteeing or intended to guarantee any Indebtedness, leases, dividends or other obligations (“primary obligations”) of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, including, without limitation, any obligation of such Person, whether or not contingent, (i) to purchase any such primary obligation or any property constituting direct or indirect security therefor, (ii) to advance or supply funds (x) for the purchase or payment of any such primary obligation or (y) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (iii) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation, or (iv) otherwise to assure or hold harmless the holder of such primary obligation against loss in respect thereof. Notwithstanding anything to the contrary contained in the immediately preceding sentence, the term Contingent Obligation shall not include endorsements of instruments for deposit or collection or reimbursement, hold harmless, indemnification and similar provisions in commercial agreements entered into in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determinable amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof (assuming such Person is required to perform thereunder) as determined by such Person in good faith.

 

“Continuing Directors” shall mean the directors of Borrower on the Effective Date and each other director, if such director’s nomination for election to the Board of Directors of Borrower is recommended, nominated or approved by a majority of then Continuing Directors or Permitted Holders.

 

“Covenant Inclusion Event” shall have the meaning provided in Section 9.08.

 

“Credit Documents” shall mean this Agreement, each Note, the Subsidiaries Guaranty, the Security Documents, the Grant of Security Interest in U.S. Trademarks, the Grant of Security Interest in U.S. Copyrights, the Grant of Security Agreement in U.S. Patents, the Additional Security Documents, and collateral assignments, pledge agreements, account assignments, control agreements, or other reimbursement agreements, any subordination agreements, intercreditor agreements and any and all other agreements, instruments and documents, including powers of attorney, consents, and all other writings heretofore, now or hereafter executed by any Credit Party and/or delivered to Lender in connection with this Agreement.

 

“Credit Event” shall mean the making of any Loan.

 

“Credit Party” shall mean Borrower and each Subsidiary Guarantor.

 

48

 

“Deed of Trust” shall mean that certain Deed of Trust, Security Agreement, Assignment of Leases and Rents and Fixture Financing Statement, dated as April 18, 2018, by Borrower in favor of Lender.

 

“Default” shall mean any event, act or condition which with notice or lapse of time, or both, would constitute an Event of Default.

 

“Delayed Draw-Down Term Loan” shall have the meaning provided in Section 1.01(c).

 

“Delayed Draw-Down Term Loans” shall have the meaning provided in Section 1.01(c).

 

“Delayed Draw-Down Term Loan Commitment” shall mean $15,000,000.

 

“Delayed Draw-Down Term Loan Effective Date” shall have the meaning provided in Section 1.06(b).

 

“Delayed Draw-Down Term Loan Maturity Date” shall mean May 28, 2025.

 

“Delayed Draw-Down Term Loan Note” shall have the meaning provided in Section 1.05(a).

 

“Disinterested Director” shall mean, with respect to any Person and transaction, a member of the Board of Directors of such Person who does not have any material direct or indirect financial interest in or with respect to such transaction.

 

“Dividend” shall mean, with respect to any Person, any payment of a distribution, interest, or dividend on any capital stock or other equity interests, as the case may be, or any purchase, redemption, or other acquisition or retirement for value of any capital stock or other equity interest, as the case may be.

 

“Dollars” and the sign “$” shall each mean lawful money of the United States.

 

“Domestic Subsidiary” shall mean each Subsidiary of Borrower incorporated or organized in the United States, any State thereof or the District of Columbia.

 

“EEA Financial Institution” shall mean (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

 

“EEA Member Country” shall mean any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

 

“EEA Resolution Authority” shall mean any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

 

49

 

“Effective Date” means the date on which (i) Borrower the Lender shall have signed a counterpart hereof (whether the same or different counterparts) and shall have delivered the same to the Lender and (ii) the conditions contained in Section 5 are met to the satisfaction of Lender or waived by Lender. Upon the satisfaction of the condition described in clause (i) of the immediately preceding sentence and upon the Lender’s good faith determination that the conditions described in clause (ii) of the immediately preceding sentence have been met, then the Effective Date shall have deemed to have occurred and Lender shall give Borrower prompt notice of the occurrence of the Effective Date.

 

“Environmental Claims” shall mean any and all administrative, regulatory or judicial actions, suits, demands, demand letters, directives, claims, liens, notices of noncompliance or violation, investigations or proceedings relating in any way to any actual or alleged violation of any Environmental Law or any permit issued, or any approval given, under any such Environmental Law (hereafter, “Claims”), including, without limitation, (a) any and all Claims by governmental or regulatory authorities for enforcement, cleanup, removal, response, remedial or other actions or damages pursuant to any applicable Environmental Law, and (b) any and all Claims by any third party seeking damages, contribution, indemnification, cost recovery, compensation or injunctive relief in connection with alleged injury or threat of injury to health, safety or the environment due to the presence of Hazardous Materials.

 

“Environmental Indemnity Agreement” shall mean that certain Environmental Indemnity Agreement, dated as April 18, 2018, by Borrower in favor of Lender.

 

“Environmental Law” shall mean any applicable Federal, state, foreign or local statute, law, rule, regulation, ordinance, code, binding and enforceable guideline, binding and enforceable written policy, or rule of common law now or hereafter in effect and in each case as amended, or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent decree or judgment, in each case, to the extent binding on Borrower or its Subsidiaries, relating to the environment, the effect of the environment on employee health and safety, or Hazardous Materials, including, without limitation and to the extent applicable, CERCLA; the Resource Conservation and Recovery Act, 42 U.S.C. § 6901 et seq.; the Federal Water Pollution Control Act, 33 U.S.C. § 1251 et seq.; the Toxic Substances Control Act, 15 U.S.C. § 2601 et seq.; the Clean Air Act, 42 U.S.C. § 7401 et seq.; the Safe Drinking Water Act, 42 U.S.C. § 3000(f) et seq.; the Oil Pollution Act of 1990, 33 U.S.C. § 2701 et seq.; the Emergency Planning and the Community Right-to-Know Act of 1986, 42 U.S.C. § 11001 et seq.; the Hazardous Material Transportation Act, 49 U.S.C. § 1801 et seq.; the Occupational Safety and Health Act, 29 U.S.C. § 651 et seq.; and other similar state and local or foreign counterparts or equivalents, in each case as amended from time to time.

 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time, and any successor statute, and the regulations promulgated and rulings issued thereunder.  Section references to ERISA are to ERISA, as in effect at the date of this Agreement and any subsequent provisions of ERISA or any successor statute, amendatory thereof, supplemental thereto, or substituted therefor.

 

“ERISA Affiliate” shall mean any Subsidiary of a Credit Party and any trade or business (whether or not incorporated), which, together with any Credit Party or any Subsidiary of a Credit Party, is treated as a single employer under Section 414 of the Code.

 

50

 

“ERISA Plan” shall mean any employee pension benefit plan as defined in Section 3(2) of ERISA, other than a "multiemployer plan" as defined in Section 3(37) of ERISA, which is subject to the provisions of Title IV or Section 302 of ERISA or Sections 412 or 430 of the Code, and that is sponsored, maintained, or contributed to by any Credit Party or ERISA Affiliate or with respect to which any Credit Party or ERISA Affiliate has any liability, contingent or otherwise.

 

“EU Bail-In Legislation Schedule” shall mean the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.

 

“Event of Default” shall have the meaning provided in Section 10.

 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Existing Credit Agreement” has the meaning specified in the recitals hereto.

 

“Existing Indebtedness” shall have the meaning provided in Section 7.20.

 

“Existing Indebtedness Agreements” shall have the meaning provided in Section 5.16(d).

 

“Fees” shall mean all amounts payable pursuant to or referred to in Section 3.01.

 

“Foreign Pension Plan” shall mean any defined benefit pension plan (including, without limitation, any superannuation fund) which is established, contributed to, or maintained by Borrower or any one or more of its Subsidiaries outside the United States of America and which is required by applicable laws to be funded.

 

“Foreign Subsidiary” shall mean each Subsidiary of Borrower that is not a Domestic Subsidiary.

 

“Governmental Authority” shall mean the government of the United States of America or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).

 

“Hazardous Materials” shall mean (a) any petroleum or petroleum products, radioactive materials, asbestos in any form that is or could become friable, urea formaldehyde foam insulation, dielectric fluid containing levels of polychlorinated biphenyls, and radon gas, in each case, in excess of applicable legal limits; (b) any chemicals, materials or substances defined as or included in the definition of “hazardous substances,” “hazardous waste,” “hazardous materials,” “extremely hazardous substances,” “restricted hazardous waste,” “toxic substances,” “toxic pollutants,” “contaminants,” or “pollutants,” or words of similar import, under any applicable Environmental Law; and (c) any other chemical, material or substance, the exposure to, or Release of which is prohibited, limited or regulated by any Governmental Authority.

 

51

 

“Health Care Laws” shall mean any and all applicable current and future laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions or binding agreements issued, promulgated or entered into by the Food and Drug Administration, the Health Care Financing Administration, the Department of Health and Human Services (“HHS”), the Office of Inspector General of HHS, the Drug Enforcement Administration or any other Governmental Authority, including any state and/or local professional licensing laws, certificate of need laws and state reimbursement laws, applicable in any way to the conduct of the business of Borrower or any Subsidiary thereof.

 

“Indebtedness” shall mean, as to any Person, without duplication, (i) all indebtedness of such Person for borrowed money or for the deferred purchase price of property or services, (ii) the maximum amount available to be drawn or paid under all letters of credit, bankers’ acceptances, bank guaranties and similar obligations issued for the account of such Person and all unpaid drawings in respect of such letters of credit, bankers’ acceptances and similar obligations, (iii) all Indebtedness of the types described in clause (i), (ii), (iv), (v), (vi), (vii) or (viii) of this definition secured by any Lien on any property owned by such Person, whether or not such Indebtedness has been assumed by such Person (provided that, if the Person has not assumed or otherwise become liable in respect of such Indebtedness, such Indebtedness shall be deemed to be in an amount equal to the fair market value of the property to which such Lien relates as determined in good faith by such Person), (iv) the aggregate amount of all Capitalized Lease Obligations of such Person, (v) all obligations of such Person to pay a specified purchase price for goods or services, whether or not delivered or accepted, i.e., take-or-pay and similar obligations, (vi) all Contingent Obligations of such Person, (vii) all obligations under any Interest Rate Protection Agreement, any Other Hedging Agreement or under any similar type of agreement, and (viii) all Attributable Debt of such Person. Notwithstanding the foregoing, Indebtedness shall not include trade payables and accrued expenses incurred by any Person in accordance with customary practices and in the ordinary course of business of such Person (including pursuant to customer service contracts).

 

“Indemnified Taxes” shall have the meaning provided in Section 4.04(a).

 

“Index” shall have the meaning provided in Section 1.06(b).

 

“Interest Rate Protection Agreement” shall mean any interest rate swap agreement, interest rate cap agreement, interest collar agreement, interest rate hedging agreement or other similar agreement or arrangement.

 

“Investments” shall have the meaning provided in Section 9.05.

 

“Leaseholds” of any Person shall mean all the right, title and interest of such Person as lessee or licensee in, to and under leases or licenses of land, improvements and/or fixtures.

 

“Lender” shall mean First National Bank of Omaha, a national banking association.

 

“LIBOR Rate” means the London Interbank offered rate for U.S. Dollar deposits published in the Wall Street Journal as the One (1) Month LIBOR Rate.

 

“Lien” shall mean any mortgage, pledge, hypothecation, collateral assignment, deposit arrangement, encumbrance, lien (statutory or other), preference, priority or other security agreement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement, any financing or similar statement or notice filed under the UCC or any other similar recording or notice statute, and any lease having substantially the same effect as any of the foregoing).

 

52

 

“Liquidity” shall mean, as of any date of determination, the sum of (i) Unrestricted cash, plus (ii) Unrestricted Cash Equivalents on Borrower’s balance sheet and available for use, plus (iii) the unused amount of the Revolving Loan Commitment.

 

“Loan” shall mean each Revolving Loan, each Delayed Draw-Down Term Loan and the Repurchase Term Loan.

 

“Management Agreements” shall have the meaning provided in Section 5.16(b).

 

“Margin Stock” shall have the meaning provided in Regulation U.

 

“Material Adverse Effect” shall mean (i) a material adverse effect on the business, operations, property or financial condition of Borrower and its Subsidiaries, taken as a whole, (ii) a material adverse effect on the ability of the Credit Parties, taken as a whole, to perform their obligations hereunder or under any other Credit Document or (iii) a material adverse effect on the rights and remedies of the Lender hereunder or under any other Credit Document. Notwithstanding anything to the contrary set forth herein, for purposes of determining the existence of a Material Adverse Effect from the Effective Date through December 31, 2021 under clause (i) of the preceding sentence, the impact of COVID-19 and associated responses on the financial condition or results of operations of Borrower that were disclosed to Lender prior to the Effective Date will be disregarded.

 

“Minimum Borrowing Amount” shall mean (i) for Revolving Loans, except as provided in Section 1.03(d), $10,000, and (ii) for Delayed Draw-Down Term Loans, $1,000,000.

 

“Minimum Liquidity Threshold” shall mean $15,000,000.

 

“Moody’s” shall mean Moody’s Investors Service, Inc., or any successor corporation thereto.

 

“Mortgaged Property(ies)” shall mean the real estate, fixtures and improvements thereon generally described as Borrower’s owner occupied building located at 1245 Q Street, Lincoln, Nebraska.

 

“Net Debt Proceeds” shall mean, with respect to any incurrence or issuance of Indebtedness for borrowed money, the cash proceeds (net of (i) underwriting discounts and commissions and other reasonable fees, expenses and costs associated therewith including, without limitation, those of attorneys, accountants and other professionals and (ii) any portion of such proceeds equal to the amount required to be and actually applied to pay Indebtedness permitted by Section 9.04 that is secured by the asset sold or disposed of (to the extent those same proceeds were used to pay such Indebtedness permitted by Section 9.04)) received by the respective Person from the respective incurrence of such Indebtedness for borrowed money.

 

“Note” shall mean the Revolving Note, the Repurchase Term Loan Note and/or the Delayed Draw-Down Term Loan Note, as the context may require.

 

53

 

“Notice of Borrowing” shall have the meaning provided in Section 1.03(c).

 

“Notice Office” shall mean the office of Lender located at 1620 Dodge Street, Stop 1029, Omaha, Nebraska 68102 Attention: Nate McKown, Telephone: (402) 323-5223 or such other office or person as Lender may hereafter designate in writing as such to the other parties hereto.

 

“Obligations” shall mean all amounts owing Lender pursuant to the terms of this Agreement or any other Credit Document, including, without limitation, all amounts in respect of any principal, interest (including any interest accruing subsequent to the filing of a petition in bankruptcy, reorganization or similar proceeding at the rate provided for in this Agreement, whether or not such interest is an allowed claim under any such proceeding or under applicable state, federal or foreign law), penalties, fees, expenses, indemnifications, reimbursements, damages and other liabilities, and guarantees of the foregoing amounts.

 

“Other Hedging Agreements” shall mean any foreign exchange contracts, currency swap agreements, commodity agreements or other similar arrangements, or arrangements designed to protect against fluctuations in currency values or commodity prices.

 

“Other Taxes” shall mean all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt perfection of a security interest under, or otherwise with respect to, any Credit Document, except any such taxes that are imposed with respect to an assignment as a result of a present or former connection between Lender or the applicable Lender and the jurisdiction imposing such tax.

 

“Patriot Act” means the Patriot Act (Title III of Pub. L. 107 56 (signed into law October 26, 2001)) as may be amended or updated.

 

“Payment Office” shall mean the office of Lender located at: 1620 Dodge Street, Stop 1029, Omaha, Nebraska 68102 Attention: Nate McKown, Telephone: (402) 323-5223, and or such other office as Lender may hereafter designate in writing as such to the other parties hereto.

 

“PBGC” shall mean the Pension Benefit Guaranty Corporation established pursuant to Section 4002 of ERISA, or any successor thereto.

 

“Permitted Acquisition” shall mean the acquisition by Borrower or a Wholly-Owned Subsidiary of Borrower of an Acquired Entity or Business (including by way of merger of such Acquired Entity or Business with and into Borrower (so long as Borrower is the surviving corporation) or a Wholly-Owned Subsidiary of Borrower (so long as such Wholly-Owned Subsidiary is the surviving corporation)), provided that (in each case) (A) in the case of the acquisition of the capital stock or other equity interests of any Person (including way of merger), such Person shall own no capital stock or other equity interests of any other Person (excluding de minimis amounts) unless either (x) such Person and/or its Wholly-Owned Subsidiaries own at least 100% of the capital stock or other equity interests of such other Person or (y) (1) such Person and/or its Wholly-Owned Subsidiaries own at least 80% of the consolidated assets of such Person and its Subsidiaries and (2) any non-Wholly-Owned Subsidiary of such Person was non-Wholly-Owned prior to the date of such Permitted Acquisition of such Person, (B) the Acquired Entity or Business acquired pursuant to the respective Permitted Acquisition is in a business permitted by Section 9.12 and (C) all applicable requirements of Section 8.15 applicable to Permitted Acquisitions are satisfied. Notwithstanding anything to the contrary contained in the immediately preceding sentence, an acquisition which does not otherwise meet the requirements set forth above in the definition of “Permitted Acquisition” shall constitute a Permitted Acquisition if, and to the extent, Lender agrees in writing that such acquisition shall constitute a Permitted Acquisition for purposes of this Agreement.

 

54

 

“Permitted Encumbrance” shall mean, with respect to any Mortgaged Property, such exceptions to title as are set forth in the mortgage title policy (or binding commitment) delivered to the Lender with respect thereto, all of which exceptions must be acceptable to the Lender in its reasonable discretion.

 

“Permitted Holders” means Michael Hays, his spouse, trusts or other entities directly or indirectly holding Borrower’s Common Stock for the benefit of Michael Hays, his wife, their respective sisters and brothers, and/or their respective lineal descendants (by blood or adoption) of any such persons, and other entities beneficially owned or economically for the benefit of Michael Hays, his spouse, their respective sisters and brothers, and/or their lineal descendants (by blood or adoption) of any such persons.

 

“Permitted Liens” shall have the meaning provided in Section 9.01.

 

“Permitted Share Repurchase” shall mean a transaction whereby Borrower purchases shares of Borrower Common Stock to the extent permitted by Section 9.03(b).

 

“Permitted Subordinated Debt” shall mean any subordinated Indebtedness of Borrower incurred in connection with, and to finance, a Permitted Acquisition or Permitted Share Repurchase, which Indebtedness may be guaranteed on a subordinated basis by Borrower and all of the terms and conditions of which (including, without limitation, with respect to interest rate, amortization, redemption provisions, maturities, covenants, defaults, remedies, guaranties, standstill provisions, cash pay limitations and subordination provisions) and the documentation therefor are reasonably satisfactory to Lender, as such Indebtedness may be amended, modified and/or supplemented from time to time in accordance with the terms hereof and thereof; provided, that in any event, unless the Lender otherwise expressly consents in writing prior to the issuance thereof, (i) the lender on such Indebtedness will be a Permitted Holder, (ii) the rate of interest applicable to such Indebtedness will at no point exceed Lender’s prime rate as in effect on the date of incurrence of such Indebtedness plus 300 basis points (3.00%), and no such Indebtedness shall be secured by any asset of Borrower or any of its Subsidiaries, (iii) no such Indebtedness shall be guaranteed by any other Person, (iv) no such Indebtedness shall be subject to scheduled amortization, redemption, sinking fund, mandatory prepayments (other than pursuant to a customary “change of control” provision that is subject to the prior repayment of the Obligations and termination of the Commitments) or similar payment or have a final maturity, in either case prior to the date occurring one year following the latest maturity date of any of the Loans, (v) the documentation governing such Indebtedness shall not include any financial maintenance covenants, and (vi) the subordination provisions contained therein shall provide for a permanent block on payments with respect to such Indebtedness upon the occurrence and continuation of a payment default with respect to “senior debt” and cover all obligations under Interest Rate Protection Agreements and Other Hedging Agreements, (vii) such Indebtedness will be subject to a subordination agreement in favor of Lender in form of substance acceptable to Lender. The incurrence of Permitted Subordinated Debt shall be deemed to be a representation and warranty by Borrower that all conditions thereto have been satisfied in all material respects and that the incurrence of such Permitted Subordinated Debt is permitted in accordance with the terms of this Agreement, which representation and warranty shall be deemed to be a representation and warranty for all purposes hereunder, including, without limitation, Sections 7 and 10.

 

55

 

“Permitted Subordinated Debt Documents” shall mean, on and after the execution and delivery thereof, each note, instrument, agreement, guaranty and other documents relating to each incurrence of Permitted Subordinated Debt, as the same may be amended, modified and/or supplemented from time to time in accordance with the terms hereof and thereof.

 

“Person” shall mean any individual, partnership, joint venture, firm, corporation, association, limited liability company, trust or other enterprise or any government or political subdivision or any agency, department or instrumentality thereof.

 

“Primary Concentration Account” shall mean the principal concentration and disbursement account utilized by Borrower for its and its Wholly-Owned Subsidiaries’ cash management systems, with account number, and other operating accounts of Borrower or its Wholly-Owned Subsidiaries maintained at Lender.

 

“Pro Forma Basis” shall mean, in connection with any calculation of compliance with any financial covenant or financial term, the calculation thereof after giving effect on a pro forma basis to (x) any disposition of a material business line or Subsidiary of Borrower consummated after the first day of the relevant Calculation Period as if such disposition (and the application of the proceeds therefrom) was consummated (and the proceeds therefrom had been applied) on the first day of the relevant Calculation Period, and/or (y) the Permitted Acquisition, Special Dividend or Permitted Share Repurchase if any, then being consummated as well as any other Permitted Acquisition, Special Dividend or Permitted Share Repurchase consummated after the first day of the relevant Calculation Period and on or prior to the date of the respective Permitted Acquisition, Special Dividend or Permitted Share Repurchase then being effected, as the case may be, as if such Permitted Acquisition was consummated on the first day of the relevant Calculation Period and taking into account factually supportable and identifiable cost savings and expenses directly attributable to any such Permitted Acquisition which would otherwise be accounted for as an adjustment pursuant to Article 11 of Regulation S-X under the Securities Act, as if such cost savings or expenses were realized on the first day of the respective period. In connection with the foregoing, any Indebtedness incurred, assumed or repaid by Borrower or any Subsidiary in connection with the disposition or Permitted Acquisition, Special Dividend or Permitted Share Repurchase (i) shall be deemed to have been incurred, assumed or repaid as of the first day of the Calculation Period and (ii) if such Indebtedness has a floating or formula rate, shall have an implied rate of interest for the applicable period for purposes of this definition determined by utilizing the rate which is or would be in effect with respect to such Indebtedness as at the relevant date of determination.

 

“Qualified Preferred Stock” shall mean any preferred stock of Borrower so long as the terms of any such preferred stock (w) do not contain any mandatory put, redemption, repayment, sinking fund or other similar provision prior to the one year anniversary of the Repurchase Term Loan Maturity Date, (x) do not require the cash payment of dividends or distributions that would otherwise be prohibited by this Agreement, (y) do not contain any covenants (other than periodic reporting covenants) and (z) are otherwise reasonably satisfactory to the Lender.

 

56

 

“Rating Agency” shall mean each of Moody’s and S&P.

 

“Real Property” of any Person shall mean all the right, title and interest of such Person in and to land, improvements and fixtures, including Leaseholds.

 

“Regulation D” shall mean Regulation D of the Board of Governors of the Federal Reserve System as from time to time in effect and any successor to all or a portion thereof establishing reserve requirements.

 

“Regulation T” shall mean Regulation T of the Board of Governors of the Federal Reserve System as from time to time in effect and any successor to all or a portion thereof.

 

“Regulation U” shall mean Regulation U of the Board of Governors of the Federal Reserve System as from time to time in effect and any successor to all or a portion thereof.

 

“Regulation X” shall mean Regulation X of the Board of Governors of the Federal Reserve System as from time to time in effect and any successor to all or a portion thereof.

 

“Release” shall mean actively or passively disposing, discharging, injecting, spilling, pumping, leaking, leaching, dumping, emitting, escaping, emptying, pouring or seeping into the environment.

 

“Reportable Event” shall mean an event described in Section 4043(c) of ERISA with respect to an ERISA Plan that is subject to Title IV of ERISA other than those events as to which the 30-day notice period is waived under subsection .22, .23, .25, .27 or .28 of PBGC Regulation Section 4043.

 

“Repurchase Term Loan” shall have the meaning provided in Section 1.01(b).

 

“Repurchase Term Loan Commitment” means $33,002,068.79.

 

“Repurchase Term Loan Maturity Date” means May 28, 2025.

 

“Repurchase Term Loan Note” shall have the meaning providing in Section 1.05(a).

 

“Restricted” shall mean, when referring to cash or Cash Equivalents of Borrower or any of its Subsidiaries, that such cash or Cash Equivalents (i) appears (or would be required under generally accepted accounting principles to appear) as “restricted” on a consolidated balance sheet of Borrower or of any such Subsidiary, (ii) are subject to any Lien in favor of any Person or (iii) are not otherwise generally available for use by Borrower or any of its Subsidiaries.

 

“Revolving Loan(s)” shall have the meaning provided in Section 1.01(a).

 

“Revolving Loan Commitment” shall mean $30,000,000.

 

57

 

“Revolving Loan Effective Date” shall have the meaning provided in Section 1.06(b).

 

“Revolving Loan Maturity Date” shall mean May 28, 2023.

 

“Revolving Note” shall have the meaning provided in Section 1.05(a).

 

“Sale and Leaseback Transaction” shall mean any arrangement, directly or indirectly, whereby a seller or transferor shall sell or otherwise transfer any real or personal property and then or thereafter lease, or repurchase under an extended purchase contract, conditional sales or other title retention agreement, the same or similar property.

 

“Sanctioned Country” means, at any time, a country or territory which is the subject or target of any comprehensive territorial Sanctions.

 

“Sanctioned Person” shall mean, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the European Union, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.

 

“Sanctions” shall mean economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, (b) the European Union or (c) Her Majesty’s Treasury of the United Kingdom.

 

“SEC” shall have the meaning provided in Section 8.01(g).

 

“Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Security Agreement” shall have the meaning provided in Section 5.10.

 

“Security Agreement Collateral” shall mean all “Pledged Collateral” as defined in the Security Agreement

 

“Security Documents” shall mean and include the Security Agreement, each Deed of Trust and each other Additional Security Document.

 

“Shareholders’ Agreements” shall have the meaning provided in Section 5.16(a).

 

“Special Dividend” shall mean any cash Dividend (or any portion thereof) in a fiscal quarter that, together with all other cash Dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash Dividends paid or declared during such fiscal quarter, to the extent permitted by Section 9.03(d).

 

“Subsidiaries Guaranty” shall have the meaning provided in Section 5.09.

 

58

 

“Subsidiary” shall mean, as to any Person, (i) any corporation more than 50% of whose stock of any class or classes having by the terms thereof ordinary voting power to elect a majority of the directors of such corporation (irrespective of whether or not at the time stock of any class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time owned by such Person and/or one or more Subsidiaries of such Person and (ii) any partnership, limited liability company, association, joint venture or other entity in which such Person and/or one or more Subsidiaries of such Person has more than a 50% equity interest at the time, and in each case, the accounts of which would be consolidated with Borrower in Borrower’s consolidated financial statements in accordance with generally accepted accounting principles.

 

“Subsidiary Guarantor” shall mean each Wholly-Owned Domestic Subsidiary of Borrower, to the extent required by Section 8.13, each Wholly-Owned Foreign Subsidiary of Borrower and any other Person that enters into the Subsidiaries Guaranty in favor of Lender after the date hereof.

 

“Tax Sharing Agreements” shall have the meaning provided in Section 5.16(c).

 

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Test Period” shall mean each period of four consecutive fiscal quarters of Borrower then last ended (in each case taken as one accounting period).

 

“Transaction” shall mean (i) the entering into of the Credit Documents and the incurrence of Loans and (ii) the payment of all fees and expenses in connection with the foregoing.

 

“UCC” shall mean the Uniform Commercial Code as from time to time in effect in the relevant jurisdiction.

 

“Unfunded Current Liability” of any ERISA Plan shall mean the amount, if any, by which the value of the accumulated plan benefits under the ERISA Plan determined on a plan termination basis in accordance with actuarial assumptions at such time consistent with those prescribed by the PBGC for purposes of Section 4044 of ERISA, exceeds the fair market value of all plan assets allocable to such liabilities under Title IV of ERISA (excluding any accrued but unpaid contribution).

 

“United States” and “U.S.” shall each mean the United States of America.

 

“Unrestricted” shall mean, when referring to cash or Cash Equivalents of Borrower or any of its Subsidiaries, that such cash or Cash Equivalents are not Restricted.

 

“Voting Power” shall mean, with respect to any class or classes of capital stock of Borrower (or any class or classes of capital stock then convertible into such capital stock at the option of the holders thereof), the voting power entitled to vote in the election of directors of Borrower.

 

“Wholly-Owned Domestic Subsidiary” shall mean, as to any Person, any Wholly-Owned Subsidiary of such Person which is also a Domestic Subsidiary of such Person.

 

“Wholly-Owned Foreign Subsidiary” shall mean, as to any Person, any Wholly-Owned Subsidiary of such Person which is also a Foreign Subsidiary of such Person.

 

59

 

“Wholly-Owned Subsidiary” shall mean, as to any Person, (i) any corporation 100% of whose capital stock is at the time owned by such Person and/or one or more Wholly-Owned Subsidiaries of such Person and (ii) any partnership, association, joint venture or other entity in which such Person and/or one or more Wholly-Owned Subsidiaries of such Person has a 100% equity interest at such time.

 

“Write-Down and Conversion Powers” shall mean, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.

 

Section 12     Miscellaneous.

 

12.01.     Payment of Expenses, Etc. Borrower hereby agrees to: (i) (A) whether or not the transactions herein contemplated are consummated, pay all reasonable out-of-pocket costs and expenses of Lender (including the reasonable fees and disbursements of Koley Jessen P.C.) in connection with the preparation, execution, delivery and administration of this Agreement and the other Credit Documents and the documents and instruments referred to herein and therein and any amendment, waiver or consent relating hereto or thereto, and (B) after the occurrence and during the continuation of an Event of Default, pay all reasonable out-of-pocket costs and expenses of Lender in connection with the enforcement of this Agreement and the other Credit Documents and the documents and instruments referred to herein and therein or in connection with any refinancing or restructuring of the credit arrangements provided under this Agreement in the nature of a “work-out” or pursuant to any insolvency or bankruptcy proceedings; and (ii) indemnify Lender and its respective officers, directors, employees, representatives, agents, affiliates, trustees and investment advisors (each such Person, an “Indemnified Person”) from and hold each of them harmless against any and all liabilities, obligations (including removal or remedial actions), losses, damages, penalties, claims, actions, judgments, suits, costs, expenses and disbursements (including reasonable attorneys’ and consultants’ fees and disbursements) (collectively, “Damages”) incurred by, imposed on or assessed against any of them as a result of, or arising out of, or in any way related to, or by reason of (a) any investigation, litigation or other proceeding (whether or not Lender is a party thereto and whether or not such investigation, litigation or other proceeding is brought by or on behalf of Borrower) related to the entering into and/or performance of this Agreement or any other Credit Document or (b) the use of any proceeds of any Loans hereunder or the consummation of the Transaction or any other transactions contemplated herein or in any other Credit Document or the exercise of any of their rights or remedies provided herein or in the other Credit Documents; provided, that such indemnity shall not, as to any Indemnified Person, be available to the extent that such Damages (x) are determined by a non-appealable order from a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of such Indemnified Person or (y) have resulted from a claim brought by any Credit Party against an Indemnified Person for material breach of such Indemnified Person’s obligations under any Credit Document. To the extent that the undertaking to indemnify, pay or hold harmless any Indemnified Person set forth in the preceding sentence may be unenforceable because it violates or would violate any law or public policy, Borrower shall make the maximum contribution to the payment and satisfaction of each of the indemnified liabilities which is permissible under applicable law. To the fullest extent permitted by applicable law, no Indemnified Person shall have any liability for any special, punitive, indirect or consequential damages relating to this Agreement or any other Credit Documents or arising out of its activities in connection herewith or therewith (whether before or after the Effective Date). This Section 12.01 shall not apply with respect to taxes other any taxes that represent losses, claims, damages, etc. arising from any non-tax claim.

 

60

 

12.02.     Right of Setoff. In addition to any rights now or hereafter granted under applicable law or otherwise, and not by way of limitation of any such rights, upon the occurrence and during the continuance of an Event of Default, Lender, and each of its Affiliates, to the fullest extent permitted by applicable law, is hereby authorized at any time or from time to time, without presentment, demand, protest or other notice of any kind to Borrower or to any other Person, any such notice being hereby expressly waived, to set off and to appropriate and apply any and all deposits (general or special) and any other Indebtedness at any time held or owing by Lender, (including, without limitation, by branches and agencies of Lender) to or for the credit or the account of Borrower or any of its Subsidiaries against and on account of the Obligations and liabilities of Borrower to Lender under this Agreement or under any of the other Credit Documents, and all other claims of any nature or description arising out of or connected with this Agreement or any other Credit Document, irrespective of whether or not Lender shall have made any demand hereunder and although said Obligations, liabilities or claims, or any of them, shall be contingent or unmatured. Lender agrees to promptly notify Borrower after any such setoff and any application made by Lender; provided, that, Lender’s failure to provide any such notice will not be a breach or default by Lender under this Agreement.

 

12.03.     Notices. Except as otherwise expressly provided herein, all notices and other communications provided for hereunder shall be in writing (including telegraphic, telex, fax, cable or electronic communication) and mailed, telegraphed, telexed, faxed, cabled or delivered (including by electronic delivery): if to Borrower, at the address specified below its signature below or in the other relevant Credit Documents; if to Lender at the Notice Office; or, as to Borrower or Lender, at such other address as shall be designated by such party in a written notice to the other parties hereto. All such notices and communications shall, when mailed, telegraphed, telexed, faxed, cabled or sent by electronic mail or overnight courier, be effective when deposited in the mails, delivered to the telegraph company, cable company or overnight courier, as the case may be, or sent by telex, fax or electronic mail (read receipt requested), except that notices and communications to Lender and Borrower shall not be effective until received by Lender or Borrower, as the case may be, during normal business hours.

 

12.04.     Benefit of Agreement; Assignments; Participations.

 

(a)     This Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective successors and assigns of the parties hereto; provided, however, Borrower may not assign or transfer any of its rights, obligations or interest hereunder without the prior written consent of Lender and, provided further, that, although Lender may sell participations in its rights hereunder without the need for notice to, or consent of, Borrower, each participant must be a national or state-chartered bank and a participant shall not constitute a “lender” hereunder. In the case of any such participation, the participant shall not have any rights under this Agreement or any of the other Credit Documents (the participant’s rights in respect of such participation to be those set forth in the agreement executed by Lender in favor of the participant relating thereto) and all amounts payable by Borrower hereunder shall be determined as if Lender had not sold such participation and Lender’s obligations under the Credit Documents shall remain unchanged.

 

61

 

(b)     Nothing in this Agreement shall prevent or prohibit Lender from pledging its Loans and Notes hereunder as security for the obligations of such Lender, including to a Federal Reserve Bank in support of borrowings made by Lender from such Federal Reserve.

 

12.05.     No Waiver; Remedies Cumulative. No failure or delay on the part of Lender in exercising any right, power or privilege hereunder or under any other Credit Document and no course of dealing between Borrower and Lender shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or under any other Credit Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder or thereunder. The rights, powers and remedies herein or in any other Credit Document expressly provided are cumulative and not exclusive of any rights, powers or remedies which Lender would otherwise have. No notice to or demand on Borrower in any case shall entitle Borrower to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of Lender to any other or further action in any circumstances without notice or demand.

 

12.06.     Amendment and Restatement. The parties hereto agree that, on the Effective Date, the following transactions shall be deemed to occur automatically, without further action by any party hereto: (a) the Existing Credit Agreement shall be deemed to be amended and restated in its entirety pursuant to this Agreement; (b) all obligations under the Existing Credit Agreement outstanding on the Effective Date shall in all respects be continuing and shall be deemed to be Obligations outstanding hereunder; and (c) the security interests and liens in favor of Lender created under the Security Documents entered into in connection with the Existing Credit Agreement shall remain in full force and effect with respect to the Obligations and are hereby reaffirmed. The parties hereto further acknowledge and agree that this Agreement constitutes an amendment to the Existing Credit Agreement made under and in accordance with the terms of Section 12.12 of the Existing Credit Agreement. Except as expressly set forth in this Agreement or in the other Credit Documents, (i) this Agreement shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the under this Agreement or any other Credit Document, and (ii) shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in any provision of any Credit Document. Except as expressly set forth in this Agreement or in the other Credit Documents, each and every term, condition, obligation, covenant and agreement contained in the Credit Documents is hereby ratified and re-affirmed in all respects and shall continue in full force and effect. Borrower reaffirms its obligations under the Credit Documents and the validity of the Liens granted by it pursuant to the Security Documents.

 

12.07.     Calculations; Computations.

 

(a)     The financial statements to be furnished to Lender pursuant hereto shall be made and prepared in accordance with generally accepted accounting principles in the United States consistently applied throughout the periods involved (except as set forth in the notes thereto or as otherwise disclosed in writing by Borrower to Lender); provided that, (i) except as otherwise specifically provided herein, all computations and all definitions (including accounting terms) used in determining compliance with any Section of this Agreement shall utilize generally accepted accounting principles and policies in conformity with those used to prepare the audited historical financial statements of Borrower referred to in Section 7.05(a) and (ii) to the extent expressly provided herein, certain calculations shall be made on a Pro Forma Basis.

 

62

 

(b)     All computations of interest and other Fees hereunder are computed on a 365/360 basis; that is, by applying the ratio of the interest rate over a year of 360 days, multiplied by the outstanding principal balance, multiplied by the actual number of days the principal balance is outstanding.

 

12.08.     GOVERNING LAW; SUBMISSION TO JURISDICTION; VENUE; WAIVER OF JURY TRIAL.

 

(a)     THIS AGREEMENT AND THE OTHER CREDIT DOCUMENTS AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT SHALL, EXCEPT AS TO ANY OTHER CREDIT DOCUMENT AS EXPRESSLY SET FORTH THEREIN, BE CONSTRUED IN ACCORDANCE WITH AND BE GOVERNED BY THE LAW OF THE STATE OF NEBRASKA. ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT SHALL BE BROUGHT IN THE COURTS OF THE STATE OF NEBRASKA OR OF THE UNITED STATES FOR THE DISTRICT OF NEBRASKA, IN EACH CASE WHICH ARE LOCATED IN THE COUNTY OF DOUGLAS. EACH PARTY HERETO HEREBY IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS. EACH PARTY HERETO HEREBY FURTHER IRREVOCABLY WAIVES ANY CLAIM THAT ANY SUCH COURTS LACK PERSONAL JURISDICTION OVER SUCH PARTY, AND AGREES NOT TO PLEAD OR CLAIM, IN ANY LEGAL ACTION PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENTS BROUGHT IN ANY OF THE AFOREMENTIONED COURTS, THAT SUCH COURTS LACK PERSONAL JURISDICTION OVER SUCH PARTY. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. EACH PARTY HERETO FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO SUCH PARTY AT ITS ADDRESS SPECIFIED IN SECTION 12.03, SUCH SERVICE TO BECOME EFFECTIVE 30 DAYS AFTER SUCH MAILING. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY OBJECTION TO SUCH SERVICE OF PROCESS AND FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY ACTION OR PROCEEDING COMMENCED HEREUNDER OR UNDER ANY OTHER CREDIT DOCUMENT THAT SERVICE OF PROCESS WAS IN ANY WAY INVALID OR INEFFECTIVE. NOTHING HEREIN SHALL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

 

63

 

(b)     EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY OF THE AFORESAID ACTIONS OR PROCEEDINGS ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT BROUGHT IN THE COURTS REFERRED TO IN CLAUSE (a) ABOVE AND HEREBY FURTHER IRREVOCABLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

(c)     EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER CREDIT DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

12.09.     Counterparts. This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which shall together constitute one and the same instrument. A set of counterparts executed by all the parties hereto shall be lodged with Borrower and Lender.

 

12.10.     Effectiveness. This Agreement shall become effective on the Effective Date.

 

12.11.     Headings Descriptive. The headings of the several sections and subsections of this Agreement are inserted for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement.

 

12.12.     Amendment or Waiver; Etc. Neither this Agreement nor any other Credit Document nor any terms hereof or thereof may be changed, waived, discharged or terminated unless such change, waiver, discharge or termination is in writing signed by Borrower and Lender.

 

12.13.     Survival. All indemnities set forth herein or in any other Credit Documents shall survive the execution, delivery and termination of this Agreement and the Notes and the making and repayment of the Obligations.

 

12.14.     Domicile of Loans. Lender may transfer and carry its Loans at, to or for the account of any office, Subsidiary or Affiliate of Lender. Notwithstanding anything to the contrary contained herein, to the extent that a transfer of Loans pursuant to this Section 12.14 would, at the time of such transfer, result in increased costs under Section 1.07, 1.08, 4.02 or 4.04 from those being charged by Lender prior to such transfer, then Borrower shall not be obligated to pay such increased costs (although Borrower shall be obligated to pay any other increased costs of the type described above resulting from any Change in Law after the date of the respective transfer).

 

64

 

12.15.     Register. Borrower hereby designates Lender to serve as its agent, solely for purposes of this Section 12.15, to maintain a register (the “Register”) on which it will record the Commitments and the Loans made by Lender, the amount of any principal or interest due and payable with respect to such Loans and each repayment in respect of the principal amount, and related interest amounts of the Loans. Failure to make any such recordation, or any error in such recordation, shall not affect Borrower’s obligations in respect of such Loans. Borrower agrees to indemnify Lender from and against any and all losses, claims, damages and liabilities of whatsoever nature which may be imposed on, asserted against or incurred by Lender in performing its duties under this Section 12.15 except to the extent resulting from Lender’s gross negligence, bad faith or willful misconduct (as determined by a court of competent jurisdiction in a final and non-appealable decision). In addition, Borrower shall have the right, upon its written request to Lender, to review a copy of the Register at any reasonable time.

 

12.16.     Confidentiality.

 

(a)     Subject to the provisions of clause (b) of this Section 12.16, Lender agrees that it will maintain the confidentiality of (with the same degree of care that it uses to protect its own confidential information, but in no event less than a reasonable degree of care) and will not disclose without the prior consent of Borrower (other than to its employees, auditors, advisors, Affiliates or counsel or Lender’s holding or parent company (collectively, “Representatives”) in its reasonable discretion determines that any such party should have access to such information, provided such Persons shall be subject to the provisions of this Section 12.16 to the same extent as such Lender) any information with respect to Borrower or any of its Subsidiaries which is now or in the future furnished pursuant to this Agreement or any other Credit Document and which is designated as confidential by Borrower or that a reasonable person would consider confidential, provided that Lender may disclose any such information (i) as has become generally available to the public other than by virtue of a breach of this Section 12.16(a) by Lender or Representatives of Lender or becomes available to Lender, or any of its respective Affiliates on a non-confidential basis from a source other than Borrower that does not owe Borrower a duty of confidentiality or a fiduciary duty, (ii) as may be required or appropriate in any report, statement or testimony submitted to any municipal, state or Federal regulatory body having or claiming to have jurisdiction over such Lender or to the Federal Reserve Board or the Federal Deposit Insurance Corporation or similar organizations (whether in the United States or elsewhere) or their successors, (iii) as may be required or appropriate in respect to any summons or subpoena or in connection with any litigation, (iv) in order to comply with any law, order, regulation or ruling applicable to such Lender, (v) to any other party hereto, (vi) to any actual or prospective direct or indirect contractual counterparty in any swap, hedge or similar agreement (or to any such contractual counterparty’s professional advisor), so long as such contractual counterparty (or such professional advisor) agrees to be bound by an agreement containing provisions substantially the same as those of this Section 12.16, (vii) to any prospective or actual transferee or participant in connection with any contemplated transfer or participation of any of the Notes, Loans or Commitments or any interest therein by such Lender, provided that such prospective transferee agrees to be bound by an agreement containing provisions substantially the same as those of this Section 12.16, and (viii) in connection with the exercise of remedies hereunder or under any other Credit Document or any action or proceeding relating to this Agreement or any other Credit Document or the enforcement of rights hereunder or thereunder.

 

(b)     Borrower hereby acknowledges and agrees that Lender may share with any of its Affiliates, and such Affiliates may share with such Lender, any information related to Borrower or any of its Subsidiaries (including, without limitation, any non-public customer information regarding the creditworthiness of Borrower and its Subsidiaries), provided such Persons shall be subject to the provisions of this Section 12.16 to the same extent as such Lender.

 

65

 

(c)     Lender acknowledges that (i) the information referred to in this Section 12.16 may include material non-public information; (ii) that it has developed compliance processes and procedures regarding the use of such information; and (iii) it will handle any material non-public information in accordance with all applicable laws, including federal and state securities laws.

 

12.17.     No Fiduciary Duty. Lender, and its Affiliates (collectively, solely for purposes of this paragraph, the “Lenders”), may have economic interests that conflict with those of the Credit Parties, their stockholders and/or their Affiliates. Borrower agrees that nothing in the Credit Documents will be deemed to create an advisory, fiduciary or agency relationship or fiduciary or other implied duty between Lender, on the one hand, and such obligor, its stockholders or its affiliates on the other. Borrower acknowledges and agrees that (i) the transactions contemplated by the Credit Documents (including the exercise of rights and remedies hereunder and thereunder) are arm’s-length commercial transactions between Lenders, on the one hand, and Borrower, on the other, and (ii) in connection therewith and with the process leading thereto, (x) no Lender has assumed an advisory or fiduciary responsibility in favor of Borrower, its stockholders or its affiliates with respect to the transactions contemplated hereby (or the exercise of rights or remedies with respect thereto) or the process leading thereto (irrespective of whether Lender has advised, is currently advising or will advise Borrower, its stockholders or its Affiliates on other matters) or any other obligation to Borrower except the obligations expressly set forth in the Credit Documents and (y) Lender is acting solely as principal and not as the agent or fiduciary of Borrower, its management, stockholders, creditors or any other Person. Borrower acknowledges and agrees that it has consulted its own legal and financial advisors to the extent it deemed appropriate and that it is responsible for making its own independent judgment with respect to such transactions and the process leading thereto.

 

12.18.     Patriot Act. Lender is subject to the Patriot Act (as hereinafter defined) and Lender hereby notifies Borrower that pursuant to the requirements of the Patriot Act (Title III of Pub. L. 107 56 (signed into law October 26, 2001)) (the “Patriot Act”), it is required to obtain, verify and record information that identifies Borrower, which information includes the name and address of Borrower and other information that will allow Lender to identify Borrower in accordance with the Patriot Act.

 

12.19.     Acknowledgement and Consent to Bail-In of EEA Financial Institutions. Notwithstanding anything to the contrary in any Credit Document or in any other agreement, arrangement or understanding among the parties thereto, each party hereto acknowledges that any liability of any EEA Financial Institution arising under any Credit Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:

 

(a)     the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an EEA Financial Institution; and

 

66

 

(b)     the effects of any Bail-In Action on any such liability, including, if applicable:

 

(i)     a reduction in full or in part or cancellation of any such liability;

 

(ii)     a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Credit Document; or

 

(iii)     the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of any EEA Resolution Authority.

 

12.20.      Credit Agreement in Writing. A CREDIT AGREEMENT MUST BE IN WRITING TO BE ENFORCEABLE UNDER NEBRASKA LAW. TO PROTECT YOU (BORROWER) AND US (LENDER) FROM ANY MISUNDERSTANDINGS OR DISAPPOINTMENTS, ANY CONTRACT, PROMISE, UNDERTAKING OR OFFER TO FOREBEAR REPAYMENT OF MONEY OR TO MAKE ANY OTHER FINANCIAL ACCOMMODATION IN CONNECTION WITH THIS LOAN OF MONEY OR GRANT OR EXTENSION OF CREDIT, OR ANY AMENDMENT OF, CANCELLATION OF, WAIVER OF, OR SUBSTITUTION FOR ANY OR ALL OF THE TERMS OR PROVISIONS OF ANY INSTRUMENT OR DOCUMENT EXECUTED IN CONNECTION WITH THIS LOAN OF MONEY OR GRANT OR EXTENSION OF CREDIT, MUST BE IN WRITING TO BE EFFECTIVE.

 

[signature page follows]

 

67

 

 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Agreement as of the date first above written.

 

 

NATIONAL RESEARCH CORPORATION, as Borrower

 

 

 

 

 

 

 

 

 

 

By:

/s/ Kevin R. Karas

 

 

 

Name:

Kevin R. Karas

 

    Title:

Senior Vice President Finance, Chief

Financial Officer, Treasurer and

Secretary

 
    Address:

1245 Q Street

Lincoln, NE 68508

 

 

 

 

 

FIRST NATIONAL BANK OF OMAHA, as

Lender     

 

 

 

 

 

 

By:

/s/ Nathan S. McKown     

 

 

 

Name:   Nathan S. McKown  

 

 

 

Title:     Director, Corporate Banking Group   

 

 

 

 

General Information

 

Document Type

Credit & Loan Agreements

   

Topic(s)

Banking & Finance

   

Transaction Type

Commercial Credit & Loan Arrangements

   

Governing Law

Nebraska

   
 

First National Bank of Omaha.

Source Document

 

Industry(SIC)

_______________________

   

Law Firms

Koley Jessen P.C., L.L.O.

   

Parties

First National Bank of Omaha, N.A.

   

Schedules

Schedule I – Subsidiaries

Schedule II – Convertible Securities

Schedule III – Indebtedness

Schedule IV – Insurance

Schedule V – Liens

Schedule VI– Investments

   

Exhibits

Exhibit A – Notice of Borrowing

Exhibit B-1 – Amended and Restated Revolving Note

Exhibit B-2 – Amended and Restated Repurchase Term Loan Note

Exhibit B-3 – Amended and Restated Delayed Draw-Down Term Loan Note

Exhibit C – Officer’s Certificate

Exhibit D – Subsidiaries Guaranty

Exhibit E –Solvency Certificate

Exhibit F – Compliance Certificate

 

 

 
EX-10.2 3 ex_196216.htm EXHIBIT 10.2 ex_196216.htm

Exhibit 10.2

 

FORM OF GRANT USED IN CONNECTION WITH THE NATIONAL RESEARCH CORPORATION
2004 NON-EMPLOYEE DIRECTOR STOCK PLAN, AS AMENDED

 

[Director name]

 

Re:     Stock Option Grant National Research Corporation Director Stock Plan

 

This letter is to confirm that on [date], you were automatically granted a nonqualified stock option to purchase [# of shares] shares of Common Stock, $.001 par value, of National Research Corporation (“Company”) pursuant to the terms of the 2004 Non-Employee Director Stock Plan (the “Plan”).

 

Your stock option to purchase up to [# of shares] shares of Common Stock is subject to the terms and conditions of the Plan. The option price is [price] per share, which was the last sale price of a share of Common Stock on the NASDAQ Stock Market on [date of grant], the date of grant.

 

In accordance with the terms of the Plan, when your options are granted on an “Annual Grant Date” (i.e., the date of the Company’s Annual Meeting of Shareholders) such options are not exercisable until the day immediately preceding the next following Annual Grant Date (the “Vesting Date”), unless your status as a director of the Company terminates because of death prior to that time, in which event the options become immediately exercisable in full and may be exercised for a period of three (3) years after the date of death. If for any reason other than death you cease to be an outside director of the Company prior to the Vesting Date, the options will be cancelled as of the date of such termination. Subject to the foregoing, the options expire ten (10) years after the date of grant, or if earlier, three (3) years after you cease to be an outside director of the Company.

 

The other terms which govern your stock options are as set forth below and as provided in the Plan.

 

Procedure for Exercise. You may exercise your options in whole or in part at any time after the options have become exercisable (as discussed above) by delivering written notice to the Company together with payment of the option price in cash, previously acquired shares of Common Stock valued at their fair market value or such other forms as the Board or Plan administrator approves.

 

Securities Laws Matters. Applicable federal and state securities laws govern the disposition by you of shares purchased through the exercise of your options. You may sell such shares only (1) pursuant to an effective registration statement under the Securities Act of 1933, as amended (“Act”), or (2) in a transaction which is exempt from registration under the Act, such as a sale which fully complies with Rule 144 under the Act.

 

Non-Transferability. Your options may not be sold or transferred other than by will or under the laws of descent and distribution, except that an option may be transferred to the extent allowed by the Board or the Plan administrator. The designation of a beneficiary will not constitute a transfer.

 

Conformity with Plan. Your options are intended to conform in all respects with, and are subject to all applicable provisions of, the Plan. Inconsistencies between this letter and the Plan will be resolved in accordance with the terms of the Plan.

 

Please execute and return the enclosed copy of this letter to the Company. By doing so, you agree to be bound by all of the terms of this letter and of the Plan.

 

Very truly yours,

 

NATIONAL RESEARCH CORPORATION

 

   
By:     [Authorized Officer]  

 

 

 

Accepted on this _____ day of _______________, [yyyy].

 

   
[Director name], Director  

 

 
EX-31.1 4 ex_195787.htm EXHIBIT 31.1

 

Exhibit 31.1

 

Certification of Chief Executive Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Michael D. Hays, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2020 /s/ Michael D. Hays  

 

Michael D. Hays

Chief Executive Officer

 

 

 
EX-31.2 5 ex_195788.htm EXHIBIT 31.2

 

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I, Kevin R. Karas, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of National Research Corporation;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2020 /s/ Kevin R. Karas  

 

Kevin R. Karas

Chief Financial Officer

 

 

 
EX-32 6 ex_195789.htm EXHIBIT 32

 

Exhibit 32

 

Certification Pursuant to 18 U.S.C. Section 1350
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

In connection with the accompanying Quarterly Report on Form 10-Q of National Research Corporation (the “Company”) for the three-month period ended June 30, 2020 (the “Report”), I, Michael D. Hays, Chief Executive Officer of the Company, and I, Kevin R. Karas, Chief Financial Officer, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

 

 

1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

  /s/ Michael D. Hays  

 

Michael D. Hays

Chief Executive Officer

 

 

 

 

 

 

 
  /s/ Kevin R. Karas  

 

Kevin R. Karas

Chief Financial Officer

 

 

 

 

 

Date: August 7, 2020

 

 

 

A signed original of this written statement required by Section 906 has been provided to National Research Corporation and will be retained by National Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

 
EX-101.SCH 7 nrc-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Contracts With Customers link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Goodwill and Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Related Party link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Segment Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 2 - Contracts With Customers (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 10 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Contracts With Customers - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 4 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Notes Payable - Summary of Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 5 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 5 - Share-based Compensation - Non-vested Stock (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 8 - Earnings Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Earnings Per Share - Net Income Per Share Computation (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 9 - Related Party (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 10 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Segment Information - Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 nrc-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 nrc-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 nrc-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield at date of grant Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Summary of Significant Accounting Policies Note 2 - Contracts With Customers Risk-free interest rate Note 4 - Notes Payable Note 5 - Share-based Compensation Note 6 - Goodwill and Other Intangible Assets Note 7 - Property and Equipment Note 8 - Earnings Per Share Note 10 - Segment Information Income Tax Disclosure [Text Block] Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time. Expected stock price volatility Note 2 - Contracts With Customers - Disaggregation of Revenue (Details) Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 4 - Notes Payable - Summary of Notes Payable (Details) Schedule of Debt [Table Text Block] Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Expected life of options (in years) (Year) Note 5 - Share-based Compensation - Non-vested Stock (Details) Other current liabilities Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Note 7 - Property and Equipment - Summary of Property and Equipment (Details) Note 8 - Earnings Per Share - Net Income Per Share Computation (Details) Note 10 - Segment Information - Assets by Geographic Area (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] Share-based Payment Arrangement, Activity [Table Text Block] Foreign currency translation adjustment us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Other comprehensive loss, foreign currency translation adjustment Vested (in dollars per share) Forfeited (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding (in dollars per share) Outstanding (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) Forfeited (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding (in shares) Outstanding (in shares) Schedule of Nonvested Share Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) Vested (in shares) First National Bank of Omaha [Member] Related to the entity First National Bank of Omaha. Other comprehensive income: Weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual term (Year) Exercisable, aggregate intrinsic value Current portion of notes payable Exercised, aggregate intrinsic value Exercisable, number of options (in shares) Outstanding, weighted average remaining contractual term (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) us-gaap_SecuredDebtCurrent Less: current portion Deferred revenue Deferred Revenue Forfeited, weighted average exercise price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses Accrued wages, bonus and profit sharing Income taxes payable Dividends payable Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, number of options (in shares) Outstanding, number of options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Forfeited, number of options (in shares) Credit Facility [Axis] Credit Facility [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Finance lease obligations originated for property and equipment us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Weighted average effect of dilutive securities – stock options (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Weighted average shares and share equivalents outstanding: Income taxes Current liabilities: us-gaap_Assets Total assets Total assets Estimated fair value of long-term debt Plan Name [Axis] Technology-Based Intangible Assets [Member] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net income attributable to common shareholders Net income attributable to common shareholders for basic computation Customer Relationships [Member] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Award Type [Domain] Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization Intangible assets, net Other intangible assets, net us-gaap_FiniteLivedIntangibleAssetsGross Amortizing intangible assets Common Stock Options [Member] Related to common stock options. Restricted Stock [Member] Share-based Payment Arrangement, Option [Member] us-gaap_GoodwillForeignCurrencyTranslationGainLoss Foreign currency translation Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite trade name us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation Net property and equipment Property and equipment, net Goodwill Goodwill, Ending Balance Balance Balance Property and equipment Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Net income Net income Net income Net income us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic Allocation of distributed and undistributed income to unvested restricted stock shareholders Cash flows from investing activities: us-gaap_RevenueFromRelatedParties Revenue from Related Parties Earnings Per Share of Common Stock: Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction CANADA Related Party Transactions Disclosure [Text Block] Provision for income taxes us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Accrued expenses, wages, bonuses and profit sharing The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid. Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive Income City Area Code us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] Shares of stock (in shares) us-gaap_IncreaseDecreaseInIncomeTaxes Income taxes receivable and payable us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue Common stock, shares outstanding (in shares) Financing Receivable, Allowance for Credit Loss [Table Text Block] Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type us-gaap_AssetImpairmentCharges Asset Impairment Charges, Total Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Dividends declared Document Information [Line Items] Document Information [Table] Service [Member] Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] London Interbank Offered Rate (LIBOR) [Member] Variable Rate [Domain] Variable Rate [Axis] Capitalized contract cost us-gaap_CapitalizedContractCostImpairmentLoss Capitalized Contract Cost, Impairment Loss us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Non-cash stock compensation expense us-gaap_IncreaseDecreaseInAccountsReceivable Trade accounts receivable Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Capitalized Contract Cost [Axis] Depreciation and amortization Entity Registrant Name Capitalized Contract Cost [Domain] Entity [Domain] us-gaap_CapitalizedContractCostAmortizationPeriod Capitalized Contract Cost, Amortization Period (Year) Customer Concentration Risk [Member] Legal Entity [Axis] Entity Address, Address Line One us-gaap_TreasuryStockValueAcquiredCostMethod Purchase of shares treasury stock Entity Address, City or Town Entity Address, Postal Zip Code Supplemental disclosure of cash paid for: Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Balance Balance at End of Period us-gaap_TreasuryStockValue Treasury stock, at cost; 5,318,423 Common shares in 2020 and 5,204,074 shares in 2019 Entity Common Stock, Shares Outstanding Revenue from Contract with Customer Benchmark [Member] Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Reserve for uncertain tax positions The current period expense charged against earnings to reserve for uncertain tax positions. Local Phone Number Shares of common stock for the exercise of stock options (in shares) Exercised, number of options (in shares) Purchasing Directors and Officers and Employment Practices Liability Insurance [Member] Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction. us-gaap_TableTextBlock Notes Tables IMA Financial Group [Member] Represents information pertaining to IMA Financial Group. us-gaap_GainLossOnDispositionOfAssets1 Loss on disposal of property and equipment us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) Forfeitures of restricted common shares (in shares) The 2001 Equity Incentive Plan [Member] Represents the 2001 equity incentive plan. Shares of restricted common shares, net of (forfeitures) (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Director Plan 2004 [Member] Represents the 2004 director plan. Issuance of common shares for the exercise of stock options us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Related Party [Axis] The 2006 Equity Incentive Plan [Member] Represents the 2006 Equity Incentive plan. Related Party [Domain] Trade Names 1 [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof. Ameritas Life Insurance Corp [Member] Represents information about related party. Selling, general and administrative Bad Debt Expense (Benefit) Granted, number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) Line of Credit Facility, Lender [Domain] Nonvested [Member] Information pertaining to nonvested shares. nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) Number of nonvested restricted shares outstanding. Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans. Retained earnings (accumulated deficit) Money Market Funds [Member] Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense nrc_NumberOfCustomers Number of Customers Number of customers accounting for a substantial portion of one reporting unit's revenue. Net changes in assets and liabilities: Canadian Subsidiary [Member] Related to Canadian Subsidiary. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Operating lease right-of-use assets us-gaap_FinanceLeasePrincipalPayments Payments on finance lease obligations us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes Fair Value Measurement, Policy [Policy Text Block] Increases due to invoicing of client, net of amounts recognized as revenue Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue Increases due to revenue recognized in the period with additional performance obligations before invoicing Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations. Accumulated other comprehensive loss, foreign currency translation adjustment Deferred contract costs, net Capitalized Contract Cost, Net, Noncurrent Other Non-cash share-based compensation expense Lessee, Leases [Policy Text Block] Cyber Attack [Member] Represents cyber attack. Operating expenses: us-gaap_AssetsCurrent Total current assets Assets, fair value nrc_DeferredTaxLiabilitiesEmployerSocialSecurityTaxBreakUnderCARESAct Deferred Tax Liabilities, Employer Social Security Tax Break Under CARES Act Amount of deferred tax liability attributable to employer social security tax break under CARES Act. Income taxes receivable Treasury stock, shares (in shares) nrc_PaymentsForInsuranceSettlementPaidDirectlyToVendors Payments for Insurance Settlement, Paid Directly to Vendors The cash outflow used for the insurance settlement paid directly to certain vendors. Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,553,546 in 2020 and 30,151,574 in 2019, outstanding 25,235,123 in 2020 and 24,947,500 in 2019 Adjustments to reconcile net income to net cash provided by operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Revenue from Contract with Customer [Policy Text Block] The Insurer [Member] Information related to the insurer. Statistical Measurement [Domain] Maximum [Member] Supplemental disclosure of non-cash investing and financing activities: Commitments and Contingencies, Policy [Policy Text Block] Minimum [Member] Product and Service [Axis] Other current assets Product and Service [Domain] Statistical Measurement [Axis] nrc_SalesAndExciseTaxPayableReversalOfLiability Sales and Excise Tax Payable (Reversal of Liability) Amount of sales and excise tax payable (reversal of liability). Deferred Charges, Policy [Policy Text Block] Nonqualified Stock Options [Member] Represents nonqualified stock options. Contract assets included in other current assets Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued Preferred stock, shares issued (in shares) Interest, net of capitalized amounts Prepaid expenses Long-lived assets Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Geographical [Domain] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Preferred stock, par value (in dollars per share) nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet Operating lease assets and liabilities, net Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities. us-gaap_ProceedsFromInsuranceSettlementOperatingActivities Proceeds from Insurance Settlement, Operating Activities Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value Hierarchy and NAV [Axis] Amortization of Capitalized Contract Cost [Table Text Block] Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. Noncatastrophic Event [Domain] Cash flows from operating activities: Noncatastrophic Event [Axis] Statement [Line Items] Allowance for doubtful accounts us-gaap_NumberOfOperatingSegments Number of Operating Segments Trade accounts receivable, less allowance for doubtful accounts of $143 and $144, respectively Accounts receivables us-gaap_NumberOfReportableSegments Number of Reportable Segments WASHINGTON AOCI Attributable to Parent [Member] Additional paid-in capital Shareholders’ equity: Other, net us-gaap_NonoperatingIncomeExpense Total other income (expense) Segment Reporting Disclosure [Text Block] Current assets: Fair Value, by Balance Sheet Grouping [Table Text Block] us-gaap_ContractWithCustomerAssetReclassifiedToReceivable Decreases due to completion of services (or portion of services) and transferred to accounts receivable us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Change in cash and cash equivalents us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Change due to cumulative catch-up adjustments arising from changes in expected contract consideration Director [Member] us-gaap_OperatingIncomeLoss Operating income us-gaap_ContractWithCustomerLiabilityRevenueRecognized Revenue recognized that was included in deferred revenue at beginning of year due to completion of services us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other income (expense): us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Effect of exchange rate changes on cash Deferred income taxes Schedule of Intangible Assets [Table Text Block] Represents the schedule of intangible assets. us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent Sales and Excise Tax Payable Consolidated Entities [Axis] Consolidated Entities [Domain] Direct us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment of employee payroll tax withholdings on share-based awards exercised us-gaap_PaymentsOfDividendsCommonStock Payment of dividends on common stock us-gaap_CostsAndExpenses Total operating expenses Direct Expenses [Member] Related to direct expenses. Retained Earnings [Member] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Revenue Title of Individual [Domain] Title of Individual [Axis] Treasury Stock [Member] nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod Incremental Costs of Obtaining a Contract, Deferred During Period Represents the amount of incremental costs of obtaining a contract deferred during the period. Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] Total carrying amount of long-term debt Long-term Debt, Total us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Other Current Assets [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes us-gaap_LineOfCredit Long-term Line of Credit, Total Timing of Transfer of Good or Service [Domain] Transferred at Point in Time [Member] us-gaap_DeferredFinanceCostsNet Less: unamortized debt issuance costs Transferred over Time [Member] us-gaap_SecuredDebt Term Loans Subscription Services [Member] Represents information pertaining to subscription services. Disaggregation of Revenue [Table Text Block] Timing of Transfer of Good or Service [Axis] Unit Price Services [Member] Represents information pertaining to unit price services. Revenue from Contract with Customer [Text Block] Fixed, Non-subscription Services [Member] Represents information pertaining to fixed, non-subscription services. Accounts Receivable [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Credit Agreement [Member] Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility. Document Transition Report Term Loan [Member] Represents information pertaining to a term loan. Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Dividends declared per common share (in dollars per share) Recoveries Delayed Draw Term Loan [Member] Represents information pertaining to a delayed draw term loan. Security Exchange Name Title of 12(b) Security Write-offs Income Statement Location [Axis] Income Statement Location [Domain] nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting. us-gaap_RepaymentsOfNotesPayable Payments on notes payable us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_RepaymentsOfLinesOfCredit Payments on line of credit Diluted (in shares) Denominator for diluted earnings per share – adjusted weighted average shares (in shares) Borrowings on line of credit Proceeds from Lines of Credit, Total Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Diluted Earnings Per Share (in dollars per share) Net income per share - diluted (in dollars per share) Basic (in shares) Weighted average common shares outstanding – basic (in shares) us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Basic Earnings Per Share (in dollars per share) Net income per share – basic (in dollars per share) Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Long-term Contract with Customer [Member] Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Income Statement [Abstract] us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other comprehensive income nrc_SalesAndExciseTaxExpense Sales and Excise Tax Expense Expense recorded during the period for statutory sales and use taxes, including value added tax. Hosting Arrangement Implementation Costs [Policy Text Block] Disclosure of accounting policy for implementation costs incurred in hosting arrangement that is service contract. nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold. VoC Platform [Member] Represents the Voice of the Customer Platform. Direct Fixed and Selling, General and Administrative Expense [Member] Primary financial statement caption encompassing direct fixed and selling, general and administrative expense. nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue Revenue from Contract with Customer, Percent of Total Revenue The percent of total revenue from contracts with customers. nrc_IncreaseDecreaseCapitalizedContractCost Deferred contract costs, net Capitalized costs incurred to obtain or fulfill contract with customer net of amortization recorded during the period. Cash flows from financing activities: Other long term liabilities PracticingExcellence.com [Member] Related to the entity PracticingExcellence.com. us-gaap_StockholdersEquity Total shareholders’ equity Balances Balances Class of Stock [Axis] Class of Stock [Domain] us-gaap_LongTermDebtNoncurrent Notes payable, net of current portion nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement. Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Notes payable, net of current portion and unamortized debt issuance costs nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement. EX-101.PRE 11 nrc-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 graph1.jpg begin 644 graph1.jpg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end GRAPHIC 13 graph2.jpg begin 644 graph2.jpg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end XML 14 nrc20200630_10q_htm.xml IDEA: XBRL DOCUMENT 0000070487 2020-01-01 2020-06-30 0000070487 2020-07-28 0000070487 2020-06-30 0000070487 2019-12-31 0000070487 2020-04-01 2020-06-30 0000070487 2019-04-01 2019-06-30 0000070487 2019-01-01 2019-06-30 0000070487 us-gaap:CommonStockMember 2019-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000070487 us-gaap:RetainedEarningsMember 2019-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000070487 us-gaap:TreasuryStockMember 2019-12-31 0000070487 2020-01-01 2020-03-31 0000070487 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000070487 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000070487 us-gaap:CommonStockMember 2020-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000070487 us-gaap:RetainedEarningsMember 2020-03-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000070487 us-gaap:TreasuryStockMember 2020-03-31 0000070487 2020-03-31 0000070487 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000070487 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000070487 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000070487 us-gaap:CommonStockMember 2020-06-30 0000070487 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000070487 us-gaap:RetainedEarningsMember 2020-06-30 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000070487 us-gaap:TreasuryStockMember 2020-06-30 0000070487 us-gaap:CommonStockMember 2018-12-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000070487 us-gaap:RetainedEarningsMember 2018-12-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000070487 us-gaap:TreasuryStockMember 2018-12-31 0000070487 2018-12-31 0000070487 2019-01-01 2019-03-31 0000070487 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000070487 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000070487 us-gaap:CommonStockMember 2019-03-31 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000070487 us-gaap:RetainedEarningsMember 2019-03-31 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000070487 us-gaap:TreasuryStockMember 2019-03-31 0000070487 2019-03-31 0000070487 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000070487 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000070487 us-gaap:CommonStockMember 2019-06-30 0000070487 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000070487 us-gaap:RetainedEarningsMember 2019-06-30 0000070487 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000070487 us-gaap:TreasuryStockMember 2019-06-30 0000070487 2019-06-30 0000070487 srt:MinimumMember 2020-06-30 0000070487 srt:MaximumMember 2020-06-30 0000070487 nrc:DirectExpensesMember 2020-04-01 2020-06-30 0000070487 nrc:DirectExpensesMember 2019-04-01 2019-06-30 0000070487 nrc:DirectExpensesMember 2020-01-01 2020-06-30 0000070487 nrc:DirectExpensesMember 2019-01-01 2019-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000070487 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000070487 2019-01-01 2019-12-31 0000070487 nrc:CanadianSubsidiaryMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0000070487 nrc:CanadianSubsidiaryMember 2020-06-30 0000070487 stpr:WA us-gaap:SubsequentEventMember 2020-07-31 0000070487 nrc:CyberAttackMember 2020-04-01 2020-06-30 0000070487 nrc:CyberAttackMember nrc:TheInsurerMember 2020-04-01 2020-06-30 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000070487 nrc:SubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-04-01 2020-06-30 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2019-04-01 2019-06-30 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-06-30 0000070487 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-06-30 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000070487 nrc:FixedNonSubscriptionServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2020-04-01 2020-06-30 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2019-04-01 2019-06-30 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-06-30 0000070487 nrc:UnitPriceServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-06-30 0000070487 nrc:VoCPlatformMember 2020-04-01 2020-06-30 0000070487 nrc:VoCPlatformMember 2019-04-01 2019-06-30 0000070487 nrc:VoCPlatformMember 2020-01-01 2020-06-30 0000070487 nrc:VoCPlatformMember 2019-01-01 2019-06-30 0000070487 us-gaap:OtherCurrentAssetsMember 2020-06-30 0000070487 us-gaap:OtherCurrentAssetsMember 2019-12-31 0000070487 us-gaap:LongTermContractWithCustomerMember 2020-07-01 2020-06-30 0000070487 us-gaap:LongTermContractWithCustomerMember 2021-01-01 2020-06-30 0000070487 us-gaap:LongTermContractWithCustomerMember 2020-06-30 0000070487 nrc:TermLoanMember 2020-06-30 0000070487 nrc:TermLoanMember 2019-12-31 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-06-30 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-05-28 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:DelayedDrawTermLoanMember 2020-06-30 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-03-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-01-01 2020-06-30 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:TermLoanMember 2020-06-30 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-06-30 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-06-30 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2019-12-31 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember nrc:DelayedDrawTermLoanMember 2020-01-01 2020-06-30 0000070487 us-gaap:RevolvingCreditFacilityMember nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-01-01 2020-06-30 0000070487 nrc:CreditAgreementMember nrc:FirstNationalBankOfOmahaMember 2020-01-01 2020-06-30 0000070487 nrc:The2001EquityIncentivePlanMember us-gaap:CommonStockMember 2020-06-30 0000070487 srt:MinimumMember us-gaap:EmployeeStockOptionMember nrc:The2001EquityIncentivePlanMember 2020-01-01 2020-06-30 0000070487 srt:MaximumMember us-gaap:EmployeeStockOptionMember nrc:The2001EquityIncentivePlanMember 2020-01-01 2020-06-30 0000070487 nrc:The2001EquityIncentivePlanMember 2015-12-31 0000070487 nrc:DirectorPlan2004Member us-gaap:CommonStockMember 2020-06-30 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2018-01-01 2018-12-31 0000070487 srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-06-30 0000070487 srt:MaximumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-06-30 0000070487 srt:MinimumMember srt:DirectorMember nrc:NonqualifiedStockOptionsMember nrc:DirectorPlan2004Member 2020-01-01 2020-06-30 0000070487 nrc:The2006EquityIncentivePlanMember us-gaap:CommonStockMember 2020-06-30 0000070487 srt:MinimumMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-06-30 0000070487 srt:MaximumMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-06-30 0000070487 nrc:CommonStockOptionsMember 2020-01-01 2020-06-30 0000070487 nrc:CommonStockOptionsMember 2019-01-01 2019-06-30 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000070487 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000070487 nrc:CommonStockOptionsMember 2019-12-31 0000070487 nrc:CommonStockOptionsMember 2019-01-01 2019-12-31 0000070487 nrc:CommonStockOptionsMember us-gaap:CommonStockMember 2019-12-31 0000070487 nrc:CommonStockOptionsMember us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000070487 nrc:CommonStockOptionsMember 2020-06-30 0000070487 nrc:CommonStockOptionsMember us-gaap:CommonStockMember 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2019-01-01 2019-06-30 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2020-01-01 2020-06-30 0000070487 nrc:NonvestedMember nrc:The2006EquityIncentivePlanMember 2020-06-30 0000070487 nrc:NonvestedMember 2020-01-01 2020-06-30 0000070487 nrc:NonvestedMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000070487 nrc:NonvestedMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000070487 nrc:NonvestedMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000070487 nrc:NonvestedMember nrc:DirectFixedAndSellingGeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000070487 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0000070487 us-gaap:CommonStockMember 2019-12-31 0000070487 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000070487 us-gaap:CommonStockMember 2020-06-30 0000070487 nrc:NonvestedMember 2020-06-30 0000070487 nrc:TradeNames1Member 2020-06-30 0000070487 nrc:TradeNames1Member 2019-12-31 0000070487 us-gaap:CustomerRelationshipsMember 2020-06-30 0000070487 us-gaap:CustomerRelationshipsMember 2019-12-31 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-06-30 0000070487 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000070487 us-gaap:TradeNamesMember 2020-06-30 0000070487 us-gaap:TradeNamesMember 2019-12-31 0000070487 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000070487 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000070487 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2020-04-01 2020-06-30 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2019-04-01 2019-06-30 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2020-01-01 2020-06-30 0000070487 nrc:AmeritasLifeInsuranceCorpMember 2019-01-01 2019-06-30 0000070487 nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember nrc:IMAFinancialGroupMember 2020-01-01 2020-06-30 0000070487 nrc:PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember nrc:IMAFinancialGroupMember 2020-04-01 2020-06-30 0000070487 nrc:PracticingExcellencecomMember 2020-04-01 2020-06-30 0000070487 nrc:PracticingExcellencecomMember 2019-04-01 2019-06-30 0000070487 nrc:PracticingExcellencecomMember 2020-01-01 2020-06-30 0000070487 nrc:PracticingExcellencecomMember 2019-01-01 2019-06-30 0000070487 country:US 2020-06-30 0000070487 country:US 2019-12-31 0000070487 country:CA 2020-06-30 0000070487 country:CA 2019-12-31 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y 0000070487 National Research Corporation false --12-31 Q2 2020 143000 144000 0.01 0.01 2000000 2000000 0 0 0.001 0.001 60000000 60000000 30553546 30151574 25235123 24947500 5318423 5204074 75980 260481 0.21 38369 148284 6793 28657 86247 6005 0.19 2977 18000 0.19 6 1 P3Y P5Y 0 0 1 P0Y6M P1Y 0 0 1.10 3.00 P1Y P5Y P5Y P10Y P1Y P10Y P3Y P5Y P10Y 0 0 P5Y 478000 6 1 10-Q true 2020-06-30 false 001-35929 WI 47-0634000 1245 Q Street Lincoln NE 68508 402 475-2525 Common Stock, $.001 par value NRC NASDAQ Yes Yes Accelerated Filer false false false 25241049 11957000 13517000 19882000 11639000 2823000 2038000 272000 69000 1763000 1894000 36697000 29157000 12355000 13530000 1541000 1728000 57829000 57935000 4582000 4204000 1312000 1628000 2465000 2503000 116781000 110685000 3966000 4378000 957000 1279000 6830000 6086000 2925000 3408000 308000 366000 5239000 16275000 16354000 1007000 1045000 32268000 38155000 28627000 29795000 7727000 7399000 2585000 2444000 71207000 77793000 0 0 31000 30000 167808000 162154000 -79165000 -93357000 -2872000 -2209000 40228000 33726000 45574000 32892000 116781000 110685000 31166000 31414000 65026000 62894000 11634000 11506000 24180000 23160000 8852000 8319000 17600000 16026000 1405000 1440000 2777000 2855000 21891000 21265000 44557000 42041000 9275000 10149000 20469000 20853000 2000 8000 13000 14000 450000 533000 914000 1103000 -270000 -139000 360000 -419000 -718000 -664000 -541000 -1508000 8557000 9485000 19928000 19345000 842000 2092000 458000 3756000 7715000 7393000 19470000 15589000 0.31 0.30 0.78 0.63 0.30 0.29 0.76 0.61 25148000 24789000 25060000 24777000 25680000 25586000 25702000 25549000 7715000 7393000 19470000 15589000 461000 255000 -663000 620000 461000 255000 -663000 620000 8176000 7648000 18807000 16209000 30000 162154000 -93357000 -2209000 -33726000 32892000 4425000 4425000 3145000 3145000 332000 332000 5278000 5278000 -1124000 -1124000 11755000 11755000 30000 165631000 -86880000 -3333000 -38151000 37297000 2077000 2077000 1000 2036000 2037000 141000 141000 461000 461000 7715000 7715000 31000 167808000 -79165000 -2872000 -40228000 45574000 30000 157312000 -106339000 -2916000 -29004000 19083000 1116000 1116000 633000 633000 302000 302000 4724000 4724000 365000 365000 8196000 8196000 30000 158247000 -102867000 -2551000 -30120000 22739000 137000 137000 137000 137000 307000 307000 4727000 4727000 255000 255000 7393000 7393000 30000 158691000 -100201000 -2296000 -30257000 25967000 19470000 15589000 2777000 2855000 328000 472000 143000 -251000 473000 609000 -40000 8382000 3088000 557000 -118000 379000 259000 1000 4000 -338000 432000 713000 -222000 -263000 -881000 -81000 696000 13903000 16106000 1427000 2280000 -1427000 -2280000 16500000 15500000 1600000 1837000 124000 161000 538000 1859000 483000 10517000 21837000 -13562000 -23318000 -474000 521000 -1560000 -8971000 13517000 12991000 11957000 4020000 884000 1066000 261000 4404000 105000 167000 4644000 770000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(<em style="font: inherit;">1</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Description of business and basis of presentation</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our <span style="-sec-ix-hidden:c63724395">six</span> operating segments are aggregated into <span style="-sec-ix-hidden:c63724397">one</span> reporting segment because they have similar economic characteristics and meet other aggregation criteria from the Financial Accounting Standards Board (“FASB”) guidance on segment disclosure. The <em style="font: inherit;">six</em> operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our condensed consolidated balance sheet at <em style="font: inherit;"> December 31, 2019 </em>was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2019, </em>filed with the Securities and Exchange Commission (the “SEC”) on <em style="font: inherit;"> March 6, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our Canadian subsidiary uses as its functional currency the local currency of the country in which it operates. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the condensed consolidated statements of income. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><br/> <b/></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">2</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Identify the performance obligations in the contract;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Determine the transaction price;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.25;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in <em style="font: inherit;">one</em> contract depends on another contract, or services in <em style="font: inherit;">one</em> or more contracts are a single performance obligation. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em> month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>One-time services – </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Fixed, non-subscription services – </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Unit-price services – </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>D</b><b>eferred Contract Costs </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c63724426">three</span> to <span style="-sec-ix-hidden:c63724427">five</span> years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. We deferred incremental costs of obtaining a contract of $599,000 and $741,000 in the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. The company deferred incremental costs of obtaining a contract of $2.2 million and $1.6 million in the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>respectively. Total amortization by expense classification for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> was as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six month</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Direct Expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">178</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">911</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">641</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,802</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $3,000 and $1,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively and $4,000 and $21,000 in the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Trade Accounts Receivable</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Trade accounts receivable are recorded at the invoiced amount. Effective <em style="font: inherit;"> January 1, 2020, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments.</i> This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on our condensed consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Some billing and collections efforts were delayed due to the security incident in the <em style="font: inherit;">first</em> quarter until we received the forensic report in the <em style="font: inherit;">second</em> quarter, resulting in an increase in accounts receivable. Additionally, the COVID-<em style="font: inherit;">19</em> pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020</em> due to our clients’ cash-flow issues.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table provides the activity in the allowance for doubtful accounts for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> (In thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning of</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Bad Debt</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Expense</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Benefit)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Write-offs</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Recoveries</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">End of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Leases</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to <em style="font: inherit;">not</em> record short-term leases with a duration of <em style="font: inherit;">12</em> months or less on the balance sheet.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Implementation Costs of Hosting Arrangements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">When a software license is included in a cloud computing arrangement and we have the ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Fair Value Measurements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019:</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of June 30, 2020</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There were <em style="font: inherit;">no</em> transfers between levels during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our long-term debt described in Note <em style="font: inherit;">4</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit. The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;"> December 31, 2019, </em>there was <span style="-sec-ix-hidden:c63724486"><span style="-sec-ix-hidden:c63724487">no</span></span> indication of impairment related to these assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Annually, we consider whether the recorded goodwill and indefinite lived intangibles have been impaired. However, goodwill and intangibles must be tested between annual tests if an event occurs or circumstances change to indicate that it is more likely than <em style="font: inherit;">not</em> that an impairment loss has been incurred (“triggering event”). We considered the current and expected future economic and market conditions, including the impact of the COVID-<em style="font: inherit;">19</em> pandemic, on each of our reporting units. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has <em style="font: inherit;">not</em> occurred which would require an interim impairment test to be performed as it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that an impairment loss has been incurred at <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our Canadian reporting unit generates service revenue from a relatively small number of customers with approximately 62.2% of its annual revenue concentrated in <span style="-sec-ix-hidden:c63724494">one</span> customer contract which currently expires in <em style="font: inherit;"> March 2021. </em>While historically we have been successful in renewing or retaining contracts with our customers, should we be unable to or choose <em style="font: inherit;">not</em> to renew a significant contract, it would likely result in an impairment of goodwill at this reporting unit. The carrying amount of goodwill related to our Canadian reporting unit at <em style="font: inherit;"> June 30, 2020 </em>was $2.3 million.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. There were <em style="font: inherit;">no</em> outstanding claims at <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A sales tax accrual of $775,000 was recorded in <em style="font: inherit;">2019</em> after we became aware that a state sales tax liability was both probable and estimable as of <em style="font: inherit;"> December 31, 2019, </em>due to sales taxes that should have been collected from customers in <em style="font: inherit;">2019</em> and certain previous years. In addition, we incurred additional sales tax expense in the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020.</em> We began collecting sales tax in <em style="font: inherit;"> July 2020. </em>State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that <em style="font: inherit;"> may </em>change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In <em style="font: inherit;"> July 2020, </em>we received a revenue ruling from the state of Washington noting that our services are <em style="font: inherit;">not</em> subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We received $2.4 million in insurance recoveries in the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020, </em>and $400,000 was paid directly to certain vendors from the insurer related to the <em style="font: inherit;"> February </em>incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020, </em>and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident has <em style="font: inherit;">not</em> had and we do <em style="font: inherit;">not</em> expect it to have a significant impact on our consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> March 2020, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or <em style="font: inherit;">no</em> notice without penalty. See Note <em style="font: inherit;">2</em> for further information about our contracts with customers. We account for revenue using the following steps:</p> <p style="margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Identify the contract, or contracts, with a customer;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Identify the performance obligations in the contract;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Determine the transaction price;</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Allocate the transaction price to the identified performance obligations; and</p> </td></tr> <tr style="vertical-align: top;"><td style="width: 18pt; line-height: 1.5;"> </td><td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">●</p> </td><td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.5;">Recognize revenue when, or as, we satisfy the performance obligations.</p> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; line-height: 1.25;">Our revenue arrangements with a client <em style="font: inherit;"> may </em>include combinations of more than <em style="font: inherit;">one</em> service offering which <em style="font: inherit;"> may </em>be executed at the same time, or within close proximity of <em style="font: inherit;">one</em> another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in <em style="font: inherit;">one</em> contract depends on another contract, or services in <em style="font: inherit;">one</em> or more contracts are a single performance obligation. For contracts that contain more than <em style="font: inherit;">one</em> separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will <em style="font: inherit;">not</em> occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do <em style="font: inherit;">not</em> contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our arrangements with customers consist principally of <em style="font: inherit;">four</em> different types of arrangements: <em style="font: inherit;">1</em>) subscription-based service agreements; <em style="font: inherit;">2</em>) <em style="font: inherit;">one</em>-time specified services performed at a single point in time; <em style="font: inherit;">3</em>) fixed, non-subscription service agreements; and <em style="font: inherit;">4</em>) unit-priced service agreements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Subscription-based services - </i>Services that are provided under subscription-based service agreements are usually for a <em style="font: inherit;">twelve</em> month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but <em style="font: inherit;"> may </em>also be billed on a quarterly and monthly basis.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>One-time services – </i>These agreements typically require us to perform a specific <em style="font: inherit;">one</em>-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Fixed, non-subscription services – </i>These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Unit-price services – </i>These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but <em style="font: inherit;">not</em> invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>D</b><b>eferred Contract Costs </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from <span style="-sec-ix-hidden:c63724426">three</span> to <span style="-sec-ix-hidden:c63724427">five</span> years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of <em style="font: inherit;">one</em> year or less. We deferred incremental costs of obtaining a contract of $599,000 and $741,000 in the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. The company deferred incremental costs of obtaining a contract of $2.2 million and $1.6 million in the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>respectively. Total amortization by expense classification for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> was as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six month</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Direct Expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">178</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">911</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">641</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,802</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $3,000 and $1,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively and $4,000 and $21,000 in the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 599000 741000 2200000 1600000 4600000 4200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six month</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Direct Expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">178</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,309</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">911</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">641</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,802</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 60000 13000 178000 19000 851000 628000 1624000 1309000 911000 641000 1802000 1328000 3000 1000 4000 21000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Trade Accounts Receivable</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Trade accounts receivable are recorded at the invoiced amount. Effective <em style="font: inherit;"> January 1, 2020, </em>we adopted Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Measurement of Credit Losses on Financial Instruments.</i> This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did <em style="font: inherit;">not</em> have an impact on our condensed consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Some billing and collections efforts were delayed due to the security incident in the <em style="font: inherit;">first</em> quarter until we received the forensic report in the <em style="font: inherit;">second</em> quarter, resulting in an increase in accounts receivable. Additionally, the COVID-<em style="font: inherit;">19</em> pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020</em> due to our clients’ cash-flow issues.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table provides the activity in the allowance for doubtful accounts for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> (In thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning of</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Bad Debt</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Expense</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Benefit)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Write-offs</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Recoveries</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">End of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning of</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Bad Debt</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Expense</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Benefit)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Write-offs</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Recoveries</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Balance at</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">End of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Six months ended June 30, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 144000 40000 62000 21000 143000 176000 -25000 37000 10000 124000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Leases</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long term liabilities. Certain lease arrangements <em style="font: inherit;"> may </em>include options to extend or terminate the lease. We include these provisions in the ROU and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do <em style="font: inherit;">not</em> contain any residual value guarantees.</p> <p style="margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is <em style="font: inherit;">not</em> readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to <em style="font: inherit;">not</em> record short-term leases with a duration of <em style="font: inherit;">12</em> months or less on the balance sheet.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Implementation Costs of Hosting Arrangements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">When a software license is included in a cloud computing arrangement and we have the ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is <em style="font: inherit;">not</em> included or we do <em style="font: inherit;">not</em> have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective <em style="font: inherit;"> January 1, 2020, </em>we prospectively adopted ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> Intangibles-Goodwill and Other-Internal Use Software (Subtopic <em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Fair Value Measurements</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (<em style="font: inherit;">1</em>) Level <em style="font: inherit;">1</em> Inputs—quoted prices in active markets for identical assets and liabilities; (<em style="font: inherit;">2</em>) Level <em style="font: inherit;">2</em> Inputs—observable market-based inputs other than Level <em style="font: inherit;">1</em> inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data; (<em style="font: inherit;">3</em>) Level <em style="font: inherit;">3</em> Inputs—unobservable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following details our financial assets within the fair value hierarchy at <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019:</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of June 30, 2020</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There were <em style="font: inherit;">no</em> transfers between levels during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our long-term debt described in Note <em style="font: inherit;">4</em> is recorded at historical cost. The fair value of long-term debt is classified in Level <em style="font: inherit;">2</em> of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit. The following are the carrying amount and estimated fair values of long-term debt:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are <em style="font: inherit;">not</em> recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;"> December 31, 2019, </em>there was <span style="-sec-ix-hidden:c63724486"><span style="-sec-ix-hidden:c63724487">no</span></span> indication of impairment related to these assets.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Annually, we consider whether the recorded goodwill and indefinite lived intangibles have been impaired. However, goodwill and intangibles must be tested between annual tests if an event occurs or circumstances change to indicate that it is more likely than <em style="font: inherit;">not</em> that an impairment loss has been incurred (“triggering event”). We considered the current and expected future economic and market conditions, including the impact of the COVID-<em style="font: inherit;">19</em> pandemic, on each of our reporting units. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has <em style="font: inherit;">not</em> occurred which would require an interim impairment test to be performed as it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that an impairment loss has been incurred at <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our Canadian reporting unit generates service revenue from a relatively small number of customers with approximately 62.2% of its annual revenue concentrated in <span style="-sec-ix-hidden:c63724494">one</span> customer contract which currently expires in <em style="font: inherit;"> March 2021. </em>While historically we have been successful in renewing or retaining contracts with our customers, should we be unable to or choose <em style="font: inherit;">not</em> to renew a significant contract, it would likely result in an impairment of goodwill at this reporting unit. The carrying amount of goodwill related to our Canadian reporting unit at <em style="font: inherit;"> June 30, 2020 </em>was $2.3 million.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 1</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 2</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Level 3</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of June 30, 2020</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,067</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">As of December 31, 2019</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Cash Equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,662</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total carrying amount of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,205</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 3067000 3067000 3067000 3067000 3662000 3662000 3662000 3662000 32681000 34281000 35293000 35205000 0.622 2300000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Commitments and Contingencies</b><br/> <br/> From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. There were <em style="font: inherit;">no</em> outstanding claims at <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A sales tax accrual of $775,000 was recorded in <em style="font: inherit;">2019</em> after we became aware that a state sales tax liability was both probable and estimable as of <em style="font: inherit;"> December 31, 2019, </em>due to sales taxes that should have been collected from customers in <em style="font: inherit;">2019</em> and certain previous years. In addition, we incurred additional sales tax expense in the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2020.</em> We began collecting sales tax in <em style="font: inherit;"> July 2020. </em>State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that <em style="font: inherit;"> may </em>change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In <em style="font: inherit;"> July 2020, </em>we received a revenue ruling from the state of Washington noting that our services are <em style="font: inherit;">not</em> subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We received $2.4 million in insurance recoveries in the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020, </em>and $400,000 was paid directly to certain vendors from the insurer related to the <em style="font: inherit;"> February </em>incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020, </em>and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the <em style="font: inherit;"> February </em>incident has <em style="font: inherit;">not</em> had and we do <em style="font: inherit;">not</em> expect it to have a significant impact on our consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </p> 775000 8000 58000 -268000 2400000 400000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recent Accounting Pronouncements <em style="font: inherit;">Not</em> Yet Adopted </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Simplifying the Accounting for Income Taxes (Topic <em style="font: inherit;">740</em>). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will <em style="font: inherit;">not</em> significantly impact our results of operations and financial position.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <em style="font: inherit;"> March 2020, </em>FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> "Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of <em style="font: inherit;"> March 12, 2020 </em>through <em style="font: inherit;"> December 31, 2022. </em>We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(<em style="font: inherit;">2</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>CONTRACTS WITH CUSTOMERS</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table disaggregates revenue for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-month periods ending <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> based on timing of revenue recognition (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,831</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,287</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">675</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,398</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,414</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,026</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our solutions within the digital VoC platform accounted for 72.9% and 62.1% of total revenue, in the <em style="font: inherit;">three</em>-month periods ending <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and 70.9% and 60.0% of total revenue in the <em style="font: inherit;">six</em>-month periods ending <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Significant changes in contract assets and contract liabilities during the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> are as follows (in thousands): </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contract</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Asset</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Deferred</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Revenue</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contract</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Asset</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Deferred</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Revenue</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Increase (Decrease)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,751</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">223</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We applied the practical expedient to <em style="font: inherit;">not</em> disclose the value of unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;"><span style="-sec-ix-hidden:c63724603"><span style="-sec-ix-hidden:c63724604">one</span></span></em> year or less. Total remaining contract revenue for contracts with original duration of greater than <em style="font: inherit;">one</em> year expected to be recognized in the future related to performance obligations that are unsatisfied at <em style="font: inherit;"> June 30, 2020 </em>approximated $281,000, of which $161,000 and $120,000 are expected to be recognized during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three months ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subscription services recognized ratably over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,831</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Services recognized at a point in time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,287</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fixed, non-subscription recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">675</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unit price services recognized over time</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,398</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,414</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,026</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 29572000 27918000 59993000 55831000 191000 1625000 1287000 2625000 158000 506000 675000 1040000 1245000 1365000 3071000 3398000 31166000 31414000 65026000 62894000 0.729 0.621 0.709 0.600 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accounts receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Contract assets included in other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,354</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended<br/> June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Six months ended<br/> June 30, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contract</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Asset</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Deferred</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Revenue</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contract</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Asset</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Deferred</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Revenue</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Increase (Decrease)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Revenue recognized that was included in deferred revenue at beginning of year due to completion of services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,226</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to invoicing of client, net of amounts recognized as revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,751</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to completion of services (or portion of services) and transferred to accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(46</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change due to cumulative catch-up adjustments arising from changes in expected contract consideration</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Decreases due to impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Increases due to revenue recognized in the period with additional performance obligations before invoicing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">223</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 19882000 11639000 120000 103000 16275000 16354000 11934000 12226000 11821000 12751000 85000 46000 -34000 -219000 102000 223000 281000 161000 120000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(<em style="font: inherit;">3</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>INCOME TAXES</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The effective tax rate for the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> June 30, 2020 </em>decreased to 9.8% compared to 22.1% for the same period in <em style="font: inherit;">2019</em> and for the <em style="font: inherit;">six</em>-month period ended <em style="font: inherit;"> June 30, 2020 </em>decreased to 2.3% compared to 19.4% for the same period in <em style="font: inherit;">2019</em> primarily from the exercise and vesting of shared-based compensation awards partially offset by higher state income taxes since we are filing in more states.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <em style="font: inherit;"> March 27, 2020, </em>the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $237,000 of employer social security tax payments into future years. We have had <em style="font: inherit;">no</em> other impacts to our consolidated financial statements or related disclosures from the CARES Act.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.098 0.221 0.023 0.194 237000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(<em style="font: inherit;">4</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>NOTES PAYABLE</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our long-term debt consists of the following:  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,966</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on <em style="font: inherit;"> May 28, 2020 </em>and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan <em style="font: inherit;"> may </em>be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The amendment increased the Line of Credit from $15,000,000 to $30,000,000.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through <em style="font: inherit;"> May 2025, </em>with a balloon payment due at maturity in <em style="font: inherit;"> May 2025. </em>The Term Loan bears interest at a fixed rate per annum of 5%.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the <em style="font: inherit;">30</em>-day London Interbank Offered Rate plus 225 basis points (2.43% at <em style="font: inherit;"> June 30, 2020). </em>Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in <em style="font: inherit;"> May 2023. </em>As of <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;"> December 31, 2019, </em>the Line of Credit did <span style="-sec-ix-hidden:c63724694"><span style="-sec-ix-hidden:c63724695">not</span></span> have a balance. There were <em style="font: inherit;">no</em> borrowings on the Line of Credit for <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020. </em>There have been no borrowings on the Delayed Draw Term Loan since origination.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions.. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of <span style="-sec-ix-hidden:c63724701">1.10x</span> for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of <span style="-sec-ix-hidden:c63724703">3.00x</span> or less for all testing periods throughout the term(s) of the Credit Facilities.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">As of <em style="font: inherit;"> June 30, 2020, </em>we were in compliance with our financial covenants.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Term Loans</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,681</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,966</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,378</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less: unamortized debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(88</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(108</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 32681000 34281000 3966000 4378000 88000 108000 28627000 29795000 30000000 33002069 15000000 15000000 30000000 33002069 462988 0.05 0.0225 0.0243 0 0.0020 5500000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(<em style="font: inherit;">5</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>SHARE-BASED COMPENSATION</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our <em style="font: inherit;">2001</em> Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over <span style="-sec-ix-hidden:c63724721">one</span> to <span style="-sec-ix-hidden:c63724722">five</span> years following the date of grant and option terms are generally <span style="-sec-ix-hidden:c63724723">five</span> to <span style="-sec-ix-hidden:c63724724">ten</span> years following the date of grant. Due to the expiration of the <em style="font: inherit;">2001</em> Equity Incentive Plan at <em style="font: inherit;"> December 31, 2015, </em>there were no shares of stock available for future grants.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our <em style="font: inherit;">2004</em> Non-Employee Director Stock Plan, as amended (the <em style="font: inherit;">“2004</em> Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The <em style="font: inherit;">2004</em> Director Plan provides for grants of nonqualified stock options to each of our directors who we do <em style="font: inherit;">not</em> employ. Beginning in <em style="font: inherit;">2018,</em> on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately <span style="-sec-ix-hidden:c63724734">one</span> year following the date of grant and option terms are generally the earlier of <span style="-sec-ix-hidden:c63724735">ten</span> years following the date of grant, or <span style="-sec-ix-hidden:c63724736">three</span> years from the termination of the outside director’s service.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our <em style="font: inherit;">2006</em> Equity Incentive Plan (the <em style="font: inherit;">“2006</em> Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common Stock. Stock options granted <em style="font: inherit;"> may </em>be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally <span style="-sec-ix-hidden:c63724740">five</span> to <span style="-sec-ix-hidden:c63724741">ten</span> years following the date of grant.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> we granted options to purchase 70,471 and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes stock option activity under the <em style="font: inherit;">2001</em> and <em style="font: inherit;">2006</em> Equity Incentive Plans and the <em style="font: inherit;">2004</em> Director Plan for the <em style="font: inherit;">six</em>-month period ended <em style="font: inherit;"> June 30, 2020:</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of<br/> Options</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Terms</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,245,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(408,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">892,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">492,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <em style="font: inherit;"> June 30, 2020, </em>the total unrecognized compensation cost related to non-vested stock option awards was approximately $2.1 million which was expected to be recognized over a weighted average period of 3.2 years.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There was $538,000 of cash received from stock options exercised for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <span style="-sec-ix-hidden:c63724755">no</span> cash was received from the exercise of options in the same period of <em style="font: inherit;">2019.</em> We recognized $216,000 and $235,000 of non-cash compensation for <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and $498,000 and $464,000 of non-cash compensation for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, related to options, which is included in direct fixed and selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2019, </em>we granted 6,005 non-vested shares of Common Stock under the <em style="font: inherit;">2006</em> Equity Incentive Plan. <span style="-sec-ix-hidden:c63724768">No</span> shares were granted during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020. </em>As of <em style="font: inherit;"> June 30, 2020, </em>we had 42,761 non-vested shares of Common Stock outstanding under the <em style="font: inherit;">2006</em> Equity Incentive Plan. These shares vest over <span style="-sec-ix-hidden:c63724772">five</span> years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or <em style="font: inherit;">not</em> vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized ($75,000) and $73,000 of non-cash compensation for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and ($26,000) and $145,000 of non-cash compensation for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, related to this non-vested stock, which is included in direct fixed and selling, general and administrative expenses. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30 2020, </em>34,622 shares vested and 6,793 shares were forfeited.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes information regarding non-vested stock granted to associates under the <em style="font: inherit;">2006</em> Equity Incentive Plan for the <em style="font: inherit;">six</em>-month period ended <em style="font: inherit;"> June 30, 2020:</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Outstanding</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date Fair</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Per Share</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">84,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34,622</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <em style="font: inherit;"> June 30, 2020, </em>the total unrecognized compensation cost related to non-vested stock awards was approximately $187,000 and is expected to be recognized over a weighted average period of 3.05 years.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 1800000 0 3000000 100000 1800000 70471 100615 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield at date of grant</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33.62</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.0184 0.0260 0.3362 0.3401 0.0135 0.0238 P7Y4M24D P7Y6M <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of<br/> Options</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Terms</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,245,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(408,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">892,138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">492,484</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 1245922 18.08 P4Y5M12D 59631000 70471 62.23 408765 12.68 17810000 15490 48.42 892138 23.51 P5Y9M7D 31281000 492484 17.55 P4Y6M29D 20022.000 2100000 P3Y2M12D 538000 216000 235000 498000 464000 6005 42761 -75000 73000 -26000 145000 34622 6793 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Outstanding</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date Fair</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Per Share</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">84,176</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34,622</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,793</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 84176 17.23 34622 13.17 6793 36.80 42761 17.40 187000 P3Y18D <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(<em style="font: inherit;">6</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>GOODWILL AND OTHER INTANGIBLE ASSETS</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following represents a summary of changes in the carrying amount of goodwill for the <em style="font: inherit;">six</em>-month period ended <em style="font: inherit;"> June 30, 2020:</em><br/>  </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance as of June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Intangible assets consisted of the following:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,270</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,908</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other intangible assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,541</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,728</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">  </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 36pt; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance as of June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 57935000 -106000 57829000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-amortizing intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Indefinite trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Amortizing intangible assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer related</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,572</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total amortizing intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,270</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,908</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other intangible assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,541</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,728</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1191000 1191000 9326000 9338000 1360000 1360000 1572000 1572000 12258000 12270000 11908000 11733000 1541000 1728000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(<em style="font: inherit;">7</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>PROPERTY AND EQUIPMENT</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28,548</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,355</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,122</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28,548</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,355</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 43477000 42078000 31122000 28548000 12355000 13530000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>(<em style="font: inherit;">8</em>)</b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>EARNINGS PER SHARE</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We had 57,719 and 83,225 options of Common Stock for the <em style="font: inherit;">three</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. We had 52,789 and 143,247 options of Common Stock for the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">For the Three Months Ended June 30</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">For the Six Months Ended June 30</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Numerator for net income per share – basic:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for net income per share – basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income per share – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Numerator for net income per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for net income per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,586</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,702</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income per share - diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> 57719 83225 52789 143247 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">For the Three Months Ended June 30</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">For the Six Months Ended June 30</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Numerator for net income per share – basic:</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,715</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Allocation of distributed and undistributed income to unvested restricted stock shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income attributable to common shareholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for net income per share – basic:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income per share – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Numerator for net income per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Net income attributable to common shareholders for basic computation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for net income per share – diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average common shares outstanding – basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average effect of dilutive securities – stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Denominator for diluted earnings per share – adjusted weighted average shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,586</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,702</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income per share - diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 7715000 7393000 19470000 15589000 15000 25000 38000 53000 7700000 7368000 19432000 15536000 25148000 24789000 25060000 24777000 0.31 0.30 0.78 0.63 7700000 7368000 19432000 15536000 25148000 24789000 25060000 24777000 532000 797000 642000 772000 25680000 25586000 25702000 25549000 0.30 0.29 0.76 0.61 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(<em style="font: inherit;">9</em>) </b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>RELATED PARTY</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Until <em style="font: inherit;"> January 2020, </em><em style="font: inherit;">one</em> of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to serve on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $42,000 and $67,000 in the <em style="font: inherit;">three</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively and $114,000 and $127,000 in the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A director, who served on our board through <em style="font: inherit;"> May 2020, </em>also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during <em style="font: inherit;">2020</em> we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. These purchases totaled $478,000 in the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During <em style="font: inherit;">2017,</em> we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in <em style="font: inherit;">2016</em> under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement was $83,000 and $170,000 in the <em style="font: inherit;">three</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and $166,000 and $323,000 in <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. We will <em style="font: inherit;">no</em> longer earn revenue under this agreement after <em style="font: inherit;"> June 30, 2021.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 42000 67000 114000 127000 478000 83000 170000 166000 323000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>(<em style="font: inherit;">1</em></b><b><em style="font: inherit;">0</em></b><b>) </b></p> </td><td> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><b>SEGMENT INFORMATION</b></span></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company’s <span style="-sec-ix-hidden:c63724951">six</span> operating segments are aggregated into <span style="-sec-ix-hidden:c63724952">one</span> reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The <em style="font: inherit;">six</em> operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations. The table below presents entity-wide information regarding the Company’s assets, after elimination of intercompany balances by geographic area:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">78,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">80,084</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95,668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>  </b></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2019</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">78,906</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,622</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">80,084</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">81,528</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95,668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,017</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">110,685</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 77621000 78906000 2463000 2622000 80084000 81528000 101134000 95668000 15647000 15017000 116781000 110685000 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2020
Jul. 28, 2020
Document Information [Line Items]    
Entity Central Index Key 0000070487  
Entity Registrant Name National Research Corporation  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2020  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2020  
Document Transition Report false  
Entity File Number 001-35929  
Entity Incorporation, State or Country Code WI  
Entity Tax Identification Number 47-0634000  
Entity Address, Address Line One 1245 Q Street  
Entity Address, City or Town Lincoln  
Entity Address, State or Province NE  
Entity Address, Postal Zip Code 68508  
City Area Code 402  
Local Phone Number 475-2525  
Title of 12(b) Security Common Stock, $.001 par value  
Trading Symbol NRC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   25,241,049
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 11,957 $ 13,517
Trade accounts receivable, less allowance for doubtful accounts of $143 and $144, respectively 19,882 11,639
Prepaid expenses 2,823 2,038
Income taxes receivable 272 69
Other current assets 1,763 1,894
Total current assets 36,697 29,157
Net property and equipment 12,355 13,530
Intangible assets, net 1,541 1,728
Goodwill 57,829 57,935
Deferred contract costs, net 4,582 4,204
Operating lease right-of-use assets 1,312 1,628
Other 2,465 2,503
Total assets 116,781 110,685
Current liabilities:    
Current portion of notes payable 3,966 4,378
Accounts payable 957 1,279
Accrued wages, bonus and profit sharing 6,830 6,086
Accrued expenses 2,925 3,408
Income taxes payable 308 366
Dividends payable   5,239
Deferred revenue 16,275 16,354
Other current liabilities 1,007 1,045
Total current liabilities 32,268 38,155
Notes payable, net of current portion and unamortized debt issuance costs 28,627 29,795
Deferred income taxes 7,727 7,399
Other long term liabilities 2,585 2,444
Total liabilities 71,207 77,793
Shareholders’ equity:    
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued 0 0
Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,553,546 in 2020 and 30,151,574 in 2019, outstanding 25,235,123 in 2020 and 24,947,500 in 2019 31 30
Additional paid-in capital 167,808 162,154
Retained earnings (accumulated deficit) (79,165) (93,357)
Accumulated other comprehensive loss, foreign currency translation adjustment (2,872) (2,209)
Treasury stock, at cost; 5,318,423 Common shares in 2020 and 5,204,074 shares in 2019 (40,228) (33,726)
Total shareholders’ equity 45,574 32,892
Total liabilities and shareholders’ equity $ 116,781 $ 110,685
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Allowance for doubtful accounts $ 143 $ 144
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 60,000,000 60,000,000
Common stock, shares issued (in shares) 30,553,546 30,151,574
Common stock, shares outstanding (in shares) 25,235,123 24,947,500
Treasury stock, shares (in shares) 5,318,423 5,204,074
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue $ 31,166 $ 31,414 $ 65,026 $ 62,894
Operating expenses:        
Direct 11,634 11,506 24,180 23,160
Selling, general and administrative 8,852 8,319 17,600 16,026
Depreciation and amortization 1,405 1,440 2,777 2,855
Total operating expenses 21,891 21,265 44,557 42,041
Operating income 9,275 10,149 20,469 20,853
Other income (expense):        
Interest income 2 8 13 14
Interest expense (450) (533) (914) (1,103)
Other, net (270) (139) 360 (419)
Total other income (expense) (718) (664) (541) (1,508)
Income before income taxes 8,557 9,485 19,928 19,345
Provision for income taxes 842 2,092 458 3,756
Net income $ 7,715 $ 7,393 $ 19,470 $ 15,589
Earnings Per Share of Common Stock:        
Basic Earnings Per Share (in dollars per share) $ 0.31 $ 0.30 $ 0.78 $ 0.63
Diluted Earnings Per Share (in dollars per share) $ 0.30 $ 0.29 $ 0.76 $ 0.61
Weighted average shares and share equivalents outstanding:        
Basic (in shares) 25,148 24,789 25,060 24,777
Diluted (in shares) 25,680 25,586 25,702 25,549
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Net income $ 7,715 $ 7,393 $ 19,470 $ 15,589
Other comprehensive income:        
Foreign currency translation adjustment 461 255 (663) 620
Other comprehensive income 461 255 (663) 620
Comprehensive Income $ 8,176 $ 7,648 $ 18,807 $ 16,209
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Balances at Dec. 31, 2018 $ 30 $ 157,312 $ (106,339) $ (2,916) $ (29,004) $ 19,083
Purchase of shares treasury stock         (1,116) (1,116)
Issuance of common shares for the exercise of stock options   633       633
Non-cash stock compensation expense   302       302
Dividends declared     (4,724)     (4,724)
Other comprehensive loss, foreign currency translation adjustment       365   365
Net income     8,196     8,196
Balances at Mar. 31, 2019 30 158,247 (102,867) (2,551) (30,120) 22,739
Balances at Dec. 31, 2018 30 157,312 (106,339) (2,916) (29,004) 19,083
Other comprehensive loss, foreign currency translation adjustment           620
Net income           15,589
Balances at Jun. 30, 2019 30 158,691 (100,201) (2,296) (30,257) 25,967
Balances at Mar. 31, 2019 30 158,247 (102,867) (2,551) (30,120) 22,739
Purchase of shares treasury stock         (137) (137)
Issuance of common shares for the exercise of stock options   137       137
Non-cash stock compensation expense   307       307
Dividends declared     (4,727)     (4,727)
Other comprehensive loss, foreign currency translation adjustment       255   255
Net income     7,393     7,393
Balances at Jun. 30, 2019 30 158,691 (100,201) (2,296) (30,257) 25,967
Balances at Dec. 31, 2019 30 162,154 (93,357) (2,209) (33,726) 32,892
Purchase of shares treasury stock         (4,425) (4,425)
Issuance of common shares for the exercise of stock options   3,145       3,145
Non-cash stock compensation expense   332       332
Dividends declared     (5,278)     (5,278)
Other comprehensive loss, foreign currency translation adjustment       (1,124)   (1,124)
Net income     11,755     11,755
Balances at Mar. 31, 2020 30 165,631 (86,880) (3,333) (38,151) 37,297
Balances at Dec. 31, 2019 30 162,154 (93,357) (2,209) (33,726) 32,892
Other comprehensive loss, foreign currency translation adjustment           (663)
Net income           19,470
Balances at Jun. 30, 2020 31 167,808 (79,165) (2,872) (40,228) 45,574
Balances at Mar. 31, 2020 30 165,631 (86,880) (3,333) (38,151) 37,297
Purchase of shares treasury stock         (2,077) (2,077)
Issuance of common shares for the exercise of stock options 1 2,036       2,037
Non-cash stock compensation expense   141       141
Other comprehensive loss, foreign currency translation adjustment       461   461
Net income     7,715     7,715
Balances at Jun. 30, 2020 $ 31 $ 167,808 $ (79,165) $ (2,872) $ (40,228) $ 45,574
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Shares of stock (in shares) 38,369 75,980 2,977 28,657
Shares of common stock for the exercise of stock options (in shares) 148,284 260,481 18,000 86,247
Dividends declared per common share (in dollars per share)   $ 0.21 $ 0.19 $ 0.19
Forfeitures of restricted common shares (in shares) 6,793      
Shares of restricted common shares, net of (forfeitures) (in shares)       6,005
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities:    
Net income $ 19,470,000 $ 15,589,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 2,777,000 2,855,000
Deferred income taxes 328,000 472,000
Reserve for uncertain tax positions 143,000 (251,000)
Non-cash share-based compensation expense 473,000 609,000
Loss on disposal of property and equipment   40,000
Net changes in assets and liabilities:    
Trade accounts receivable (8,382,000) (3,088,000)
Prepaid expenses and other current assets (557,000) 118,000
Deferred contract costs, net (379,000) (259,000)
Operating lease assets and liabilities, net (1,000) (4,000)
Accounts payable (338,000) 432,000
Accrued expenses, wages, bonuses and profit sharing 713,000 (222,000)
Income taxes receivable and payable (263,000) (881,000)
Deferred revenue (81,000) 696,000
Net cash provided by operating activities 13,903,000 16,106,000
Cash flows from investing activities:    
Purchases of property and equipment (1,427,000) (2,280,000)
Net cash used in investing activities (1,427,000) (2,280,000)
Cash flows from financing activities:    
Borrowings on line of credit   16,500,000
Payments on line of credit   (15,500,000)
Payments on notes payable (1,600,000) (1,837,000)
Payments on finance lease obligations (124,000) (161,000)
Proceeds from the exercise of stock options 538,000  
Payment of employee payroll tax withholdings on share-based awards exercised (1,859,000) (483,000)
Payment of dividends on common stock (10,517,000) (21,837,000)
Net cash used in financing activities (13,562,000) (23,318,000)
Effect of exchange rate changes on cash (474,000) 521,000
Change in cash and cash equivalents (1,560,000) (8,971,000)
Cash and cash equivalents at beginning of period 13,517,000 12,991,000
Cash and cash equivalents at end of period 11,957,000 4,020,000
Supplemental disclosure of cash paid for:    
Interest, net of capitalized amounts 884,000 1,066,000
Income taxes 261,000 4,404,000
Supplemental disclosure of non-cash investing and financing activities:    
Finance lease obligations originated for property and equipment 105,000 167,000
Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans $ 4,644,000 $ 770,000
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

(1)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Description of business and basis of presentation

 

National Research Corporation, doing business as NRC Health (“NRC Health,” the “Company,” “we,” “our,” “us” or similar terms), is a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States and Canada. Our portfolio of solutions represents a unique set of capabilities that individually and collectively provide value to our clients. The solutions are offered at an enterprise level through the Voice of the Customer ("VoC") platform, The Governance Institute, and legacy Experience solutions. 

 

Our six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet other aggregation criteria from the Financial Accounting Standards Board (“FASB”) guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations.

 

Our condensed consolidated balance sheet at December 31, 2019 was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.

 

Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2020.

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary, National Research Corporation Canada. All significant intercompany transactions and balances have been eliminated.

 

Our Canadian subsidiary uses as its functional currency the local currency of the country in which it operates. It translates its assets and liabilities into U.S. dollars at the exchange rate in effect at the balance sheet date. It translates its revenue and expenses at the average exchange rate during the period. We include translation gains and losses in accumulated other comprehensive income (loss), a component of shareholders’ equity. Gains and losses related to transactions denominated in a currency other than the functional currency of the country in which we operate and short-term intercompany accounts are included in other income (expense) in the condensed consolidated statements of income. 

 


Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 2 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

Identify the contract, or contracts, with a customer;

 

Identify the performance obligations in the contract;

 

Determine the transaction price;

 

Allocate the transaction price to the identified performance obligations; and

 

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.  

 

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $599,000 and $741,000 in the three months ended June 30, 2020 and 2019, respectively. The company deferred incremental costs of obtaining a contract of $2.2 million and $1.6 million in the six-month periods ended June 30, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at June 30, 2020 and December 31, 2019, respectively. Total amortization by expense classification for the three and six-months ended June 30, 2020 and 2019 was as follows:

 

  

Three months

ended
June 30, 2020

  

Three months

ended
June 30, 2019

  

Six month

ended
June 30, 2020

  

Six months

ended
June 30, 2019

 
  

(In thousands)

 

Direct Expenses

 $60  $13  $178  $19 

Selling, general and administrative expenses

  851   628   1,624   1,309 

Total amortization

 $911  $641  $1,802  $1,328 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $3,000 and $1,000 for the three months ended June 30, 2020 and 2019, respectively and $4,000 and $21,000 in the six months ended June 30, 2020 and 2019, respectively.

 

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our condensed consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Some billing and collections efforts were delayed due to the security incident in the first quarter until we received the forensic report in the second quarter, resulting in an increase in accounts receivable. Additionally, the COVID-19 pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the second quarter of 2020 due to our clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the six months ended June 30, 2020 and 2019 (In thousands):

 

  

Balance at

Beginning of

Period

  

Bad Debt

Expense

(Benefit)

  

Write-offs

  

Recoveries

  

Balance at

End of Period

 
                     

Six months ended June 30, 2020

 $144  $40  $62  $21  $143 

Six months ended June 30, 2019

 $176  $(25

)

 $37  $10  $124 

 

Leases

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

We elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Implementation Costs of Hosting Arrangements

 

When a software license is included in a cloud computing arrangement and we have the ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at June 30, 2020 and December 31, 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of June 30, 2020

                

Money Market Funds

 $3,067  $-  $-  $3,067 

Total Cash Equivalents

 $3,067  $-  $-  $3,067 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $-  $-  $3,662 

Total Cash Equivalents

 $3,662  $-  $-  $3,662 

 

There were no transfers between levels during the three-month period ended June 30, 2020.

 

Our long-term debt described in Note 4 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit. The following are the carrying amount and estimated fair values of long-term debt:

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $32,681  $34,281 

Estimated fair value of long-term debt

 $35,293  $35,205 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of June 30, 2020, and December 31, 2019, there was no indication of impairment related to these assets.

 

Annually, we consider whether the recorded goodwill and indefinite lived intangibles have been impaired. However, goodwill and intangibles must be tested between annual tests if an event occurs or circumstances change to indicate that it is more likely than not that an impairment loss has been incurred (“triggering event”). We considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on each of our reporting units. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an interim impairment test to be performed as it is not more likely than not that an impairment loss has been incurred at June 30, 2020.

 

Our Canadian reporting unit generates service revenue from a relatively small number of customers with approximately 62.2% of its annual revenue concentrated in one customer contract which currently expires in March 2021. While historically we have been successful in renewing or retaining contracts with our customers, should we be unable to or choose not to renew a significant contract, it would likely result in an impairment of goodwill at this reporting unit. The carrying amount of goodwill related to our Canadian reporting unit at June 30, 2020 was $2.3 million.

 

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. There were no outstanding claims at June 30, 2020.

 

A sales tax accrual of $775,000 was recorded in 2019 after we became aware that a state sales tax liability was both probable and estimable as of December 31, 2019, due to sales taxes that should have been collected from customers in 2019 and certain previous years. In addition, we incurred additional sales tax expense in the three and six-month periods ended June 30, 2020 of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the second quarter of 2020. We began collecting sales tax in July 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In July 2020, we received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020.

 

We received $2.4 million in insurance recoveries in the three-month period ended June 30, 2020, and $400,000 was paid directly to certain vendors from the insurer related to the February incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the three-month period ended June 30, 2020, and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the February incident has not had and we do not expect it to have a significant impact on our consolidated financial statements.

  

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

 

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

(2)

CONTRACTS WITH CUSTOMERS

 

The following table disaggregates revenue for the three and six-month periods ending June 30, 2020 and 2019 based on timing of revenue recognition (in thousands):

 

  

Three months ended

  

Six months ended

 
  

June 30, 2020

  

June 30, 2019

  

June 30, 2020

  

June 30, 2019

 

Subscription services recognized ratably over time

 $29,572  $27,918  $59,993  $55,831 

Services recognized at a point in time

  191   1,625   1,287   2,625 

Fixed, non-subscription recognized over time

  158   506   675   1,040 

Unit price services recognized over time

  1,245   1,365   3,071   3,398 

Total revenue

 $31,166  $31,414  $65,026  $62,894 

 

Our solutions within the digital VoC platform accounted for 72.9% and 62.1% of total revenue, in the three-month periods ending June 30, 2020 and 2019, respectively, and 70.9% and 60.0% of total revenue in the six-month periods ending June 30, 2020 and 2019, respectively. The remaining revenue consists of legacy Experience and Governance Solutions.  

 

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (In thousands):

 

  

June 30,

2020

  

December 31,

2019

 

Accounts receivables

 $19,882  $11,639 

Contract assets included in other current assets

 $120  $103 

Deferred Revenue

 $(16,275

)

 $(16,354

)

 

Significant changes in contract assets and contract liabilities during the three and six-months ended June 30, 2020 and 2019 are as follows (in thousands): 

 

  

Six months ended
June 30, 2020

  

Six months ended
June 30, 2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(11,934

)

 $-  $(12,226

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   11,821   -   12,751 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (85

)

  -   (46

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

      34       219 

Decreases due to impairment

  -   -   -   - 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  102   -   223   - 

 

We applied the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at June 30, 2020 approximated $281,000, of which $161,000 and $120,000 are expected to be recognized during 2020 and 2021, respectively.

 

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Income Taxes
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

(3)

INCOME TAXES

 

The effective tax rate for the three-month period ended June 30, 2020 decreased to 9.8% compared to 22.1% for the same period in 2019 and for the six-month period ended June 30, 2020 decreased to 2.3% compared to 19.4% for the same period in 2019 primarily from the exercise and vesting of shared-based compensation awards partially offset by higher state income taxes since we are filing in more states.

 

In March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak which, among other things, contains numerous income tax provisions. As a result of the CARES Act, we have deferred $237,000 of employer social security tax payments into future years. We have had no other impacts to our consolidated financial statements or related disclosures from the CARES Act.

 

 

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Notes Payable
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Debt Disclosure [Text Block]

(4)

NOTES PAYABLE

 

Our long-term debt consists of the following:  

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Term Loans

 $32,681  $34,281 

Less: current portion

  (3,966

)

  (4,378

)

Less: unamortized debt issuance costs

  (88

)

  (108

)

Notes payable, net of current portion

 $28,627  $29,795 

 

Our credit agreement (the “Credit Agreement”) with First National Bank of Omaha (“FNB”) was amended and restated on May 28, 2020 and includes (i) a $30,000,000 revolving credit facility (the “Line of Credit”), (ii) a $33,002,069 term loan (the “Term Loan”) and (iii) a $15,000,000 delayed draw-dawn term facility (the “Delayed Draw Term Loan” and, together with the Line of Credit and the Term Loan, the “Credit Facilities”). The Delayed Draw Term Loan may be used to fund any permitted future business acquisitions or repurchases of our Common Stock and the Line of Credit can be used to fund ongoing working capital needs and for other general corporate purposes. The amendment increased the Line of Credit from $15,000,000 to $30,000,000.

 

The amended Term Loan revised the remaining payments for the existing balance outstanding of $33,002,069 to monthly installments of $462,988 through May 2025, with a balloon payment due at maturity in May 2025. The Term Loan bears interest at a fixed rate per annum of 5%.

 

Borrowings under the Line of Credit and the Delayed Draw Term Loan, if any, bear interest at a floating rate equal to the 30-day London Interbank Offered Rate plus 225 basis points (2.43% at June 30, 2020). Interest on the Line of Credit accrues and is payable monthly. Principal amounts outstanding under the Line of Credit are due and payable in full at maturity, in May 2023. As of June 30, 2020, and December 31, 2019, the Line of Credit did not have a balance. There were no borrowings on the Line of Credit for three and six-month periods ended June 30, 2020. There have been no borrowings on the Delayed Draw Term Loan since origination.

 

We are obligated to pay ongoing unused commitment fees quarterly in arrears pursuant to the Line of Credit and the Delayed Draw Term Loan facility at a rate of 0.20% per annum based on the actual daily unused portions of the Line of Credit and the Delayed Draw Term Loan facility, respectively.

 

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our Common Stock and acquisitions, subject in each case to certain exceptions.. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes, unless our liquidity falls below a specified threshold, (i) any cash dividend in a fiscal quarter that, together with all other cash dividends paid or declared during such fiscal quarter, exceeds $5,500,000 in total cash dividends paid or declared, (ii) the portion of the purchase price for any permitted share repurchase of our shares paid with cash on hand, and (iii) the portion of any acquisition consideration for a permitted acquisition paid with cash on hand. We are also required to maintain a cash flow leverage ratio of 3.00x or less for all testing periods throughout the term(s) of the Credit Facilities.

As of June 30, 2020, we were in compliance with our financial covenants.

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

(5)

SHARE-BASED COMPENSATION

 

We measure and recognize compensation expense for all share-based payments based on the grant-date fair value of those awards. All of our existing stock option awards and unvested stock awards have been determined to be equity-classified awards. We account for forfeitures as they occur.

 

Our 2001 Equity Incentive Plan provided for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common stock. Stock options granted could have been either nonqualified or incentive stock options. Stock options vest over one to five years following the date of grant and option terms are generally five to ten years following the date of grant. Due to the expiration of the 2001 Equity Incentive Plan at December 31, 2015, there were no shares of stock available for future grants.

 

Our 2004 Non-Employee Director Stock Plan, as amended (the “2004 Director Plan”), is a nonqualified plan that provides for the granting of options with respect to 3,000,000 shares of our Common Stock. The 2004 Director Plan provides for grants of nonqualified stock options to each of our directors who we do not employ. Beginning in 2018, on the date of each annual meeting of shareholders, options to purchase shares of Common Stock equal to an aggregate grant date fair value of $100,000 are granted to each non-employee director that is elected or retained as a director at each such meeting. Stock options vest approximately one year following the date of grant and option terms are generally the earlier of ten years following the date of grant, or three years from the termination of the outside director’s service.

 

Our 2006 Equity Incentive Plan (the “2006 Equity Incentive Plan”), as amended, provides for the granting of stock options, stock appreciation rights, restricted stock, performance shares and other share-based awards and benefits up to an aggregate of 1,800,000 shares of our Common Stock. Stock options granted may be either incentive stock options or nonqualified stock options. Vesting terms vary with each grant and option terms are generally five to ten years following the date of grant.

 

During the six months ended June 30, 2020 and 2019, we granted options to purchase 70,471 and 100,615 shares of Common Stock, respectively. Options to purchase shares of common stock are typically granted with exercise prices equal to the fair value of the common stock on the date of grant. We do, in certain limited situations, grant options with exercise prices that exceed the fair value of the common shares on the date of grant. The fair value of stock options granted was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

 

  

2020

  

2019

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

Expected stock price volatility

  33.62

%

  34.01

%

Risk-free interest rate

  1.35

%

  2.38

%

Expected life of options (in years)

  7.4   7.5 

 

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

 

The following table summarizes stock option activity under the 2001 and 2006 Equity Incentive Plans and the 2004 Director Plan for the six-month period ended June 30, 2020:

 

  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Outstanding at December 31, 2019

  1,245,922  $18.08   4.45  $59,631 

Granted

  70,471  $62.23         

Exercised

  (408,765

)

 $12.68      $17,810 

Forfeited

  (15,490) $48.42         

Outstanding at June 30, 2020

  892,138  $23.51   5.77  $31,281 

Exercisable at June 30, 2020

  492,484  $17.55   4.58  $20.022 

 

As of June 30, 2020, the total unrecognized compensation cost related to non-vested stock option awards was approximately $2.1 million which was expected to be recognized over a weighted average period of 3.2 years.

 

There was $538,000 of cash received from stock options exercised for the three months ended June 30, 2020 and no cash was received from the exercise of options in the same period of 2019. We recognized $216,000 and $235,000 of non-cash compensation for three months ended June 30, 2020 and 2019, respectively, and $498,000 and $464,000 of non-cash compensation for the six months ended June 30, 2020 and 2019, respectively, related to options, which is included in direct fixed and selling, general and administrative expenses.

 

During the six months ended June 30, 2019, we granted 6,005 non-vested shares of Common Stock under the 2006 Equity Incentive Plan. No shares were granted during the six months ended June 30, 2020. As of June 30, 2020, we had 42,761 non-vested shares of Common Stock outstanding under the 2006 Equity Incentive Plan. These shares vest over five years following the date of grant and holders thereof are entitled to receive dividends from the date of grant, whether or not vested. The fair value of the awards is calculated as the fair market value of the shares on the date of grant. We recognized ($75,000) and $73,000 of non-cash compensation for the three months ended June 30, 2020 and 2019, respectively, and ($26,000) and $145,000 of non-cash compensation for the six months ended June 30, 2020 and 2019, respectively, related to this non-vested stock, which is included in direct fixed and selling, general and administrative expenses. During the six months ended June 30 2020, 34,622 shares vested and 6,793 shares were forfeited.

 

The following table summarizes information regarding non-vested stock granted to associates under the 2006 Equity Incentive Plan for the six-month period ended June 30, 2020:

 

  

Common

Shares

Outstanding

  

Weighted

Average

Grant Date Fair

Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  -   - 

Vested

  (34,622

)

  13.17 

Forfeited

  (6,793

)

 $36.80 

Outstanding at June 30, 2020

  42,761  $17.40 

 

As of June 30, 2020, the total unrecognized compensation cost related to non-vested stock awards was approximately $187,000 and is expected to be recognized over a weighted average period of 3.05 years.

 

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Goodwill and Other Intangible Assets
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

(6)

GOODWILL AND OTHER INTANGIBLE ASSETS

 

The following represents a summary of changes in the carrying amount of goodwill for the six-month period ended June 30, 2020:
 

  

(In thousands)

 

Balance as of December 31, 2019

 $57,935 

Foreign currency translation

  (106

)

Balance as of June 30, 2020

 $57,829 

 

Intangible assets consisted of the following:

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Non-amortizing intangible assets:

        

Indefinite trade name

 $1,191  $1,191 

Amortizing intangible assets:

        

Customer related

  9,326   9,338 

Technology

  1,360   1,360 

Trade names

  1,572   1,572 

Total amortizing intangible assets

  12,258   12,270 

Accumulated amortization

  (11,908

)

  (11,733

)

Other intangible assets, net

 $1,541  $1,728 

 

  

 

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Property and Equipment
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

(7)

PROPERTY AND EQUIPMENT

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Property and equipment

 $43,477  $42,078 

Accumulated depreciation

  (31,122

)

  (28,548

)

Property and equipment, net

 $12,355  $13,530 

 

 

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Earnings Per Share
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Earnings Per Share [Text Block]

(8)

EARNINGS PER SHARE

 

Basic net income per share was computed using the weighted-average number of common shares outstanding during the period.

 

Diluted net income per share was computed using the weighted-average number of common shares and, if dilutive, the potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options is reflected in diluted earnings per share by application of the treasury stock method.

 

We had 57,719 and 83,225 options of Common Stock for the three-month periods ended June 30, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. We had 52,789 and 143,247 options of Common Stock for the six-month periods ended June 30, 2020 and 2019, respectively which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive.

 

  

For the Three Months Ended June 30

  

For the Six Months Ended June 30

 
  

2020

  

2019

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share – basic:

 $7,715  $7,393  $19,470  $15,589 

Net income

                

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (15

)

  (25

)

  (38

)

  (53

)

Net income attributable to common shareholders

  7,700   7,368   19,432   15,536 

Denominator for net income per share – basic:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Net income per share – basic

 $0.31  $0.30  $0.78  $0.63 

Numerator for net income per share – diluted:

                

Net income attributable to common shareholders for basic computation

  7,700   7,368   19,432   15,536 

Denominator for net income per share – diluted:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Weighted average effect of dilutive securities – stock options

  532   797   642   772 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,680   25,586   25,702   25,549 

Net income per share - diluted

 $0.30  $0.29  $0.76  $0.61 

 

 

 

 

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Related Party
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

(9

RELATED PARTY

 

Until January 2020, one of our directors served as an officer and director of Ameritas Life Insurance Corp. (“Ameritas”) and continues to serve on the board of directors of Ameritas. In connection with our regular assessment of our insurance-based associate benefits, which is conducted by an independent insurance broker, and the costs associated therewith, we purchase dental and vision insurance for certain of our associates from Ameritas. The total value of these purchases was $42,000 and $67,000 in the three-month periods ended June 30, 2020 and 2019, respectively and $114,000 and $127,000 in the six-month periods ended June 30, 2020 and 2019, respectively.

 

A director, who served on our board through May 2020, also served as a board member of IMA Financial Group. In connection with our regular assessment of our liability coverage, during 2020 we began purchasing directors and officers and employment practices liability insurance through IMA Financial Group. These purchases totaled $478,000 in the three and six-month periods ended June 30, 2020, respectively.

 

During 2017, we acquired a cost method investment in convertible preferred stock of Practicing Excellence.com, Inc., a privately-held Delaware Corporation (“PX”), which is included in other non-current assets and is carried at cost, adjusted for changes resulting from observable price changes in orderly transactions of the same investment in PX, if any.  We also have an agreement with PX which commenced in 2016 under which we act as a reseller of PX services and PX receives a portion of the revenues. The total revenue earned from the PX reseller agreement was $83,000 and $170,000 in the three-month periods ended June 30, 2020 and 2019, respectively, and $166,000 and $323,000 in six-month periods ended June 30, 2020 and 2019, respectively. We will no longer earn revenue under this agreement after June 30, 2021.

 

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

(10

SEGMENT INFORMATION

 

The Company’s six operating segments are aggregated into one reporting segment because they have similar economic characteristics and meet the other aggregation criteria from the FASB guidance on segment disclosure. The six operating segments are Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Transitions, which offer a portfolio of solutions that address specific needs around market insight, experience, transparency and governance for healthcare providers, payers and other healthcare organizations. The table below presents entity-wide information regarding the Company’s assets, after elimination of intercompany balances by geographic area:

 

  

June 30, 2020

  

December 31, 2019

 
  

(In thousands)

 

Long-lived assets:

        

United States

 $77,621  $78,906 

Canada

  2,463   2,622 

Total

 $80,084  $81,528 

Total assets:

        

United States

 $101,134  $95,668 

Canada

  15,647   15,017 

Total

 $116,781  $110,685 

  

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

We derive a majority of our revenues from our annually renewable subscription-based service agreements with our customers, which include performance measurement and improvement services, healthcare analytics and governance education services. Such agreements are generally cancelable on short or no notice without penalty. See Note 2 for further information about our contracts with customers. We account for revenue using the following steps:

 

 

Identify the contract, or contracts, with a customer;

 

Identify the performance obligations in the contract;

 

Determine the transaction price;

 

Allocate the transaction price to the identified performance obligations; and

 

Recognize revenue when, or as, we satisfy the performance obligations.

 

Our revenue arrangements with a client may include combinations of more than one service offering which may be executed at the same time, or within close proximity of one another. We combine contracts with the same customer into a single contract for accounting purposes when the contract is entered into at or near the same time and the contracts are negotiated together, consideration in one contract depends on another contract, or services in one or more contracts are a single performance obligation. For contracts that contain more than one separately identifiable performance obligation, the total transaction price is allocated to the identified performance obligations based upon the relative stand-alone selling prices of the performance obligations. The stand-alone selling prices are based on an observable price for services sold to other comparable customers, when available, or an estimated selling price using a cost-plus margin or residual approach. We estimate the amount of total contract consideration we expect to receive for variable arrangements based on the most likely amount we expect to earn from the arrangement based on the expected quantities of services we expect to provide and the contractual pricing based on those quantities. We only include some or a portion of variable consideration in the transaction price when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. We consider the sensitivity of the estimate, our relationship and experience with the client and variable services being performed, the range of possible revenue amounts and the magnitude of the variable consideration to the overall arrangement. Our revenue arrangements do not contain any significant financing element due to the contract terms and the timing between when consideration is received and when the service is provided.

 

Our arrangements with customers consist principally of four different types of arrangements: 1) subscription-based service agreements; 2) one-time specified services performed at a single point in time; 3) fixed, non-subscription service agreements; and 4) unit-priced service agreements.

 

Subscription-based services - Services that are provided under subscription-based service agreements are usually for a twelve month period and represent a single promise to stand ready to provide reporting, tools and services throughout the subscription period as requested by the customer. These agreements are renewable at the option of the customer at the completion of the initial contract term for an agreed upon price increase each year. These agreements represent a series of distinct monthly services that are substantially the same, with the same pattern of transfer to the customer as the customer receives and consumes the benefits throughout the contract period. Accordingly, subscription services are recognized ratably over the subscription period. Subscription services are typically billed annually in advance but may also be billed on a quarterly and monthly basis.

 

One-time services – These agreements typically require us to perform a specific one-time service in a particular month. We are entitled to a fixed payment upon completion of the service. Under these arrangements, we recognize revenue at the point in time we complete the service and it is accepted by the customer.

 

Fixed, non-subscription services – These arrangements typically require us to perform an unspecified amount of services for a fixed price during a fixed period of time. Revenues are recognized over time based upon the costs incurred to date in relation to the total estimated contract costs. In determining cost estimates, management uses historical and forecasted cost information which is based on estimated volumes, external and internal costs and other factors necessary in estimating the total costs over the term of the contract. Changes in estimates are accounted for using a cumulative catch up adjustment which could impact the amount and timing of revenue for any period.

 

Unit-price services – These arrangements typically require us to perform certain services on a periodic basis as requested by the customer for a per-unit amount which is typically billed in the month following the performance of the service. Revenue under these arrangements is recognized over the time the services are performed at the per-unit amount.

 

Revenue is presented net of any sales tax charged to our clients that we are required to remit to taxing authorities. We recognize contract assets or unbilled receivables related to revenue recognized for services completed but not invoiced to the clients. Unbilled receivables are classified as receivables when we have an unconditional right to contract consideration. A contract liability is recognized as deferred revenue when we invoice clients in advance of performing the related services under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.  

 

Deferred Charges, Policy [Policy Text Block]

Deferred Contract Costs

 

Deferred contract costs, net is stated at gross deferred costs less accumulated amortization. We defer commissions and incentives, including payroll taxes, if they are incremental and recoverable costs of obtaining a renewable customer contract. Deferred contract costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. The contract term was estimated by considering factors such as historical customer attrition rates and product life. The amortization period is adjusted for significant changes in the estimated remaining term of a contract.  An impairment of deferred contract costs is recognized when the unamortized balance of deferred contract costs exceeds the remaining amount of consideration we expect to receive net of the expected future costs directly related to providing those services.  We have elected the practical expedient to expense contract costs when incurred for any nonrenewable contracts with a term of one year or less. We deferred incremental costs of obtaining a contract of $599,000 and $741,000 in the three months ended June 30, 2020 and 2019, respectively. The company deferred incremental costs of obtaining a contract of $2.2 million and $1.6 million in the six-month periods ended June 30, 2020 and 2019, respectively. Deferred contract costs, net of accumulated amortization was $4.6 million and $4.2 million at June 30, 2020 and December 31, 2019, respectively. Total amortization by expense classification for the three and six-months ended June 30, 2020 and 2019 was as follows:

 

  

Three months

ended
June 30, 2020

  

Three months

ended
June 30, 2019

  

Six month

ended
June 30, 2020

  

Six months

ended
June 30, 2019

 
  

(In thousands)

 

Direct Expenses

 $60  $13  $178  $19 

Selling, general and administrative expenses

  851   628   1,624   1,309 

Total amortization

 $911  $641  $1,802  $1,328 

 

Additional expense included in selling, general and administrative expenses for impairment of costs capitalized due to lost clients was $3,000 and $1,000 for the three months ended June 30, 2020 and 2019, respectively and $4,000 and $21,000 in the six months ended June 30, 2020 and 2019, respectively.

 

Accounts Receivable [Policy Text Block]

Trade Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount. Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) 2016-13, Measurement of Credit Losses on Financial Instruments. This ASU requires the measurement of all expected credit losses for financial assets, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The adoption of this standard did not have an impact on our condensed consolidated financial statements. The allowance for doubtful accounts is our best estimate of the amount of probable credit losses in our existing accounts receivable, determined based on our historical write-off experience, current economic conditions and reasonable and supportable forecasts about the future. We review the allowance for doubtful accounts monthly. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Some billing and collections efforts were delayed due to the security incident in the first quarter until we received the forensic report in the second quarter, resulting in an increase in accounts receivable. Additionally, the COVID-19 pandemic has also resulted in an increase in accounts receivables as some clients have delayed payments and some invoicing was deferred during the second quarter of 2020 due to our clients’ cash-flow issues.

 

The following table provides the activity in the allowance for doubtful accounts for the six months ended June 30, 2020 and 2019 (In thousands):

 

  

Balance at

Beginning of

Period

  

Bad Debt

Expense

(Benefit)

  

Write-offs

  

Recoveries

  

Balance at

End of Period

 
                     

Six months ended June 30, 2020

 $144  $40  $62  $21  $143 

Six months ended June 30, 2019

 $176  $(25

)

 $37  $10  $124 

 

Lessee, Leases [Policy Text Block]

Leases

 

We determine whether a lease is included in an agreement at inception. Operating lease ROU assets are included in operating lease right-of-use assets in our consolidated balance sheet. Finance lease assets are included in property and equipment. Operating and finance lease liabilities are included in other current liabilities and other long term liabilities. Certain lease arrangements may include options to extend or terminate the lease. We include these provisions in the ROU and lease liabilities only when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term and is included in direct expenses and selling, general and administrative expenses. Our lease agreements do not contain any residual value guarantees.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments during the lease term. ROU assets and lease liabilities are recorded at lease commencement based on the estimated present value of lease payments. Because the rate of interest implicit in each lease is not readily determinable, we use our estimated incremental collateralized borrowing rate at lease commencement, to calculate the present value of lease payments. When determining the appropriate incremental borrowing rate, we consider our available credit facilities, recently issued debt and public interest rate information.

 

We elected the practical expedient to account for lease and non-lease components as a single lease component for all asset classifications. We have also made a policy election to not record short-term leases with a duration of 12 months or less on the balance sheet.

 

Hosting Arrangement Implementation Costs [Policy Text Block]

Implementation Costs of Hosting Arrangements

 

When a software license is included in a cloud computing arrangement and we have the ability and feasibility to download the software, it is accounted for as software, included in property and equipment, and amortized. If a software license is not included or we do not have the ability or feasibility to download software included in a cloud computing arrangement, it is accounted for as a service contract, which is expensed to direct expenses or selling, general and administrative expenses during the service period. Effective January 1, 2020, we prospectively adopted ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The adoption did not significantly impact our results of operations and financial position.

 

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

Our valuation techniques are based on maximizing observable inputs and minimizing the use of unobservable inputs when measuring fair value. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. The inputs are then classified into the following hierarchy: (1) Level 1 Inputs—quoted prices in active markets for identical assets and liabilities; (2) Level 2 Inputs—observable market-based inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets, quoted prices for similar or identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; (3) Level 3 Inputs—unobservable inputs.

 

The following details our financial assets within the fair value hierarchy at June 30, 2020 and December 31, 2019:

 

  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of June 30, 2020

                

Money Market Funds

 $3,067  $-  $-  $3,067 

Total Cash Equivalents

 $3,067  $-  $-  $3,067 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $-  $-  $3,662 

Total Cash Equivalents

 $3,662  $-  $-  $3,662 

 

There were no transfers between levels during the three-month period ended June 30, 2020.

 

Our long-term debt described in Note 4 is recorded at historical cost. The fair value of long-term debt is classified in Level 2 of the fair value hierarchy and was estimated based primarily on estimated current rates available for debt of the same remaining duration and adjusted for nonperformance and credit. The following are the carrying amount and estimated fair values of long-term debt:

 

  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $32,681  $34,281 

Estimated fair value of long-term debt

 $35,293  $35,205 

 

The carrying amounts of accounts receivable, accounts payable, and accrued expenses approximate their fair value. All non-financial assets that are not recognized or disclosed at fair value in the financial statements on a recurring basis, which includes ROU assets, property and equipment, goodwill, intangibles and cost method investments, are measured at fair value in certain circumstances (for example, when there is evidence of impairment). As of June 30, 2020, and December 31, 2019, there was no indication of impairment related to these assets.

 

Annually, we consider whether the recorded goodwill and indefinite lived intangibles have been impaired. However, goodwill and intangibles must be tested between annual tests if an event occurs or circumstances change to indicate that it is more likely than not that an impairment loss has been incurred (“triggering event”). We considered the current and expected future economic and market conditions, including the impact of the COVID-19 pandemic, on each of our reporting units. We also assessed our current market capitalization compared to book value, forecasts and margins in our last quantitative impairment testing. We concluded that a triggering event has not occurred which would require an interim impairment test to be performed as it is not more likely than not that an impairment loss has been incurred at June 30, 2020.

 

Our Canadian reporting unit generates service revenue from a relatively small number of customers with approximately 62.2% of its annual revenue concentrated in one customer contract which currently expires in March 2021. While historically we have been successful in renewing or retaining contracts with our customers, should we be unable to or choose not to renew a significant contract, it would likely result in an impairment of goodwill at this reporting unit. The carrying amount of goodwill related to our Canadian reporting unit at June 30, 2020 was $2.3 million.

 

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. Legal fees, net of estimated insurance recoveries, are expensed as incurred. There were no outstanding claims at June 30, 2020.

 

A sales tax accrual of $775,000 was recorded in 2019 after we became aware that a state sales tax liability was both probable and estimable as of December 31, 2019, due to sales taxes that should have been collected from customers in 2019 and certain previous years. In addition, we incurred additional sales tax expense in the three and six-month periods ended June 30, 2020 of $8,000 and $58,000, respectively. We are working through voluntary disclosure agreements with certain states and began remitting sales tax in the second quarter of 2020. We began collecting sales tax in July 2020. State and local jurisdictions have differing rules and regulations governing sales, use, and other taxes and these rules and regulations can be complex and subject to varying interpretations that may change over time. As a result, we could face the possibility of tax assessment and audits, and our liability for these taxes and associated interest and penalties could exceed our original estimates. In July 2020, we received a revenue ruling from the state of Washington noting that our services are not subject to retail sales tax, and therefore, will be reversing $268,000 of sales tax accrual for the state of Washington in the third quarter of 2020.

 

We received $2.4 million in insurance recoveries in the three-month period ended June 30, 2020, and $400,000 was paid directly to certain vendors from the insurer related to the February incident. These were recorded in selling general and administrative expenses. A final loss claim was submitted to insurance during the three-month period ended June 30, 2020, and an insurance recovery will be recorded when it is probable of collection. Due to insurance recoveries, the February incident has not had and we do not expect it to have a significant impact on our consolidated financial statements.

  

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements Not Yet Adopted

 

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). Among other clarifications and simplifications related to income tax accounting, this ASU simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, hybrid taxes and the recognition of deferred tax liabilities for outside basis differences.  The guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years.  Early adoption is permitted in interim or annual periods with any adjustments reflected as of the beginning of the annual period that includes that interim period.  Additionally, entities that elect early adoption must adopt all the amendments in the same period.  Amendments are to be applied prospectively, except for certain amendments that are to be applied either retrospectively or with a modified retrospective approach through a cumulative effect adjustment recorded to retained earnings.  We believe the adoption will not significantly impact our results of operations and financial position.

 

In March 2020, FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. We expect to apply the optional expedient for contract modification to account for the change in the reference rate on impacted credit facilities prospectively by adjusting the effective interest rate.

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Amortization of Capitalized Contract Cost [Table Text Block]
  

Three months

ended
June 30, 2020

  

Three months

ended
June 30, 2019

  

Six month

ended
June 30, 2020

  

Six months

ended
June 30, 2019

 
  

(In thousands)

 

Direct Expenses

 $60  $13  $178  $19 

Selling, general and administrative expenses

  851   628   1,624   1,309 

Total amortization

 $911  $641  $1,802  $1,328 
Financing Receivable, Allowance for Credit Loss [Table Text Block]
  

Balance at

Beginning of

Period

  

Bad Debt

Expense

(Benefit)

  

Write-offs

  

Recoveries

  

Balance at

End of Period

 
                     

Six months ended June 30, 2020

 $144  $40  $62  $21  $143 

Six months ended June 30, 2019

 $176  $(25

)

 $37  $10  $124 
Fair Value, by Balance Sheet Grouping [Table Text Block]
  

Level 1

  

Level 2

  

Level 3

  

Total

 
  

(In thousands)

 

As of June 30, 2020

                

Money Market Funds

 $3,067  $-  $-  $3,067 

Total Cash Equivalents

 $3,067  $-  $-  $3,067 
                 

As of December 31, 2019

                

Money Market Funds

 $3,662  $-  $-  $3,662 

Total Cash Equivalents

 $3,662  $-  $-  $3,662 
  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Total carrying amount of long-term debt

 $32,681  $34,281 

Estimated fair value of long-term debt

 $35,293  $35,205 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Three months ended

  

Six months ended

 
  

June 30, 2020

  

June 30, 2019

  

June 30, 2020

  

June 30, 2019

 

Subscription services recognized ratably over time

 $29,572  $27,918  $59,993  $55,831 

Services recognized at a point in time

  191   1,625   1,287   2,625 

Fixed, non-subscription recognized over time

  158   506   675   1,040 

Unit price services recognized over time

  1,245   1,365   3,071   3,398 

Total revenue

 $31,166  $31,414  $65,026  $62,894 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

June 30,

2020

  

December 31,

2019

 

Accounts receivables

 $19,882  $11,639 

Contract assets included in other current assets

 $120  $103 

Deferred Revenue

 $(16,275

)

 $(16,354

)

  

Six months ended
June 30, 2020

  

Six months ended
June 30, 2019

 
  

Contract

Asset

  

Deferred

Revenue

  

Contract

Asset

  

Deferred

Revenue

 
  

Increase (Decrease)

 

Revenue recognized that was included in deferred revenue at beginning of year due to completion of services

 $-  $(11,934

)

 $-  $(12,226

)

Increases due to invoicing of client, net of amounts recognized as revenue

  -   11,821   -   12,751 

Decreases due to completion of services (or portion of services) and transferred to accounts receivable

  (85

)

  -   (46

)

  - 

Change due to cumulative catch-up adjustments arising from changes in expected contract consideration

      34       219 

Decreases due to impairment

  -   -   -   - 

Increases due to revenue recognized in the period with additional performance obligations before invoicing

  102   -   223   - 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Notes Payable (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Debt [Table Text Block]
  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Term Loans

 $32,681  $34,281 

Less: current portion

  (3,966

)

  (4,378

)

Less: unamortized debt issuance costs

  (88

)

  (108

)

Notes payable, net of current portion

 $28,627  $29,795 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

2020

  

2019

 

Expected dividend yield at date of grant

  1.84

%

  2.60

%

Expected stock price volatility

  33.62

%

  34.01

%

Risk-free interest rate

  1.35

%

  2.38

%

Expected life of options (in years)

  7.4   7.5 
Share-based Payment Arrangement, Activity [Table Text Block]
  

Number of
Options

  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Contractual

Terms

(Years)

  

Aggregate

Intrinsic

Value

(In

thousands)

 

Outstanding at December 31, 2019

  1,245,922  $18.08   4.45  $59,631 

Granted

  70,471  $62.23         

Exercised

  (408,765

)

 $12.68      $17,810 

Forfeited

  (15,490) $48.42         

Outstanding at June 30, 2020

  892,138  $23.51   5.77  $31,281 

Exercisable at June 30, 2020

  492,484  $17.55   4.58  $20.022 
Schedule of Nonvested Share Activity [Table Text Block]
  

Common

Shares

Outstanding

  

Weighted

Average

Grant Date Fair

Value

Per Share

 

Outstanding at December 31, 2019

  84,176  $17.23 

Granted

  -   - 

Vested

  (34,622

)

  13.17 

Forfeited

  (6,793

)

 $36.80 

Outstanding at June 30, 2020

  42,761  $17.40 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Goodwill and Other Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Goodwill [Table Text Block]
  

(In thousands)

 

Balance as of December 31, 2019

 $57,935 

Foreign currency translation

  (106

)

Balance as of June 30, 2020

 $57,829 
Schedule of Intangible Assets [Table Text Block]
  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Non-amortizing intangible assets:

        

Indefinite trade name

 $1,191  $1,191 

Amortizing intangible assets:

        

Customer related

  9,326   9,338 

Technology

  1,360   1,360 

Trade names

  1,572   1,572 

Total amortizing intangible assets

  12,258   12,270 

Accumulated amortization

  (11,908

)

  (11,733

)

Other intangible assets, net

 $1,541  $1,728 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Property and Equipment (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

June 30,

2020

  

December 31,

2019

 
  

(In thousands)

 

Property and equipment

 $43,477  $42,078 

Accumulated depreciation

  (31,122

)

  (28,548

)

Property and equipment, net

 $12,355  $13,530 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Earnings Per Share (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

For the Three Months Ended June 30

  

For the Six Months Ended June 30

 
  

2020

  

2019

  

2020

  

2019

 
  

(In thousands, except per share data)

 

Numerator for net income per share – basic:

 $7,715  $7,393  $19,470  $15,589 

Net income

                

Allocation of distributed and undistributed income to unvested restricted stock shareholders

  (15

)

  (25

)

  (38

)

  (53

)

Net income attributable to common shareholders

  7,700   7,368   19,432   15,536 

Denominator for net income per share – basic:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Net income per share – basic

 $0.31  $0.30  $0.78  $0.63 

Numerator for net income per share – diluted:

                

Net income attributable to common shareholders for basic computation

  7,700   7,368   19,432   15,536 

Denominator for net income per share – diluted:

                

Weighted average common shares outstanding – basic

  25,148   24,789   25,060   24,777 

Weighted average effect of dilutive securities – stock options

  532   797   642   772 

Denominator for diluted earnings per share – adjusted weighted average shares

  25,680   25,586   25,702   25,549 

Net income per share - diluted

 $0.30  $0.29  $0.76  $0.61 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information (Tables)
6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
  

June 30, 2020

  

December 31, 2019

 
  

(In thousands)

 

Long-lived assets:

        

United States

 $77,621  $78,906 

Canada

  2,463   2,622 

Total

 $80,084  $81,528 

Total assets:

        

United States

 $101,134  $95,668 

Canada

  15,647   15,017 

Total

 $116,781  $110,685 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies (Details Textual)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Jul. 31, 2020
USD ($)
Number of Operating Segments     6      
Number of Reportable Segments     1      
Incremental Costs of Obtaining a Contract, Deferred During Period $ 599,000 $ 741,000 $ 2,200,000 $ 1,600,000    
Capitalized Contract Cost, Net, Noncurrent 4,582,000   4,582,000   $ 4,204,000  
Asset Impairment Charges, Total     0   0  
Goodwill, Ending Balance 57,829,000   57,829,000   57,935,000  
Sales and Excise Tax Payable         $ 775,000  
Sales and Excise Tax Expense 8,000   $ 58,000      
Cyber Attack [Member]            
Proceeds from Insurance Settlement, Operating Activities 2,400,000          
Cyber Attack [Member] | The Insurer [Member]            
Payments for Insurance Settlement, Paid Directly to Vendors $ 400,000          
WASHINGTON | Subsequent Event [Member]            
Sales and Excise Tax Payable (Reversal of Liability)           $ (268,000)
Canadian Subsidiary [Member]            
Number of Customers 1   1      
Goodwill, Ending Balance $ 2,300,000   $ 2,300,000      
Canadian Subsidiary [Member] | Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]            
Concentration Risk, Percentage     62.20%      
Selling, General and Administrative Expenses [Member]            
Capitalized Contract Cost, Impairment Loss $ 3,000 $ 1,000 $ 4,000 $ 21,000    
Minimum [Member]            
Capitalized Contract Cost, Amortization Period (Year) 3 years   3 years      
Maximum [Member]            
Capitalized Contract Cost, Amortization Period (Year) 5 years   5 years      
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Capitalized contract cost $ 911 $ 641 $ 1,802 $ 1,328
Direct Expenses [Member]        
Capitalized contract cost 60 13 178 19
Selling, General and Administrative Expenses [Member]        
Capitalized contract cost $ 851 $ 628 $ 1,624 $ 1,309
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Balance $ 144 $ 176
Bad Debt Expense (Benefit) 40 (25)
Write-offs 62 37
Recoveries 21 10
Balance at End of Period $ 143 $ 124
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Total carrying amount of long-term debt $ 32,681 $ 34,281
Estimated fair value of long-term debt 35,293 35,205
Fair Value, Recurring [Member]    
Assets, fair value 3,067 3,662
Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value 3,067 3,662
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]    
Assets, fair value 3,067 3,662
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | Fair Value, Recurring [Member]    
Assets, fair value $ 3,067 $ 3,662
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers 1 (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Long-term Contract with Customer [Member]        
Revenue, Remaining Performance Obligation, Amount $ 281,000   $ 281,000  
VoC Platform [Member]        
Revenue from Contract with Customer, Percent of Total Revenue 72.90% 62.10% 70.90% 60.00%
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers 2 (Details Textual) - Long-term Contract with Customer [Member]
Jun. 30, 2020
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 281,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01  
Revenue, Remaining Performance Obligation, Amount $ 161,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01  
Revenue, Remaining Performance Obligation, Amount $ 120,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue $ 31,166 $ 31,414 $ 65,026 $ 62,894
Transferred over Time [Member] | Subscription Services [Member]        
Revenue 29,572 27,918 59,993 55,831
Transferred over Time [Member] | Fixed, Non-subscription Services [Member]        
Revenue 158 506 675 1,040
Transferred over Time [Member] | Unit Price Services [Member]        
Revenue 1,245 1,365 3,071 3,398
Transferred at Point in Time [Member] | Service [Member]        
Revenue $ 191 $ 1,625 $ 1,287 $ 2,625
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Accounts receivables $ 19,882   $ 11,639
Deferred Revenue (16,275)   (16,354)
Revenue recognized that was included in deferred revenue at beginning of year due to completion of services (11,934) $ (12,226)  
Increases due to invoicing of client, net of amounts recognized as revenue 11,821 12,751  
Decreases due to completion of services (or portion of services) and transferred to accounts receivable (85) (46)  
Change due to cumulative catch-up adjustments arising from changes in expected contract consideration 34 219  
Increases due to revenue recognized in the period with additional performance obligations before invoicing 102 $ 223  
Other Current Assets [Member]      
Contract assets included in other current assets $ 120   $ 103
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Income Taxes (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Effective Income Tax Rate Reconciliation, Percent, Total 9.80% 22.10% 2.30% 19.40%
Deferred Tax Liabilities, Employer Social Security Tax Break Under CARES Act $ 237,000   $ 237,000  
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Notes Payable (Details Textual)
6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
May 28, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Long-term Debt, Total $ 32,681,000       $ 34,281,000
Proceeds from Lines of Credit, Total   $ 16,500,000      
Credit Agreement [Member] | First National Bank of Omaha [Member]          
Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio 1.10        
Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold $ 5,500,000        
Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio 3.00        
Credit Agreement [Member] | First National Bank of Omaha [Member] | London Interbank Offered Rate (LIBOR) [Member]          
Debt Instrument, Basis Spread on Variable Rate 2.25%        
Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate 2.43%        
Credit Agreement [Member] | First National Bank of Omaha [Member] | Term Loan [Member]          
Debt Instrument, Face Amount     $ 33,002,069    
Long-term Debt, Total     $ 33,002,069    
Debt Instrument, Periodic Payment, Total $ 462,988        
Debt Instrument, Interest Rate, Stated Percentage 5.00%        
Credit Agreement [Member] | First National Bank of Omaha [Member] | Delayed Draw Term Loan [Member]          
Line of Credit Facility, Maximum Borrowing Capacity $ 15,000,000        
Proceeds from Lines of Credit, Total 0        
Credit Agreement [Member] | First National Bank of Omaha [Member] | Revolving Credit Facility [Member]          
Line of Credit Facility, Maximum Borrowing Capacity 30,000,000     $ 15,000,000  
Long-term Line of Credit, Total $ 0       $ 0
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.20%        
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Notes Payable - Summary of Notes Payable (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Less: current portion $ (3,966) $ (4,378)
Less: unamortized debt issuance costs (88) (108)
Notes payable, net of current portion 28,627 29,795
Term Loan [Member]    
Term Loans $ 32,681 $ 34,281
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2018
Dec. 31, 2015
Proceeds from Stock Options Exercised $ 538,000 $ 0 $ 538,000      
Share-based Payment Arrangement, Option [Member]            
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total 2,100,000   $ 2,100,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     3 years 2 months 12 days      
Share-based Payment Arrangement, Option [Member] | Direct Fixed and Selling, General and Administrative Expense [Member]            
Share-based Payment Arrangement, Expense 216,000 235,000 $ 498,000 $ 464,000    
Common Stock Options [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)     70,471 100,615    
Nonvested [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)     5 years      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total 187,000   $ 187,000      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     3 years 18 days      
Nonvested [Member] | Direct Fixed and Selling, General and Administrative Expense [Member]            
Share-based Payment Arrangement, Expense $ (75,000) $ 73,000 $ (26,000) $ 145,000    
Restricted Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     34,622      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)     6,793      
The 2001 Equity Incentive Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)           0
The 2001 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)     1 year      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     5 years      
The 2001 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)     5 years      
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     10 years      
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Director [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)     1 year      
Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount         $ 100,000  
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Minimum [Member] | Director [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     3 years      
Director Plan 2004 [Member] | Nonqualified Stock Options [Member] | Maximum [Member] | Director [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     10 years      
The 2006 Equity Incentive Plan [Member] | Minimum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     5 years      
The 2006 Equity Incentive Plan [Member] | Maximum [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)     10 years      
The 2006 Equity Incentive Plan [Member] | Nonvested [Member]            
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)     0 6,005    
Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares) 42,761   42,761      
Common Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     34,622      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)     6,793      
Common Stock [Member] | The 2001 Equity Incentive Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 1,800,000   1,800,000      
Common Stock [Member] | Director Plan 2004 [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 3,000,000   3,000,000      
Common Stock [Member] | The 2006 Equity Incentive Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 1,800,000   1,800,000      
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) - Common Stock [Member]
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Expected dividend yield at date of grant 1.84% 2.60%
Expected stock price volatility 33.62% 34.01%
Risk-free interest rate 1.35% 2.38%
Expected life of options (in years) (Year) 7 years 4 months 24 days 7 years 6 months
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Exercised, number of options (in shares) (148,284) (260,481) (18,000) (86,247)      
Common Stock Options [Member]              
Outstanding, number of options (in shares)   1,245,922     1,245,922    
Outstanding, weighted average exercise price (in dollars per share)   $ 18.08     $ 18.08    
Outstanding, weighted average remaining contractual term (Year)         5 years 9 months 7 days   4 years 5 months 12 days
Granted, number of options (in shares)         70,471 100,615  
Granted, weighted average exercise price (in dollars per share)         $ 62.23    
Exercised, number of options (in shares)         (408,765)    
Exercised, weighted average exercise price (in dollars per share)         $ 12.68    
Forfeited, number of options (in shares)         (15,490)    
Forfeited, weighted average exercise price (in dollars per share)         $ 48.42    
Outstanding, number of options (in shares) 892,138       892,138   1,245,922
Outstanding, weighted average exercise price (in dollars per share) $ 23.51       $ 23.51   $ 18.08
Exercisable, number of options (in shares) 492,484       492,484    
Weighted average exercise price (in dollars per share) $ 17.55       $ 17.55    
Exercisable, weighted average remaining contractual term (Year)         4 years 6 months 29 days    
Common Stock Options [Member] | Common Stock [Member]              
Outstanding, aggregate intrinsic value $ 31,281,000       $ 31,281,000   $ 59,631,000
Exercised, aggregate intrinsic value         17,810,000    
Exercisable, aggregate intrinsic value $ 20,022.000       $ 20,022.000    
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Share-based Compensation - Non-vested Stock (Details) - Common Stock [Member]
6 Months Ended
Jun. 30, 2020
$ / shares
shares
Outstanding (in shares) | shares 84,176
Outstanding (in dollars per share) | $ / shares $ 17.23
Vested (in shares) | shares (34,622)
Vested (in dollars per share) | $ / shares $ 13.17
Forfeited (in shares) | shares (6,793)
Forfeited (in dollars per share) | $ / shares $ 36.80
Outstanding (in shares) | shares 42,761
Outstanding (in dollars per share) | $ / shares $ 17.40
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2020
USD ($)
Balance $ 57,935
Foreign currency translation (106)
Balance $ 57,829
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Amortizing intangible assets $ 12,258 $ 12,270
Accumulated amortization (11,908) (11,733)
Other intangible assets, net 1,541 1,728
Customer Relationships [Member]    
Amortizing intangible assets 9,326 9,338
Technology-Based Intangible Assets [Member]    
Amortizing intangible assets 1,360 1,360
Trade Names [Member]    
Amortizing intangible assets 1,572 1,572
Trade Names 1 [Member]    
Indefinite trade name $ 1,191 $ 1,191
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Property and equipment $ 43,477 $ 42,078
Accumulated depreciation (31,122) (28,548)
Property and equipment, net $ 12,355 $ 13,530
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Earnings Per Share (Details Textual) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Share-based Payment Arrangement, Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 57,719 83,225 52,789 143,247
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Earnings Per Share - Net Income Per Share Computation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Net income $ 7,715 $ 11,755 $ 7,393 $ 8,196 $ 19,470 $ 15,589
Allocation of distributed and undistributed income to unvested restricted stock shareholders (15)   (25)   (38) (53)
Net income attributable to common shareholders $ 7,700   $ 7,368   $ 19,432 $ 15,536
Weighted average common shares outstanding – basic (in shares) 25,148   24,789   25,060 24,777
Net income per share – basic (in dollars per share) $ 0.31   $ 0.30   $ 0.78 $ 0.63
Net income attributable to common shareholders for basic computation $ 7,700   $ 7,368   $ 19,432 $ 15,536
Weighted average effect of dilutive securities – stock options (in shares) 532   797   642 772
Denominator for diluted earnings per share – adjusted weighted average shares (in shares) 25,680   25,586   25,702 25,549
Net income per share - diluted (in dollars per share) $ 0.30   $ 0.29   $ 0.76 $ 0.61
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Related Party (Details Textual) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Ameritas Life Insurance Corp [Member]        
Related Party Transaction, Amounts of Transaction $ 42,000 $ 67,000 $ 114,000 $ 127,000
IMA Financial Group [Member] | Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]        
Related Party Transaction, Amounts of Transaction 478,000   478,000  
PracticingExcellence.com [Member]        
Revenue from Related Parties $ 83,000 $ 170,000 $ 166,000 $ 323,000
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information (Details Textual)
6 Months Ended
Jun. 30, 2020
Number of Operating Segments 6
Number of Reportable Segments 1
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Segment Information - Assets by Geographic Area (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Long-lived assets $ 80,084 $ 81,528
Total assets 116,781 110,685
UNITED STATES    
Long-lived assets 77,621 78,906
Total assets 101,134 95,668
CANADA    
Long-lived assets 2,463 2,622
Total assets $ 15,647 $ 15,017
EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

UD-T_W^[R\#,*;*? O-^=(>_E/;=\/M-J ]KM M)C0G^%"]-CDGI#N4)ZMI59">G?^N+ *#"[A3TFK*D8&OPI9PYTVC-C!XYHL* MS?EL:,F>TQKF.^S;#IM]!SN#SP1:&OA%%EB\U1^2G[VS;._L+3L)^*F5EY!$ M(;"(12?PDC[XQ.,E)X(WT,5W F[4PXT\W.@[>VH7)M6A\,,Z>R"E;&G.UDN)? M9$N$7U FJ-&BR5*IP! MFX;IF#EA'$[C"0GI-)Q.$R>DX22)X>D=)&Z!0Z.$M"!D!Q5/8XC#C*7T99,Q M,"]_$%LL0I!*7IA#]PZP7KV)TPFD40;9V(%$HPB^2&&AT63^W8 .5$,V:Y::7VZ=\X82E(\#2<31Y>8SCJ9OH; 74B&V)!7K2,Q MT4+9DA#S5FN4_0;2)'OTC1*RND1:+/JR.X-!G(6,CO]\)R?IB.2C$CF:>)O: M8^0?K7^4.3V1!F% J?#2>;]V0#A;$O,W_&VXBCL-I,O+1=V,6,B+G>>^?V>,(N58BWQG(*T$I MIC*CT&C(Z_[H^H(UO7<7[NPF+'8""\=I#/N0S0^<'"A-1:__/W_N24OIE6:7 M"(+@Q_R!P<0=[ 4,1IG_ORNY7&%OM*W;BKLW'W)N\_*B;8 7?U/U4$]!0%P+ MX^)=:E5#[E7=.0!N&^H8R&J^/V,2C"A0=]VZA7ZV[[5NNA;C=7O7J'WFFLAHH,(EJ4:78[HN M=-?\= .K&M]P+)2EF\J+)?6+J-T&6E\J>G=W V>@[T#G_P%02P,$% @ M*DL'40J[&UL M?53;;MLP#/T5PNA#"GBU8[O.!4F IMVP%NT0M-WV,.Q!L9G8J"5YDMRD^_I1 MLNME0YL7BZ0.#R\6.=M)]:0+1 -[7@D]]PICZFD0Z*Q SO29K%'0S48JS@RI M:AOH6B'+G1.O@B@,TX"S4GB+F;.MU&(F&U.5 E<*=,,Y4R]+K.1N[@V]5\-] MN2V,-02+6Z%-""O,C&5@=#SC)5:5):(T?G6<7A_2.A[*K^R?7.U4RYIIO)35 M]S(WQ=P;>Y#CAC65N9>[S]C5H<(I=W&\AE><4,6\R4W(&R:&*S@BO5>5-RI; _Y<$HNBW)SRR^ M2(.0P >P@H85>V'K"F'P: ]].@L,!;'0(.L(ERUA] YA"G=2F$+#1Y%C_J]_ M0,GU&4:O&2ZCHX0WC3B#./0A"J/P"%_<5QP[OOA(Q1K:^H[0)3U=XNB2=^@> M:$SRAEHF-W"%:P,_'#4\XM[ LI+9T\^WFGB4U$[B5-6B'Q(Q)N4>LI MO2^E4!BHI7(C,HC]29K"*0P2/QZ-26AQC6#<0GYC3B^>:BRU;IC($#*IC8;! MV&('P] >;7_K]B'Y(&BQ4&O^#W4"T=A/HY$5)OYH<@YO_8O@X&%S5%LWOIJB M-L*T;[RW]AOBHAV,O_!VO=PQM2VI%Q5NR#4\&YU[H-J1;14C:S7/P!4$L#!!0 ( "I+!U$-]>@M# 0 '$) 9 M >&PO=V]R:W-H965TU-=]<)_/O.KH,+A7.I4/#N>N:99U[7LX.0 M]VJ+J.&AJ5LU=[9:[\Y\7Y5;;)CRQ Y;>K,6LF&:MG+CJYU$5EFEIO:C(,C\ MAO'669D;<"MQP/ZMD:C"=W0MR;S64U=P)#"&LL MM4%@]-CC!=:U 2(:?QTQG<&D47R^?D+_9'TG7^Z8P@M1?^>5WLZ=PH$*UZRK M];4X?,:C/ZG!*T6M['\X'&4#!\I.:=$LM)3R^NA$9(X11NMDSBJ7&P@@O1 M4-(5LW&;?&-W-:J3F:_)GM'RRR/V>8\=_0 [@R^BU5L%']L*JY?Z/O$G(\M7CSBO(+>OQ&X9(!++%SR [@;ZIBJJQ'$ M^D4X5^R1REC#\L!DY<*-%N4]?-V9Z"H7;EG=]9%>*FJ-_AC^L*S@&SYH.*]) MX<^WXC_*Q_3SF=JQ$N<.-:Q"N4=G84)'\0NG\/%A1ZU!_"J^YQ6V%3QRK"M@ M&BJFK1<;R8AWZ!4)_ R1EP7T&-24]6,G>8FP%S7Y4'/]"''L91')Q8D7A/2\ MYNK^="T1@;<:B8<&:>!#+TXM:EP\1ZWYVIH6QT!,> N/R*0Z@=Q+Z)?"2*K2 M(57I>*K>2H\D;S=HUBXLS;0P[KPO$:/6WD[$5=?C@Y@L]RAI$E(P M4)9<(:QL<%^]OT8S;GF[H4YMM:3)UK&:*,J&XO5['ZSE9B-Q8P)]22*3D2'5E0W5E[QX$5Z+=4\V3@[;F_F]AC1IZ MN[!H>CZG>"4U7M%UNZ9L(I1&@]VM!=\MQ8PP,7UF+OP%02P,$% @ *DL'41NH M*:<# P )@< !D !X;"]W;W)K&ULC57);MLP M$/V5@=!# KC1%GF#;Z6O3(EHX:82TLR#TMK=- Q-7F+%S)':H:2=C=(5LS35V]#L-++" M&U4B3*)H&%:,RV Q\VOG>C%3M15_-@#"Z2M5)7;G)6 MS(/($4*!N74(C+IK/$$A'!#1^--B!IU+9_AP?(?^WL=.L:R9P1,E?O+"EO-@ M'$"!&U8+^TWM/V(;CR>8*V%\"_OF;)8%D-?&JJHU)@85ETW/;EH='AB,HQ<, MDM8@\;P;1Y[E*;-L,=-J#]J=)C0W\*%Z:R+'I;N4"ZMIEY.=77Q1%F$(;^&# M4L6>"P%,%O#5EJCA3%HFMWPM$);&H#5P<,EH9@YGH27?#B',6S^KQD_R@I\A M?%;2E@;>R0*+_^U#XMP13^Z(KY)>P$^U/((T&D 2)5$/7MH)D7J\M$<( TU\ M/7#''=RQASM^ >Z"7D]1DW)J MT"LTJ*\Q6!R<2;"EJ@U=GCF$%1-,Y@C,./>GF&.UIOM,8Z=6/($WD(T&DS0# M2FQ*6TF)IC7*_!:L9M((YA_,01P-X3$8R8Z=[ W0.)E CV)9IUCV:L6>9M[K MI.OU\+QT_P?T5*M'TGY1\BVKE+;\+Y=;X/=$F2Y4%+CD]*Y(S0)!L@I) MJ7@03^*N7_9BG/B'3S0TTF5@ 9-!F@Q=FXY)@[R42JCM+6&EPZAM+SMGAE:R M4=*VE\HR>M4]_B!.!DDV]MTH@F6>UU7=^&W-[A(B'DRB,>6$&XW2E$9-I7@" M.0!)'XH+-CMN@AXEXV>S)'Q0NRCBK:_0!G)52]N4L6ZU^P263>V[/][\()^9 MWG)I0."&3*.C$:6#;JIR,[%JYROA6EF2UP]+^LA0NP.TOU%4!-J)<]!]C8M_ M4$L#!!0 ( "I+!U'6M9@$:0( "T% 9 >&PO=V]R:W-H965T$R3Y"P6K))D/@UK2SV?JL;R2N)2@VF$8/I] M@5QM9V1(=@L/U::T?B&>3VNVP4>T/^NE=E[D8NAQ>+S,>' M@%\5;LV>#;Z2E5+/WKDM9B3Q@I!C;CT#<[]7O$+./9&3\=)QDCZE!^[;._9O MH797RXH9O%+\=U78S\Q_*(HSA*RRU.VAMWX') FY>FJIVK;

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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 194 323 1 false 58 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://nrchealth.com/20200630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Contracts With Customers Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers Note 2 - Contracts With Customers Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Income Taxes Sheet http://nrchealth.com/20200630/role/statement-note-3-income-taxes Note 3 - Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Notes Payable Notes http://nrchealth.com/20200630/role/statement-note-4-notes-payable Note 4 - Notes Payable Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Share-based Compensation Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation Note 5 - Share-based Compensation Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Goodwill and Other Intangible Assets Sheet http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets Note 6 - Goodwill and Other Intangible Assets Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Property and Equipment Sheet http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment Note 7 - Property and Equipment Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Earnings Per Share Sheet http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share Note 8 - Earnings Per Share Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Related Party Sheet http://nrchealth.com/20200630/role/statement-note-9-related-party Note 9 - Related Party Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Segment Information Sheet http://nrchealth.com/20200630/role/statement-note-10-segment-information Note 10 - Segment Information Notes 18 false false R19.htm 018 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies 19 false false R20.htm 019 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies 20 false false R21.htm 020 - Disclosure - Note 2 - Contracts With Customers (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables Note 2 - Contracts With Customers (Tables) Tables http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers 21 false false R22.htm 021 - Disclosure - Note 4 - Notes Payable (Tables) Notes http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables Note 4 - Notes Payable (Tables) Tables http://nrchealth.com/20200630/role/statement-note-4-notes-payable 22 false false R23.htm 022 - Disclosure - Note 5 - Share-based Compensation (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables Note 5 - Share-based Compensation (Tables) Tables http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation 23 false false R24.htm 023 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables Note 6 - Goodwill and Other Intangible Assets (Tables) Tables http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets 24 false false R25.htm 024 - Disclosure - Note 7 - Property and Equipment (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables Note 7 - Property and Equipment (Tables) Tables http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment 25 false false R26.htm 025 - Disclosure - Note 8 - Earnings Per Share (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables Note 8 - Earnings Per Share (Tables) Tables http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share 26 false false R27.htm 026 - Disclosure - Note 10 - Segment Information (Tables) Sheet http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables Note 10 - Segment Information (Tables) Tables http://nrchealth.com/20200630/role/statement-note-10-segment-information 27 false false R28.htm 027 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables 28 false false R29.htm 028 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details) Details 29 false false R30.htm 029 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Details 30 false false R31.htm 030 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Sheet http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details) Details 31 false false R32.htm 031 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual Note 2 - Contracts With Customers 1 (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables 32 false false R33.htm 032 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual Note 2 - Contracts With Customers 2 (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables 33 false false R34.htm 033 - Disclosure - Note 2 - Contracts With Customers - Disaggregation of Revenue (Details) Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details Note 2 - Contracts With Customers - Disaggregation of Revenue (Details) Details 34 false false R35.htm 034 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Sheet http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details) Details 35 false false R36.htm 035 - Disclosure - Note 3 - Income Taxes (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual Note 3 - Income Taxes (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-3-income-taxes 36 false false R37.htm 036 - Disclosure - Note 4 - Notes Payable (Details Textual) Notes http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual Note 4 - Notes Payable (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables 37 false false R38.htm 037 - Disclosure - Note 4 - Notes Payable - Summary of Notes Payable (Details) Notes http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details Note 4 - Notes Payable - Summary of Notes Payable (Details) Details 38 false false R39.htm 038 - Disclosure - Note 5 - Share-based Compensation (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual Note 5 - Share-based Compensation (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables 39 false false R40.htm 039 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details) Details 40 false false R41.htm 040 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details) Details 41 false false R42.htm 041 - Disclosure - Note 5 - Share-based Compensation - Non-vested Stock (Details) Sheet http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details Note 5 - Share-based Compensation - Non-vested Stock (Details) Details 42 false false R43.htm 042 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Sheet http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details) Details 43 false false R44.htm 043 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Sheet http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details Note 7 - Property and Equipment - Summary of Property and Equipment (Details) Details 45 false false R46.htm 045 - Disclosure - Note 8 - Earnings Per Share (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual Note 8 - Earnings Per Share (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables 46 false false R47.htm 046 - Disclosure - Note 8 - Earnings Per Share - Net Income Per Share Computation (Details) Sheet http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details Note 8 - Earnings Per Share - Net Income Per Share Computation (Details) Details 47 false false R48.htm 047 - Disclosure - Note 9 - Related Party (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual Note 9 - Related Party (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-9-related-party 48 false false R49.htm 048 - Disclosure - Note 10 - Segment Information (Details Textual) Sheet http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual Note 10 - Segment Information (Details Textual) Details http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables 49 false false R50.htm 049 - Disclosure - Note 10 - Segment Information - Assets by Geographic Area (Details) Sheet http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details Note 10 - Segment Information - Assets by Geographic Area (Details) Details 50 false false All Reports Book All Reports nrc20200630_10q.htm ex_195787.htm ex_195788.htm ex_195789.htm ex_196045.htm ex_196216.htm nrc-20200630.xsd nrc-20200630_cal.xml nrc-20200630_def.xml nrc-20200630_lab.xml nrc-20200630_pre.xml graph1.jpg graph2.jpg http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nrc20200630_10q.htm": { "axisCustom": 0, "axisStandard": 33, "contextCount": 194, "dts": { "calculationLink": { "local": [ "nrc-20200630_cal.xml" ] }, "definitionLink": { "local": [ "nrc-20200630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nrc20200630_10q.htm" ] }, "labelLink": { "local": [ "nrc-20200630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "nrc-20200630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nrc-20200630.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 429, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 56, "http://nrchealth.com/20200630": 3, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 65 }, "keyCustom": 23, "keyStandard": 300, "memberCustom": 24, "memberStandard": 31, "nsprefix": "nrc", "nsuri": "http://nrchealth.com/20200630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://nrchealth.com/20200630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Contracts With Customers", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "shortName": "Note 2 - Contracts With Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Income Taxes", "role": "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "shortName": "Note 3 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Notes Payable", "role": "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "shortName": "Note 4 - Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Share-based Compensation", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "shortName": "Note 5 - Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Goodwill and Other Intangible Assets", "role": "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "shortName": "Note 6 - Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Property and Equipment", "role": "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "shortName": "Note 7 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Earnings Per Share", "role": "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "shortName": "Note 8 - Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Related Party", "role": "http://nrchealth.com/20200630/role/statement-note-9-related-party", "shortName": "Note 9 - Related Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Segment Information", "role": "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "shortName": "Note 10 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 2 - Contracts With Customers (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "shortName": "Note 2 - Contracts With Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 4 - Notes Payable (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "shortName": "Note 4 - Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 5 - Share-based Compensation (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "shortName": "Note 5 - Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 6 - Goodwill and Other Intangible Assets (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "shortName": "Note 6 - Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 7 - Property and Equipment (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "shortName": "Note 7 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Earnings Per Share (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables", "shortName": "Note 8 - Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 10 - Segment Information (Tables)", "role": "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "shortName": "Note 10 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "nrc:IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:AmortizationOfCapitalizedContractCostTableTextBlock", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 2 - Contracts With Customers 1 (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "shortName": "Note 2 - Contracts With Customers 1 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_ProductOrServiceAxis-VoCPlatformMember", "decimals": "3", "lang": null, "name": "nrc:RevenueFromContractWithCustomerPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 2 - Contracts With Customers 2 (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual", "shortName": "Note 2 - Contracts With Customers 2 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30_ContractWithCustomerDurationAxis-LongTermContractWithCustomerMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01", "decimals": "INF", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 2 - Contracts With Customers - Disaggregation of Revenue (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "shortName": "Note 2 - Contracts With Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_ProductOrServiceAxis-SubscriptionServicesMember_TimingOfTransferOfGoodOrServiceAxis-TransferredOverTimeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "shortName": "Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 3 - Income Taxes (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual", "shortName": "Note 3 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 4 - Notes Payable (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "shortName": "Note 4 - Notes Payable (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-FirstNationalBankOfOmahaMember", "decimals": "INF", "lang": null, "name": "nrc:DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 4 - Notes Payable - Summary of Notes Payable (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details", "shortName": "Note 4 - Notes Payable - Summary of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromStockOptionsExercised", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 5 - Share-based Compensation (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "shortName": "Note 5 - Share-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DirectOperatingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "shortName": "Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-CommonStockOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "shortName": "Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30_AwardTypeAxis-CommonStockOptionsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 5 - Share-based Compensation - Non-vested Stock (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "shortName": "Note 5 - Share-based Compensation - Non-vested Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31_StatementClassOfStockAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "shortName": "Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:ScheduleOfIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "shortName": "Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nrc:ScheduleOfIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "shortName": "Note 7 - Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 8 - Earnings Per Share (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual", "shortName": "Note 8 - Earnings Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 8 - Earnings Per Share - Net Income Per Share Computation (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details", "shortName": "Note 8 - Earnings Per Share - Net Income Per Share Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_RelatedPartyTransactionsByRelatedPartyAxis-AmeritasLifeInsuranceCorpMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 9 - Related Party (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual", "shortName": "Note 9 - Related Party (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30_RelatedPartyTransactionsByRelatedPartyAxis-AmeritasLifeInsuranceCorpMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 10 - Segment Information (Details Textual)", "role": "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual", "shortName": "Note 10 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-04-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 10 - Segment Information - Assets by Geographic Area (Details)", "role": "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details", "shortName": "Note 10 - Segment Information - Assets by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-TreasuryStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Summary of Significant Accounting Policies", "role": "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "shortName": "Note 1 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nrc20200630_10q.htm", "contextRef": "d_2020-01-01_2020-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r467" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-document-and-entity-information", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables", "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual", "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-document-and-entity-information", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables", "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual", "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nrc_AmeritasLifeInsuranceCorpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about related party.", "label": "Ameritas Life Insurance Corp [Member]" } } }, "localname": "AmeritasLifeInsuranceCorpMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_AmortizationOfCapitalizedContractCostTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Amortization of Capitalized Contract Cost [Table Text Block]" } } }, "localname": "AmortizationOfCapitalizedContractCostTableTextBlock", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "nrc_CanadianSubsidiaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to Canadian Subsidiary.", "label": "Canadian Subsidiary [Member]" } } }, "localname": "CanadianSubsidiaryMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to common stock options.", "label": "Common Stock Options [Member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "nrc_ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right to consideration in exchange for good or service transferred to customer with right conditioned on satisfaction of other performance obligations.", "label": "Increases due to revenue recognized in the period with additional performance obligations before invoicing" } } }, "localname": "ContractWithCustomerAssetIncreaseRevenueRecognizedConditionalConsideration", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_ContractWithCustomerLiabilityBillings": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in obligation to transfer good or service to customer due to billings to customer in excess of revenue", "label": "Increases due to invoicing of client, net of amounts recognized as revenue" } } }, "localname": "ContractWithCustomerLiabilityBillings", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "nrc_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to a credit agreement, providing a revolving credit facility, term loan facility, and delayed draw-down term facility.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_CyberAttackMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents cyber attack.", "label": "Cyber Attack [Member]" } } }, "localname": "CyberAttackMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The maximum amount of quarterly dividends included in the fixed charge coverage calculation unless liquidity falls below a specified threshold.", "label": "nrc_DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "terseLabel": "Debt Instrument, Covenant, Exception, Fixed Charge Coverage Ratio, Dividend Threshold" } } }, "localname": "DebtInstrumentCovenantExceptionFixedChargeCoverageRatioDividendThreshold", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum cash flow leverage ratio the borrower is allowable to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "terseLabel": "Debt Instrument, Covenant, Maximum Cash Flow Leverage Ratio" } } }, "localname": "DebtInstrumentCovenantMaximumCashFlowLeverageRatio", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum fixed charge coverage ratio the borrower is required to maintain under a debt instrument agreement.", "label": "nrc_DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "terseLabel": "Debt Instrument, Covenant, Minimum Fixed Charge Coverage Ratio" } } }, "localname": "DebtInstrumentCovenantMinimumFixedChargeCoverageRatio", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "pureItemType" }, "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of debt instrument borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "nrc_DebtInstrumentPercentageBearingVariableInterestPercentageRate", "terseLabel": "Debt Instrument, Percentage Bearing Variable Interest, Percentage Rate" } } }, "localname": "DebtInstrumentPercentageBearingVariableInterestPercentageRate", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "nrc_DeferredTaxLiabilitiesEmployerSocialSecurityTaxBreakUnderCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to employer social security tax break under CARES Act.", "label": "nrc_DeferredTaxLiabilitiesEmployerSocialSecurityTaxBreakUnderCARESAct", "terseLabel": "Deferred Tax Liabilities, Employer Social Security Tax Break Under CARES Act" } } }, "localname": "DeferredTaxLiabilitiesEmployerSocialSecurityTaxBreakUnderCARESAct", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_DelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to a delayed draw term loan.", "label": "Delayed Draw Term Loan [Member]" } } }, "localname": "DelayedDrawTermLoanMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DirectExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to direct expenses.", "label": "Direct Expenses [Member]" } } }, "localname": "DirectExpensesMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "nrc_DirectFixedAndSellingGeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing direct fixed and selling, general and administrative expense.", "label": "Direct Fixed and Selling, General and Administrative Expense [Member]" } } }, "localname": "DirectFixedAndSellingGeneralAndAdministrativeExpenseMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_DirectorPlan2004Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the 2004 director plan.", "label": "Director Plan 2004 [Member]" } } }, "localname": "DirectorPlan2004Member", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_FirstNationalBankOfOmahaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to the entity First National Bank of Omaha.", "label": "First National Bank of Omaha [Member]" } } }, "localname": "FirstNationalBankOfOmahaMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "nrc_FixedNonSubscriptionServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to fixed, non-subscription services.", "label": "Fixed, Non-subscription Services [Member]" } } }, "localname": "FixedNonSubscriptionServicesMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_HostingArrangementImplementationCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for implementation costs incurred in hosting arrangement that is service contract.", "label": "Hosting Arrangement Implementation Costs [Policy Text Block]" } } }, "localname": "HostingArrangementImplementationCostsPolicyTextBlock", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "nrc_IMAFinancialGroupMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to IMA Financial Group.", "label": "IMA Financial Group [Member]" } } }, "localname": "IMAFinancialGroupMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_IncreaseDecreaseCapitalizedContractCost": { "auth_ref": [], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Capitalized costs incurred to obtain or fulfill contract with customer net of amortization recorded during the period.", "label": "nrc_IncreaseDecreaseCapitalizedContractCost", "negatedTerseLabel": "Deferred contract costs, net" } } }, "localname": "IncreaseDecreaseCapitalizedContractCost", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing": { "auth_ref": [], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net change during the reporting period in the aggregate amount of expenses and accrued compensation incurred but not yet paid.", "label": "Accrued expenses, wages, bonuses and profit sharing" } } }, "localname": "IncreaseDecreaseInAccruedExpensesWagesBonusesAndProfitSharing", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet": { "auth_ref": [], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating lease assets after deduction of operating lease liabilities.", "label": "nrc_IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "negatedLabel": "Operating lease assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLeaseLiabilitiesNet", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of incremental costs of obtaining a contract deferred during the period.", "label": "nrc_IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "terseLabel": "Incremental Costs of Obtaining a Contract, Deferred During Period" } } }, "localname": "IncrementalCostsOfObtainingAContractDeferredDuringPeriod", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_NonqualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents nonqualified stock options.", "label": "Nonqualified Stock Options [Member]" } } }, "localname": "NonqualifiedStockOptionsMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NonvestedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to nonvested shares.", "label": "Nonvested [Member]" } } }, "localname": "NonvestedMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_NumberOfCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of customers accounting for a substantial portion of one reporting unit's revenue.", "label": "nrc_NumberOfCustomers", "terseLabel": "Number of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "nrc_PaymentsForInsuranceSettlementPaidDirectlyToVendors": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow used for the insurance settlement paid directly to certain vendors.", "label": "nrc_PaymentsForInsuranceSettlementPaidDirectlyToVendors", "terseLabel": "Payments for Insurance Settlement, Paid Directly to Vendors" } } }, "localname": "PaymentsForInsuranceSettlementPaidDirectlyToVendors", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_PracticingExcellencecomMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related to the entity PracticingExcellence.com.", "label": "PracticingExcellence.com [Member]" } } }, "localname": "PracticingExcellencecomMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information about purchasing directors and officers and employment practices liability insurance in a related party transaction.", "label": "Purchasing Directors and Officers and Employment Practices Liability Insurance [Member]" } } }, "localname": "PurchasingDirectorsAndOfficersAndEmploymentPracticesLiabilityInsuranceMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "nrc_ReserveForUncertainTaxPositions": { "auth_ref": [], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings to reserve for uncertain tax positions.", "label": "Reserve for uncertain tax positions" } } }, "localname": "ReserveForUncertainTaxPositions", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percent of total revenue from contracts with customers.", "label": "nrc_RevenueFromContractWithCustomerPercentOfTotalRevenue", "terseLabel": "Revenue from Contract with Customer, Percent of Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerPercentOfTotalRevenue", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual" ], "xbrltype": "percentItemType" }, "nrc_SalesAndExciseTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expense recorded during the period for statutory sales and use taxes, including value added tax.", "label": "nrc_SalesAndExciseTaxExpense", "terseLabel": "Sales and Excise Tax Expense" } } }, "localname": "SalesAndExciseTaxExpense", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_SalesAndExciseTaxPayableReversalOfLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sales and excise tax payable (reversal of liability).", "label": "nrc_SalesAndExciseTaxPayableReversalOfLiability", "terseLabel": "Sales and Excise Tax Payable (Reversal of Liability)" } } }, "localname": "SalesAndExciseTaxPayableReversalOfLiability", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_ScheduleOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the schedule of intangible assets.", "label": "Schedule of Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the fair value granted for share based compensation arrangement to each non-employee director at the annual meeting.", "label": "nrc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Award Annual Options Grant Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardAnnualOptionsGrantAmount", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of nonvested restricted shares outstanding.", "label": "nrc_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Nonvested Restricted Stock, Outstanding Number (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedRestrictedStockOutstandingNumber", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "nrc_StockTenderedCashlessExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of stock tendered to the company for cashless exercise of stock options in connection with equity incentive plans.", "label": "Stock tendered to the Company for cashless exercise of stock options in connection with equity incentive plans" } } }, "localname": "StockTenderedCashlessExerciseOfStockOptions", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nrc_SubscriptionServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to subscription services.", "label": "Subscription Services [Member]" } } }, "localname": "SubscriptionServicesMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to a term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "nrc_The2001EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the 2001 equity incentive plan.", "label": "The 2001 Equity Incentive Plan [Member]" } } }, "localname": "The2001EquityIncentivePlanMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_The2006EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the 2006 Equity Incentive plan.", "label": "The 2006 Equity Incentive Plan [Member]" } } }, "localname": "The2006EquityIncentivePlanMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "nrc_TheInsurerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to the insurer.", "label": "The Insurer [Member]" } } }, "localname": "TheInsurerMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nrc_TradeNames1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names 1 [Member]" } } }, "localname": "TradeNames1Member", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "nrc_UnitPriceServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to unit price services.", "label": "Unit Price Services [Member]" } } }, "localname": "UnitPriceServicesMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "nrc_VoCPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the Voice of the Customer Platform.", "label": "VoC Platform [Member]" } } }, "localname": "VoCPlatformMember", "nsuri": "http://nrchealth.com/20200630", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual" ], "xbrltype": "domainItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Amortization Expense Classification (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Fair Value of Financial Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-1-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-segment-information-assets-by-geographic-area-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Segment Information - Assets by Geographic Area (Details)" } } }, "localname": "statement-statement-note-10-segment-information-assets-by-geographic-area-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-10-segment-information-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 10 - Segment Information" } } }, "localname": "statement-statement-note-10-segment-information-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-2-contracts-with-customers-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Contracts With Customers - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Contracts With Customers - Information About Receivables, Contract Assets, and Contract Liabilities From Contracts With Customers (Details)" } } }, "localname": "statement-statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-2-contracts-with-customers-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 2 - Contracts With Customers" } } }, "localname": "statement-statement-note-2-contracts-with-customers-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-4-notes-payable-summary-of-notes-payable-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Notes Payable - Summary of Notes Payable (Details)" } } }, "localname": "statement-statement-note-4-notes-payable-summary-of-notes-payable-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-4-notes-payable-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 4 - Notes Payable" } } }, "localname": "statement-statement-note-4-notes-payable-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-sharebased-compensation-nonvested-stock-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Share-based Compensation - Non-vested Stock (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-nonvested-stock-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Share-based Compensation - Stock Option Activity Under Equity Incentive Plans and Director Plan (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Share-based Compensation - Stock Options Valuation Assumptions (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-5-sharebased-compensation-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 5 - Share-based Compensation" } } }, "localname": "statement-statement-note-5-sharebased-compensation-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 6 - Goodwill and Other Intangible Assets - Summary of Changes in the Carrying Amount of Goodwill (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 6 - Goodwill and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details)" } } }, "localname": "statement-statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-6-goodwill-and-other-intangible-assets-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 6 - Goodwill and Other Intangible Assets" } } }, "localname": "statement-statement-note-6-goodwill-and-other-intangible-assets-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-property-and-equipment-summary-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-7-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 7 - Property and Equipment" } } }, "localname": "statement-statement-note-7-property-and-equipment-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Earnings Per Share - Net Income Per Share Computation (Details)" } } }, "localname": "statement-statement-note-8-earnings-per-share-net-income-per-share-computation-details", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-note-8-earnings-per-share-tables": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Note 8 - Earnings Per Share" } } }, "localname": "statement-statement-note-8-earnings-per-share-tables", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "nrc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://nrchealth.com/20200630", "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r332", "r333", "r338", "r339", "r464" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r332", "r333", "r338", "r339" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r264", "r265", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r438", "r441" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r264", "r265", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r438", "r441" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r159", "r245", "r249", "r393", "r437", "r439" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r159", "r245", "r249", "r393", "r437", "r439" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r254", "r264", "r265", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r438", "r441" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r254", "r264", "r265", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r438", "r441" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r160", "r161", "r245", "r250", "r440", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r160", "r161", "r245", "r250", "r440", "r449", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r165", "r378" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r18", "r166", "r167" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $143 and $144, respectively", "terseLabel": "Accounts receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r13", "r412", "r425" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r27", "r209" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r43", "r45", "r46", "r47", "r353" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated other comprehensive loss, foreign currency translation adjustment" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r47", "r48", "r96", "r97", "r98", "r337", "r442", "r443" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r96", "r97", "r98", "r298", "r299", "r300" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r266", "r268", "r304", "r305" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Non-cash stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r268", "r294", "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "auth_ref": [ "r170", "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r173", "r179", "r180", "r184" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r24", "r173", "r179" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "Recoveries" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r81", "r206" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r145", "r149", "r155", "r177", "r332", "r338", "r357", "r410", "r424" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r42", "r91", "r177", "r332", "r338", "r357" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r269", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r342", "r343" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r85", "r86" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Finance lease obligations originated for property and equipment" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized contract cost" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_CapitalizedContractCostAmortizationPeriod", "terseLabel": "Capitalized Contract Cost, Amortization Period (Year)" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_CapitalizedContractCostAxis": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Axis]" } } }, "localname": "CapitalizedContractCostAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostDomain": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.", "label": "Capitalized Contract Cost [Domain]" } } }, "localname": "CapitalizedContractCostDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "us-gaap_CapitalizedContractCostImpairmentLoss", "terseLabel": "Capitalized Contract Cost, Impairment Loss" } } }, "localname": "CapitalizedContractCostImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "auth_ref": [ "r189" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.", "label": "Deferred contract costs, net", "terseLabel": "Capitalized Contract Cost, Net, Noncurrent" } } }, "localname": "CapitalizedContractCostNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r25", "r83" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Assets, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r77", "r83", "r87" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r77", "r358" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r90", "r91", "r112", "r116", "r117", "r120", "r122", "r130", "r131", "r132", "r177", "r357" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r88", "r213", "r450", "r451" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r96", "r97" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r217" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,553,546 in 2020 and 30,151,574 in 2019, outstanding 25,235,123 in 2020 and 24,947,500 in 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r57", "r418", "r433" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r134", "r135", "r163", "r355", "r356" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r134", "r135", "r163", "r355", "r356", "r447" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r134", "r135", "r163", "r355", "r356", "r447" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r134", "r135", "r163", "r355", "r356" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r134", "r135", "r163", "r355", "r356" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r221", "r223", "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract assets included in other current assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable", "negatedLabel": "Decreases due to completion of services (or portion of services) and transferred to accounts receivable" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r245", "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [ "r245", "r251" ], "lang": { "en-US": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "negatedLabel": "Change due to cumulative catch-up adjustments arising from changes in expected contract consideration" } } }, "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r221", "r222", "r246" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue", "negatedTerseLabel": "Deferred Revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "negatedLabel": "Revenue recognized that was included in deferred revenue at beginning of year due to completion of services" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r60" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r133", "r163" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r411", "r413", "r423" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r367", "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r36", "r422" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment, Total" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r28", "r88" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r28", "r368" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "us-gaap_DeferredFinanceCostsNet", "negatedLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r81", "r92", "r314", "r319", "r320", "r321" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r307", "r308" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r81", "r207" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectOperatingCosts": { "auth_ref": [ "r63" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate direct operating costs incurred during the reporting period.", "label": "Direct" } } }, "localname": "DirectOperatingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-9-related-party" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r9", "r33" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share of Common Stock:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r58", "r101", "r102", "r103", "r104", "r105", "r109", "r112", "r120", "r121", "r122", "r126", "r127", "r419", "r434" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic Earnings Per Share (in dollars per share)", "terseLabel": "Net income per share \u2013 basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r58", "r101", "r102", "r103", "r104", "r105", "r112", "r120", "r121", "r122", "r126", "r127", "r419", "r434" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted Earnings Per Share (in dollars per share)", "terseLabel": "Net income per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r123", "r124", "r125", "r128" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r358" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued wages, bonus and profit sharing" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r96", "r97", "r98", "r100", "r106", "r108", "r129", "r178", "r217", "r218", "r298", "r299", "r300", "r315", "r316", "r359", "r360", "r361", "r362", "r363", "r364", "r442", "r443", "r444" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r345", "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r345", "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r346", "r383", "r384", "r385" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r345", "r346", "r347", "r348", "r352" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r255", "r256", "r261", "r263", "r346", "r383" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r383", "r384", "r385" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r350", "r352" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r371", "r373" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r202" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r197", "r199", "r202", "r204", "r394", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r202", "r395" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Amortizing intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r197", "r201" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r81" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r191", "r192", "r409" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill, Ending Balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r56", "r145", "r148", "r151", "r154", "r157", "r408", "r417", "r421", "r435" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r311", "r312", "r313", "r317", "r322", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-3-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r92", "r107", "r108", "r144", "r309", "r318", "r323", "r436" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r40", "r415", "r432" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "us-gaap_IncreaseDecreaseInIncomeTaxes", "terseLabel": "Income taxes receivable and payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r113", "r114", "r115", "r122" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Weighted average effect of dilutive securities \u2013 stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r198", "r203" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r203" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite trade name" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r198", "r203" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r196", "r200" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "totalLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r143", "r366", "r368", "r420" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r74", "r78", "r84" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest, net of capitalized amounts" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r65", "r142" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r91", "r150", "r177", "r333", "r338", "r339", "r357" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r91", "r177", "r357", "r414", "r429" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r91", "r177", "r333", "r338", "r339", "r357" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r14", "r413", "r423" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LineOfCredit", "terseLabel": "Long-term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r30", "r93" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermContractWithCustomerMember": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which duration is classified as long-term.", "label": "Long-term Contract with Customer [Member]" } } }, "localname": "LongTermContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r215", "r413", "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Total carrying amount of long-term debt", "terseLabel": "Long-term Debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Estimated fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebtNoncurrent", "terseLabel": "Notes payable, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r36" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion and unamortized debt issuance costs" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r36", "r214" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r77", "r79", "r82" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r101", "r102", "r103", "r104", "r109", "r110", "r119", "r122", "r145", "r148", "r151", "r154", "r157" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "terseLabel": "Net income attributable to common shareholders for basic computation", "totalLabel": "Net income attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncatastrophicEventAxis": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Axis]" } } }, "localname": "NoncatastrophicEventAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NoncatastrophicEventDomain": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Domain]" } } }, "localname": "NoncatastrophicEventDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r145", "r148", "r151", "r154", "r157" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r330", "r331", "r336" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "terseLabel": "Other comprehensive loss, foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r50", "r53", "r330", "r331", "r336" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r342", "r344" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r33" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r118", "r119" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "negatedTerseLabel": "Allocation of distributed and undistributed income to unvested restricted stock shareholders" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r71" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Payment of dividends on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Payment of employee payroll tax withholdings on share-based awards exercised" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r269", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r3", "r5", "r186", "r187" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r73", "r76" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities", "terseLabel": "Proceeds from Insurance Settlement, Operating Activities" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r70", "r94" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Borrowings on line of credit", "terseLabel": "Proceeds from Lines of Credit, Total" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r69", "r297" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from the exercise of stock options", "terseLabel": "Proceeds from Stock Options Exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r49", "r52", "r75", "r91", "r99", "r107", "r108", "r145", "r148", "r151", "r154", "r157", "r177", "r330", "r334", "r335", "r340", "r341", "r357", "r421" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r212", "r452", "r453", "r454" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r26", "r208" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r210", "r430" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Net property and equipment", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r59", "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad Debt Expense (Benefit)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r262", "r376", "r377" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r376", "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r262", "r376", "r377", "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r262", "r376", "r379", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r374", "r375", "r377", "r380", "r381" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r72", "r94" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r72" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "us-gaap_RepaymentsOfNotesPayable", "negatedLabel": "Payments on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r218", "r301", "r428", "r445", "r446" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r96", "r97", "r98", "r100", "r106", "r108", "r178", "r298", "r299", "r300", "r315", "r316", "r442", "r444" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r140", "r141", "r147", "r152", "r153", "r159", "r160", "r163", "r244", "r245", "r393" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r134", "r163" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r89", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r253" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r231", "r234", "r235", "r248", "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r61", "r448" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "us-gaap_RevenueFromRelatedParties", "terseLabel": "Revenue from Related Parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "auth_ref": [ "r416", "r431" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.", "label": "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent", "terseLabel": "Sales and Excise Tax Payable" } } }, "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r194", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r62", "r162" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r280", "r284", "r286" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r14", "r413", "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebt", "terseLabel": "Term Loans" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r12", "r411", "r426" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "us-gaap_SecuredDebtCurrent", "negatedTerseLabel": "Less: current portion" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r136", "r138", "r139", "r145", "r146", "r151", "r155", "r156", "r157", "r158", "r159", "r162", "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-10-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Non-cash share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield at date of grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Forfeited, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, number of options (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r275", "r296" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, number of options (in shares)", "periodStartLabel": "Outstanding, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r267", "r273" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r289", "r302" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life of options (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r296" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "durationItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r90", "r91", "r112", "r116", "r117", "r120", "r122", "r130", "r131", "r132", "r177", "r217", "r357" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r96", "r97", "r98", "r100", "r106", "r108", "r129", "r178", "r217", "r218", "r298", "r299", "r300", "r315", "r316", "r359", "r360", "r361", "r362", "r363", "r364", "r442", "r443", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables", "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual", "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r96", "r97", "r98", "r129", "r393" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-amortization-expense-classification-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-fair-value-of-financial-assets-and-liabilities-details", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20200630/role/statement-note-10-segment-information", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-assets-by-geographic-area-details", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-details-textual", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-1-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-2-details-textual", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-information-about-receivables-contract-assets-and-contract-liabilities-from-contracts-with-customers-details", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes", "http://nrchealth.com/20200630/role/statement-note-3-income-taxes-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-summary-of-notes-payable-details", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-nonvested-stock-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-options-valuation-assumptions-details", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-changes-in-the-carrying-amount-of-goodwill-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-summary-of-property-and-equipment-details", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-details-textual", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables", "http://nrchealth.com/20200630/role/statement-note-9-related-party", "http://nrchealth.com/20200630/role/statement-note-9-related-party-details-textual", "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r16", "r17", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Forfeitures of restricted common shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r17", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Shares of restricted common shares, net of (forfeitures) (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r217", "r218", "r277" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Shares of common stock for the exercise of stock options (in shares)", "negatedTerseLabel": "Exercised, number of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-stock-option-activity-under-equity-incentive-plans-and-director-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r39", "r217", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common shares for the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r91", "r175", "r177", "r357" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r365", "r382" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies", "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental disclosure of cash paid for:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://nrchealth.com/20200630/role/statement-note-10-segment-information-tables", "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-tables", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-tables", "http://nrchealth.com/20200630/role/statement-note-5-sharebased-compensation-tables", "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-tables", "http://nrchealth.com/20200630/role/statement-note-7-property-and-equipment-tables", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r245", "r252" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r245", "r252" ], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r168", "r169", "r171", "r172", "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-6-goodwill-and-other-intangible-assets-summary-of-goodwill-and-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred at Point in Time [Member]" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred over Time [Member]" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-2-contracts-with-customers-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r38", "r219" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r38", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r17", "r217", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Shares of stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r38", "r219", "r220" ], "calculation": { "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 5,318,423 Common shares in 2020 and 5,204,074 shares in 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r217", "r218", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Purchase of shares treasury stock" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-note-4-notes-payable", "http://nrchealth.com/20200630/role/statement-note-4-notes-payable-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r122" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Denominator for diluted earnings per share \u2013 adjusted weighted average shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted average shares and share equivalents outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r122" ], "calculation": { "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding \u2013 basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://nrchealth.com/20200630/role/statement-condensed-consolidated-statements-of-income-unaudited", "http://nrchealth.com/20200630/role/statement-note-8-earnings-per-share-net-income-per-share-computation-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r467": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r468": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r469": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r470": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080549-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 72 0001437749-20-016985-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-016985-xbrl.zip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�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